var title_f41_16_42240="Genu recurvatum";
var content_f41_16_42240=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Genu recurvatum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 463px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In genu recurvatum, the knee is hyperextended such that the angle between the femur and tibia (usually 180 degrees) is increased, as depicted above.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_16_42240=[""].join("\n");
var outline_f41_16_42240=null;
var title_f41_16_42241="EEG recording leads";
var content_f41_16_42241=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F51413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F51413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    EEG recording leads in ECT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 355px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electroencephalogram (EEG) electrode placement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Handbook of ECT (Copyright 1997). American Psychiatric Publishing, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_16_42241=[""].join("\n");
var outline_f41_16_42241=null;
var title_f41_16_42242="PCLBCL-LT clinical presentation II";
var content_f41_16_42242=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F79655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F79655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patient with a primary cutaneous diffuse large B-cell lymphoma, leg type presenting with extensive skin tumors on the left leg",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_16_42242=[""].join("\n");
var outline_f41_16_42242=null;
var title_f41_16_42243="Mepivacaine (dental): Patient drug information";
var content_f41_16_42243=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Mepivacaine (dental): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/16/27907?source=see_link\">",
"     see \"Mepivacaine (dental): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F192996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Carbocaine&reg;;",
"     </li>",
"     <li>",
"      Polocaine&reg; Dental;",
"     </li>",
"     <li>",
"      Scandonest&reg; 3% Plain",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F192997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Polocaine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691288",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before dental care to numb the area.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702468",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to mepivacaine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfite allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat while your mouth feels numb. You may bite your tongue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696006",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11561 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B987512CC0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_16_42243=[""].join("\n");
var outline_f41_16_42243=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192996\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192997\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025698\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025697\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025702\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025703\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025705\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025700\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025701\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025706\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025707\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/16/27907?source=related_link\">",
"      Mepivacaine (dental): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_16_42244="Ethionamide: Drug information";
var content_f41_16_42244=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ethionamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/2/26660?source=see_link\">",
"    see \"Ethionamide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/24/21891?source=see_link\">",
"    see \"Ethionamide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Trecator&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F168673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Trecator&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F168692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antitubercular Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F168674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tuberculosis: Oral: 15-20 mg/kg/day; initiate dose at 250 mg/day for 1-2 days, then increase to 250 mg twice daily for 1-2 days, with gradual increases to highest tolerated dose; average adult dose: 750 mg/day (maximum: 1 g/day in 3-4 divided doses)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F168686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/24/21891?source=see_link\">",
"      see \"Ethionamide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tuberculosis: Oral: 15-20 mg/kg/day in 2-3 divided doses, not to exceed 1 g/day (CDC, 2009; WHO, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F168675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F168676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15881393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in patients with severe hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F168646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trecator&reg;: 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F168633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F168650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neurotoxic effects may be prevented or relieved by the coadministration of pyridoxine (see Pyridoxine monograph for dosing). May be taken with or without meals. Gastrointestinal adverse effects may be decreased by administration at meals or bedtime, decreased dose, or giving antiemetics.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F168649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of tuberculosis and other mycobacterial diseases, in conjunction with other antituberculosis agents, when first-line agents have failed or resistance has been demonstrated",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F168690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Depression, dizziness, drowsiness, headache, psychiatric disturbances, restlessness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, alopecia, photosensitivity, purpura, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gynecomastia, hypoglycemia, hypothyroidism or goiter, menstrual irregularities, pellagra-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, excessive salivation, metallic taste, nausea, stomatitis, vomiting, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Bilirubin increased, hepatitis, jaundice, liver function tests increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, peripheral neuritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia, optic neuritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Olfactory disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F168653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ethionamide or any component of the formulation; severe hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F168637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may cause hypoglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: May cause hepatotoxicity; monitor liver function tests monthly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use not recommended; porphyria-inducing in animal and",
"     <i>",
"      in vitro",
"     </i>",
"     studies.(WHO, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction; hypothyroidism (reversible) has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cycloserine: Use with caution in patients receiving cycloserine; seizures have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Isoniazid: Use with caution in patients receiving isoniazid; temporarily increases isoniazid levels. Some cross-resistance has been reported if inhA mutation is present. (WHO, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Drug-resistant tuberculosis develops rapidly if ethionamide is used alone; must administer with at least one other antituberculosis agent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Eye exams: Periodic eye exams are recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Ethionamide. Specifically, there may be a risk for a psychotic episode/reaction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSERINE: Ethionamide may enhance the adverse/toxic effect of CycloSERINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Ethionamide may increase the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F168668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid excessive ethanol ingestion; psychotic reaction may occur.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F168642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F168656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethionamide crosses the placenta; teratogenic effects were observed in animal studies. Use during pregnancy is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F168680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F168657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If ethionamide is used while breast-feeding, monitor the infant for adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F168658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Healthcare provider may recommend an increase in dietary intake of pyridoxine to prevent neurotoxic effects of ethionamide. Avoid alcohol.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Trecator Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $422.09",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F168644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial and periodic serum ALT and AST; blood glucose; TSH every 6 months; initial and periodic ophthalmic exams",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ethatyl (ZA);",
"     </li>",
"     <li>",
"      Ethiocol (PE);",
"     </li>",
"     <li>",
"      Ethomid (CO, PK);",
"     </li>",
"     <li>",
"      Eton-250 (TH);",
"     </li>",
"     <li>",
"      Myobid-250 (IN);",
"     </li>",
"     <li>",
"      Trecator (FR, GR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F168636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits peptide synthesis; bacteriostatic",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F168652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid, complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses placenta; V",
"     <sub>",
"      d",
"     </sub>",
"     : 93.5 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Prodrug; extensively hepatic to active and inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;1% as unchanged drug; as active and inactive metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Arbex MA, Varella Mde C, de Siqueira HR, et al, \"Antituberculosis Drugs: Drug Interactions, Adverse Effects, and Use in Special Situations. Part 2: Second-Line Drugs,\"",
"      <i>",
"       J Bras Pneumol",
"      </i>",
"      , 2010, 36(5):641-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/16/42244/abstract-text/21085831/pubmed\" id=\"21085831\" target=\"_blank\">",
"        21085831",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blumberg HM, Burman WJ, Chaisson RE, et al, &ldquo;American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2003, 167(4):603-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/16/42244/abstract-text/12588714/pubmed\" id=\"12588714\" target=\"_blank\">",
"        12588714",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Treatment of Tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2003, 52(RR11);26, 64.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/16/42244/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-4):1-207. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/pdf/rr/rr5804.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/pdf/rr/rr5804.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donald PR and Seifart HI,&ldquo;Cerebrospinal Fluid Concentrations of Ethionamide in Children With Tuberculous Meningitis,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1989, 115(3):483-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/16/42244/abstract-text/2769511/pubmed\" id=\"2769511\" target=\"_blank\">",
"        2769511",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pattyn SR, Janssens L, Bourland J, et al, &ldquo;Hepatotoxicity of the Combination of Rifampin-Ethionamide in the Treatment of Multibacillary Leprosy,&rdquo;",
"      <i>",
"       Int J Lepr Other Mycobact Dis",
"      </i>",
"      , 1984, 52(1):1-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/16/42244/abstract-text/6368424/pubmed\" id=\"6368424\" target=\"_blank\">",
"        6368424",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Starke JR and Correa AG, &ldquo;Management of Mycobacterial Infection and Disease in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(6):455-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/16/42244/abstract-text/7667049/pubmed\" id=\"7667049\" target=\"_blank\">",
"        7667049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      World Health Organization, &ldquo;Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis, Emergency Update 2008,&rdquo; 2008, World Health Organization, Geneva. Available at file://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9438 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.69.132.100-0D12DA5E94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_16_42244=[""].join("\n");
var outline_f41_16_42244=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168672\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168673\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168692\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168674\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168686\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168675\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168676\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881393\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168646\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168633\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168650\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168649\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168690\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168653\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168637\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299299\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220232\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168668\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168642\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168656\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168680\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168657\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168658\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524566\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168644\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038613\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168636\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168652\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9438\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9438|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/2/26660?source=related_link\">",
"      Ethionamide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/24/21891?source=related_link\">",
"      Ethionamide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_16_42245="SLN melanoma metastasis HandE";
var content_f41_16_42245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F77565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F77565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sentinel lymph node metastasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 273px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAERAXMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDp9N8KQWmrSagLuaRWthbtGR8rYXGc/QVNa39ta2Ijgtnjgjl8hsdYwDgsfaq9pf6zo/ha5vvEam4likLIkIHCn7o4HrmsrRLe/XVrXV4pni028zJcWk/WPI4PvzX0VnK7m72PQjorJHc6EblbXUYzOLi1d1kgBT5YwODyfU1lahc3N1qhhVB5BbLsw+U+w9an03xHbah56afcJJ5Z2yBD3q3BF55JlURgDKnruPpWGsZNyQ4xtdsjtYLaGdp1t4kuHXbvx82B0GfSrkUBu7O4trgFhIjKEPHy45P5VnRJINSmlcERiExxsfu7vXFVvC41GDRNurXPmXglYh/7qk8DNJx0vcHfYoPoPhfRrXyGjjn8pCkTSyZaPJJIFVdHsvDc1tcz28dvslYGQy87T24PSrPiDw82qGSe1k27sb4yMBvcVjapokGlaQUVlDuVVmlcDbk8Y9/rXXDllFLnd2CTTsddBp2l288tzpumRSSXUOyfAyJffFFrp1jY2Kxw2dvBCzbthA6/jVTTr5tD0m1muYiPK2o2z0PFZ/ii5s/EiwabZ3JgvA3nYwcOv/1qxUJOVr6d/QPhZ2cgxaKY1C7AOOy/hVS0lRjuLEtn77DisK1l1y11m10+RIbjTWjIa5Xg5A43c9zxXJatqGsXlhbC+tb2zubi5MUcdsmQu08MR1xg/pShQ5na6J5ktGjtfENnFPcQy2CQieWQG6BA3SJ0/SvJ/EujXvh26LF5b22MpLSmPd5qHoh64xit+ez8Sa5reoyWSvZy2EQiRmOwT4POM9z1qVLzxfdG4trrTTbSQldo24Lnpj0PriuyinTslJPuJtS0scjBDDfTOfsd9cGCEXcSoNhA242A46A/ypNSEqf2XYWFtN9viTzxDOSXw3LZA46fpXUXmr63pmsBNUiT7OIciMJtJbbkD8+tad7rhu73QdQNvHaXskQWaQIN5Unbtz1xj+db887ppXXqTynJy2F8NSfWdHlkZpG3pbsp5buPp1xmuggj0bxNo1/cS2sq635ZLxR8b2UdveukvJmsdUtIrOMRqHVmKj7xJxk1yOpXlhF42slmFzHPb3f2eUwJhJg/Qn6Z/Gsud1Fpp2HL3SW21RLyHQI1spIL42rwwqU+aMqcfePqK6PSLSWTMdzbvErEM3mdR+NP0CDUvPu7LUJbcXdhKzxHIDzxNnB9QBWb4rstcs5sWOpmS3ugVeM8mDI+8DWTkpPkjZf1cqMrEV9BcT+Ibya2vE1C2ggDQWYySrjAz9Kh/tjQ5ryaTxDFNZ3oVC6OpxnsAOvvWromqad4V8P6ddXXnXM53Rl0jw7nuT7dK5zWLm113UtV1XU/sziXEVnA4IcuMbcY645qoJt2s7LS/Ui/Yu65qepa5YTS6fYQ/uZvLOOZfK9RnoazfBcIhv73QrzTZrS2vYmJuHY/exkZPbNLpdvrGluk+nrG897dnzlueNwwMY9Oc1oa7q630JtLMTo0RzecZKnOPlHcZNXytfu47fl/THZWMjxJbaTplzpnh+4jmkkQN5EiPko0nGSfTvisnw94I/tW2mvL28WGDP2a3YfenlVuuOuMd60vG2lQ2Fi99HqjC+8yJEQggg55Oe1SeF9OuLueZ7TUnjtGSSGRFBbynIHzAe/r1q07U+ZMlrWyNd7ZJPFt/Y2tpA7W8Qtp78/eUlcbgfrVDRrye90rWbW4lt47e1QWkF95eZUcH8+eea0RM+h6TaC2vLa8k3/vJlGc9gGJ789KzPGsp02SxuNHxDY35V542i3I7knLZHbIqIq9o9+voG4eG9SudK8OauNLXzNQhuFFxvGS0eMeZ70WHi023iZ9SvtPNwlvCixKq5UyMOvtUEmkRnQVvZNXW0n1CQSPwdrqp5VRWXcy6ZZXuv2lwJ47a5mUo8Z6Acggdx7VooQk5aXv/wABMdrI2RfC/wBQvNQ1BZtJv5XaC1U58uTdnnHXIz16V0IjisdK0XQdYL3M91Oy3EjNggABgB7ZIrk0+0RX+niJzPZyoXs7yUE7QvXAPQ8YNdYfEWneLY9NeeMWN7YSBHnkHyyZ4IB9eKyqQeltvy7eZN2jM13xXdW99qNvptrJJFFGMqQTleAenStXwz4lsr+809r1reCTY8LI2TtJ+7hj0PSrfm6s91rUwKQReW8QiK/eGMDH4c1X0HQ9AHhux07VoryYpN5hukj2gv6Z64zxzWUnDks1229BybRJ4qvLK7gm07dZveW2JphOw2qMgdTwe1Idfgn8QtpCbfMe2VlnTG0tszge2OlZjaFBr2v61NqNoyRRERwyKdoO3oM/zpdI0prCza8vWt11IbksycFUIGFA9RSUIKPK9/1ZpeSdzV8H29tZJ9gN291qNtuaV2HQE9B9M/rWb44iv5tQVtNvTFMg/exRttYKBkZHfn+daHhrUJ5bizf+z0lWUYu71ByHHb6c/nUkqX51i8nvDDBahHH7wATdePc0leNRyYXWxzGoNDr7WuoTyg39tbmOa1dtqzEjoPQ5qp4Q8TzW7QWEdstpbWKs1yZGzvGfmzn+VWrPRYZ9OMqrLNN52Q+MqeM8kdjT/iBFbWcP2PTbMxatcqHLMvyqh42/U11e437O1/0/q5LirXIbpNS1fTzeTa6tvaPdCSzEeRvQZG0Dtgkda57VfDotb/UbKxvSL+yCS3PmDCysxHT1xmrul6lcatpjaBb2du01mN9nKuQCf4gc/nWn4l8Qx6W8VhLYQ3VzNCoupyMO59AfQdqqKnCXLH7tNv6/EhPuPTVrvTtL1CXzBeaZLAkQsIlw4k4Bcei5z+dX/CkkHinUmjFp5NlaWhhkE0nKHByfc57Vz1hHdaVrdzqGn2d19m3LBtlG5Sh5wD9RWlrehrPd3sPhtmUq5mutjcxEjJH4HNTKMdVtfr29Q66Gd4RjuLnS/EEWgEXd5IyKLG4QZKg4Oc9sVj6ppuo6Brto+q2htoVmEcZXlHJxuGR9a7T4O3diviyaPyl8u7tnQ35GCko65z04rYvNO8Q6JJPZx21rqulGXzYGcb8kjgr3B9aTrOnVcdOm/XpuTzatHG2Ot6aLZRf6aRcqzK+2TI4Yj+WKK9LPgfwteYub6QW13KA8sKXIARzyQPxorL63Q6qX4/5k+0k9pHJQX3iOzuLi5Gl3U0ktyImt5Xyirjll9v5V6DJeQwzQ+enlxyKYm3DdtJFY2p6hqNtfWCWtmtxbTybZXXkoT3+lWbe4fVbm5hubCSKGNt0csgGJDnsOtYVHz2k0vkdVraHJ+HdL1LQvFn2JrVPs8gz58Cbkdz0ye1d5eu1tdWkMkcrtO2Pl/hx1zWb4pvr3RrC3uNGtzc3HmLFIpGSM9GGOorNt9b1eJ5JdTgbzkcl2dOFXPeqalXtPTsK7Wh01t55luJxtSJMhGdclmGelcdB41up445LrSrqGGe4MCS8kA9iV966uTVomspVRXfy0MuAvLsRnj2rNTWTa+F7fUry2kV532vb4BdPQ89sVnBd43G+7K+papfeF7KO88QeXNa3M+Ld4CCNhHf3zmk1XS7DxhBujvFks+Q6x8kMOhz6ipPFOn2/iTwiLRRuULvtWYENGSepHtzxVK48HS+HtFMXh+8mTUMJOQz/KzcHH0OKuMorW9pX+QlzXJtJuZn1nWtK1GPztOt0SJEUclCvUH14zWJpuh/ZNVDGSRvLyEYqRuX+lbmp6gul2Wn3T2Ur3twf9L8s5RXxjArqIbeOS0idzmTA2sRjtT9rKmrpaP9A06mFPdxvZm3srox3K8oWPBb0P41Y03Vbs2kK6kYku1yG2nHHbOKu6hotsLaK7dokSRwu4SDJf0Oe9Yl4ied9iEU0YmIVZ4x3+tZrkmrIqCT1ZqapfWywW5v0kwsoKvG/H0PscCszU7zW/7T/tC1lSe1Pz+UWGPqB61mPZ6vby3WnatLbPpxXNpK7YfcOgPr71LocmtQ2lzFqFgrCJPMga3bKyj+7z3rSMIxV1Z/5CVr7EVz5l3dpqniJyJBLmKMDO7HQFauXEVhrd3BdoUIQhiNhBQ/Ss241WW7iST+zVmiDASQyAlsHrjHIOe9ej6EmgWuj2tisYg8w/OznJz7n9KdaTppO2vlshN8uy0MBrW2+1C7eRHmRdqkH7v4VkRLrGn6ooFxaz2Etx50sk4GUUDhRnp9awvFMg03xm0GmyCeGOQneDyc9j+da2t6Wuo6bJEbny4XGQ+euOv1p+z5VFt6PyKSU0UZvD11ceLbnVrq8JhCkWzK2MDspPcVzHivRdde4ur54TcxTRBH+yyZwCR91fbArtPD02my6F9hsr8XAtVALMc8jv9M1Xi1DUbSebzGjS1C7lckHJ9vT6YrSEpp2XTTXsJRUtipDplzejUbe+sb1oLaNWgXfls4HGe/FZsWoWUqXOmx+H7l2sojdh3cq7SAjgcfX64re0zVtQ1DVoLm0l/wBDiO2aNwM9OvvzTvE+oO8LzQqt44lCywrJsZVx145xTblzcsvzehPK2vI0vslzeXQASOLSru2FwyuMzRS8Y59j2FYGq3s9rqc3k2sKXU6APMo+aT8K2fDxRbO6kN0ZbNGBgLH5l45GaqJZRanO99PIiQsNquWGAO5z2rODUZPm2Q4qyKvh+OPXtRhguYIrm2ifbPFIPuydiT2q34pZdIur2ysWhtZpgyRGLAUP0ySO9c3bQeIoNcsWhtYlW4uzcrcw8oyLwA2OCCKqW2ial4jsNZvLMOb66vSslu3G1P7yZ5wDxmtXCLlzNqxPPZ37jNJhXw/NcLrEkU1iNk85zvDyZ+YL6nsa621RdXa6vdNeG7tLdA3kRNgop6IV7Vka74dGm6RbQ2Usb3iI1uPOdSDIWGRz/FWNLAJTawRQ3OlX1xeiK6wSEuHAHI9BnP51baqap/16E6rYpXc8sr/2rGskiWU4t/sckW6LOTwCPpXYa3aS6hNpqz6JbyI7iS4ZDzEegH0xXNXNjPNrV94fivDDE+J2EfKBs5JI9a6u3D2WoXZS9V7tYFCxyNj5QR836U6nRo0glfU0oIhpHhyW2s8XV3FvMUcgGOSTj2rG8S3ttN4DYPDCNUjuInnigx+6foc4qxrJuIL1bm1bf5/ykAZGTjn+WKm8KW2nvPqc9/B5N6pP2l85V8c52/zNc/Lyr2j16iki7Drc0V7pMGo4/tK8Vco7YCIBj5T0JxisbxzqslvG9vo188AdwUQYZU2nLZPbNZmreJIr3R765v7NY7rT2H9n3YBKl8/d/Lmsq6u7SeOzSRwY7gBrh4gGaEnGBk+5rSlQ15miW1sdwNSj1hodBEJU3NsZHZG5JPO71HPNQ6joqQeC7WyNxtv9PkZt0p2q6sfu9eTXO2OoRy+P7QaFdNbzWypaCRxn7VxjjsK7Hxm+i+JNNezS7ls7/S23TtKhKsOhI9TmoadOceXRb/194ubWxU8c35sJNLttLkW1lXyggc7FOF5475JFV9VF3qFlDd6jG1tOm4zecCMc/erC8aaVBdaraXU18q28NoqxRq373IxtcL3z1rastXvvFfh69spLUQOhWOCaT+L1JPf3+tOMeWEZL5scZW3OeOtXlhamx1WFreC4kW5tZbUfKED45I9eK6Hxfp9xqeoTJpN7DPq1tHHvaRv3m08fT0rnvGNrdWujaZ/bUvkajau8Mdvt/d3CDG0jt3rS0zUGiS41aayWLULuJYnKcfMOOh6etaWbSnDz/r7hLcl0DQ7/AErWgks0UNs6bWXfhpSByAOtVPFWoWX/AAkitbJbXLmQq0DJuKAYwK0o9Z03+2dIuNQlkW/RHt9h+7hujGqutWWn6Z4nkk1HMU+1ZrUIACx6jcff3pRcvaXmtbfeXdanV6nc6romneHINCtlc3Dg3LkZKdyD6fX2rldJihki1PV9L+1xKl6wnjdvlZm/mKq+BL3VtUu7/dG4kCyPBK0m/wAqUdAR/Spr/wAZ3V5Z6Pp+jmze/Z9t/GUCI8u7GQKhU5QlyrV9X666mUVZi6Zo1pcwXlms7Kl8fMbyUw0Lg/qO1ReGJbmZdV0d77zLK2bFvMH2spHBH9ar+ILi+vtO1R41Fu1lMrJ9gPEuDgjI6jvUPhLT4NR1DZNptzY28kZkMpYguWPO7+QxWr1i3JlpK9zSs/C2kQWyR3N1ezzjl5A33iTn+tFdHH4Ct50EkV1PFGfuo4GQBwM0Vl9Yh/z8Y7w7HUW91BfQQ3se1S2CVXp6cGopLu3KsySsywsUJA6H0zWE2lqvlT2E8jWkaBTBu+RVH8X9ap33ii2g04DSIEuYhLtw3Cyn0X1Oa51R5n7mv6F7HRXGpfubd7QtNBJHkuV+6T2x69KvWc8l3bF7hMCRSHDgDPbkHtWDoqSz3VlqUUlzYpsO+yP3QehBH9au3V6LLWI5pNQto7KNQphkOS7nsc1MoK/LHf8ArQLdSHwtrdlrGtXmj/ZZ7RrVGRWccMR936Dj9aZ4Z1aXUZr2z1CER3MBztKYynbrViXxFp8V5t+02kMxbZ1AYt2FJq0d3fpOdPvEtZpIgiuqg7WBznPfI4p2Wt1a4csovU7AHSI4IjNZy98sOnTpWdi1lkzChjXAwHk4A/nXKXWs3Hh2OxstRZr/ACvmSTpn5gew9xVXX/F+iazb2jaYXsXtphG5l/d7s+h7++amOGm2rbPqTfl7nRjWvO18aLZWLhEi8yS4K5jzjI5NUtYOrrOGtkMluW2OirnGfataPVrVbWGXSna5vk4mRGBRaZ9ua6gnedTbXb5wzKdqnHHApRfK78v3jW1ziNF8NaedWvtOurm7uJUnE8UUrEbMc5HPP+FbVtrDnV9dt7m3kjtdPtvOiYKczt6A9KSy1q3soydXcSaiPlMkcfzKnqSO1V9X1F7W4W/t981lKBgL/d9V9D9a6JRnOVpf0/IaslZaHPeKr+xNroerazYXZvXQ+VZK5xznBPftXQaf4/sLXwlYzzWU0MlttjeBSWK8noT/AFrorWGw8yK5e1t55NpMDSgMQG5zj1qtFpunJaXNp9igkjnbe+5MljnPeodSElyyT08yeRvU4vQvEF9YRSapdpFc217ct5EmFDAcnBHr/hW7b+JEu7Wa4u9PkVA2FVx/rOMgn0Hal1yw0+509LWWxkiitSDEIxs2n1HrVnQfJlWaeCNvOkOyQyfNwOg+laTdOUeflKSa6nAw3XiJdSjujZRKszOjI0Ywvy8H1x71oeG9G1gy6bqmpjzba3R2a2BIZzzj8/6V1HjW5utN0P7fpSW9zJHtMiSc7FHUgVfm8XWNnpHh+/jsJ5v7T4w44U8Dj8e1N15yj7kVroQ2lvcyJrK10XS5ZNF02CC/viHS2kkIDZ52gHv+lZdvqbXENsdQ05Zg8jRzNACDAw6KwrU8S+NtHe4S7+yyXk9rM1orRxcREDsenP8ASqOtHSLrTLyXStWtor141upIlfluxGB1ailfTnT16hzLvYjPiDQ9IkaOCO7E7RszwLH0wcc+mcmsyGfRta1O+nZLuA2kQnZHGPMXHRfeul8M6vpMzQQT6dvmlgFu94V+Zyecevaqmu+ELW7u70288lu0zIY2xkIq9gPeqUlCTUrp9xrmlsZzJaavaaNFbTk6PNKWmaRvKK44Ck9v61N4hksm0S+8P6SfLubQGWePZlTGeoB7nkVYvPAdtLdXSzyPJamMeVaAlFWTgljj1/rVr4ewQnWNYtvEU9j9tVEjj2qFkwo6H17flSc425ou9tRSbWrItB1uNLvw9p1hazLpa2eGlnU7+Mk+w5ql4wu30XxlDrekXTSXEC+U9mijKpjOSPQ1p/2tp0F4VuropFbPtcLyQDyoAHrXNmC7itb/AFq+lhGr6gpjg8tsYQEcbf72O9OEPf5rf8G5DX2Tr/EtlZeMdIW/hDLcFPtELfcCuRjOB7iuVvo/FGlRWmoXE8OpWdoEBjAzlzxk8ZJ561WuYdYttD068lu5LWS2R3lhZiHePtx3/wDr1pNqV/eaNoOsWskem6ZHIDdF2ID9skd+/FCg6asmmr/19/kUrNWsUGuIb+61S7srfyrpJjFceYM7iOg/H09qpapb3WiarY6ncwLKJVMciOuUZcg4HftXW6Daw3niW/1G0Jk0y4gW4iGMIzhuSB68ZrN8Q6vemeC5srZNSgjd5ZobuMHHdSnsOa0jUd1FLT/gbBK/Q6vQNStrx4NU01CwT5GiZeUcdiPyrm0nufEHii/hsrV44I2aOV8EeYWHzDFZGjXfidrrU7vSYII4Jf8ASSgGVlZgBjnrj+ddbrk+sJ4Ot7yzlTT9WYxtMISADzzz6n0rBw9nLS13pvt6j5ne3U57T9B0y01PUEk846ZYW7yXNtMCyux6FSe/P6VQ03w/Olhb6lpVtbf2XtmM6XPznAPynjrg46V1uoeI7C2vF0q+tWlbUkAlYLhS2M4J+tZmjS3heRw3kabEjfuk5BUdV2/1rRTm4uT09QUG2c58O9PvNXvZ5i1osCRSNBFF97zf4Sp6jB9aSfWby1vYU1FZIrS6BtrhfJy8rE4LEnuParVho/2jVID4S1b7IZLUt5YQ5Clj3Hf261b8SXniaKO9tZkt7yKIRmMiNTIBjBkI6jnvWjknO3fo9GiOVmXfLZQqt/b2t7d+Vm0bJ2gkDG/1Ax+oq7H4YttZs4rTwhqrRyW0ha4WaQgAkA/0qtBPqsOo2Ul/qFus9u7QPkfLKrLxwBg9a1PD11FpvhSWWGSzOtSzzIRv2mfB7n6Z4om5xV4vUduhk31ta6nNqMWt6vDdIriaEwyZaIKMMAD/ACrZ03Q7S78E/wBqT3LvaMrSB8YZSvr+VYGtWugWN8nnW/lxvGHdIJcs2/uPpzXfanHHNDYaXaRyrpBiWONYz8rKQM7sdzU1JOKiou1/0Haz0OKvxb3Hh+01Ky0k3UqSpAZHySyDuMflViNl1HxC48QRyNp0S/LeFsYA6Lnp14qG5sLrwbe3n+kNLpc4MUEcbkvGT0696ydNh1W70FLa6YRabHK0UiZxhic5f361rFcyvF6Pr6je3meoeC9M060ttek0IKjRAvJG53HDDn5q4mw0rRbGVbiQIlzFIz27F/vO2eD6+1ReDNcezudV0i7uYILOUrCtwJMh88Dce4Ipt5pCXLaudYIt7XTifs8oIXfJnCjPoeKyjT5JS5nvb1EmtbmbpG+KK7sbESC/tS0rGT5Ubpkj356VQ1m/v7i9vYTcuWRYUmgyV2jjJH0P860NLk1IXltfK+bi6t/KNu3VXU9cfqKj1+aS4kubbU9PM9zJD5ktwzbWyOVXI9a6vtA1oSar4p8ZabqE9nb30wgiO2PJU5THynP0xRVo6MdQWO6ubZYJZI0zGzNlcKAB+QFFY3prRpfcJQi9T0rTwLzRYdsXlWc1s0U1uoKsxI/hPrWfpsF3Z25nktI4FgBhhhYbti5+Ulh3xUljqtgwtba/u5YG+18KB/Fg4B/CofDep6qlzrVncCOe1YsYmdchD2/HFcvJJc2n9XL3ehg6pqt7I11aSXUlteNASob5UPcDPY1i+HfsF07f8JC80spaOV4TnehUkA/j39qv+LNStLjS5YL1Cbi0kTz3jGGU54qPUrRNM8SRtqMqNc3VqskF+5xGCy5TcCMHsDXbFLlta1+3kLmSeup0OrWPhPVob6/lspvNQ+bvGULHgevauY8M61NpMd1AsV2im4RYmdc7g3r74rHa3vr68e2a7eK9i2q1rEcebhs5GK6x9T1S5v8A7AlvBaXHnxsFuV4UjqPc46Gl7PkTjuvNho7tvU6W31+0m+1KLm3MtpneGYAKe3PauM86x1rV7g3257ViuI48JtOeo+vTPeux1bwhp/2C51fR7iN9DkjYanbou6QOAScH0z09K4PwxYW08t3fNbsui29sxgaeTa5boAT65zWND2dnKN/66DVW8bHS2Wm3ujz6nfWF9EbO5O7aV2GMDoc9OKuaTrsVppITWL6F7gKZcg5ZkzwRjrWNe6lI3h62srmwWOC5UjJYkumcDHvU6R6Pptzog/sZzLOn2RGcFkRSepz1OTRODa99X+7oO+l4mpr+oW93ZLCLMmd1DRSOuDg9s1oeFJbwWlxCbBAUTFuJPuNx39MVzI8TTpZX0UkcS3sLNHE7quyYg4AUd+K3fD/iXzZQlyiwX0Kq0y/wEkdB+dZzpyVPlUS20Z2iagIZVufEMbf2g9wwiaBSREo42kCvSNYS1isrRtPYTSyY3H+6O+abqMekJ4WF3awRPqKNuUKPnJ9PpXB2d3dGyvTrVxMhmGY4EIEgHc49Kwa9v7y0t0/yRlF8zNS9nv8A+3IbWyaC608L++lJBZTnpWjDFF5MxCBC+5cKdp2kdeOhrjpLezuNSj0621eaG6bEwCdCPTI71Za5sLHU7s/2rJLdXIAWCR+jD0+taSpXSS/ItM3oNCOjeFJNNsZkupGLSxyXXPUcqT6VXgm1dvC8MEJ06XVIWwsSsMDnj9Kw/wC2popLVr8yyQXepWumumNpjWcuPNHqF2D5ep3dRis2+vtP0q8FpN5rlJTGwBVWj9NxHPrShByk4N3as9iU47I67wjDPLb31vrcQtVLlyiqAkjnvx1Nc2ul6BpviE2qaXGvlttaUuc4bqR7Y79q0/DHijSdUUWFnIqSkNM017nIUdsjtT7y/kgczSQWNxZuDH50R/hIwfz5qlGSm7q1+mw00+pJN4g8O2k0T2QhdHUxp5Y3bVHHX19/erGo6fNqtqs1vcMEcia1DHZjgjk+max9GtoQVsl02D7IM7cxYCqerbq3dfjiudNtxcXBtLa2i2JLEdiqgOaUkoSSW/fcdraHJ6n4v1j7Q1pKT/acGGkVVxhcYAPbFdBf3un6TKviF0WbVYbRozAEBEruBhie2P5VSj8O2mrafdCW+V5rlAsV8ifMyjkKx7jpUtoH0W6Om63DFJENkUE8ILKxxweetXLklpFardLS/wDXYVls9jIL22py6XbXNgv2rU4WuJ50UjawJAH4AVa1TwlF9isyZ5WjtwWBUZIGc5Na63FxJ5tsdn2+GPcDGvBHoPfArSsnN1YvM7GLaAGLH5cds1Mqs4WcdEUkrpsyfF3iHTrO60uz1Wya4uliUB40xlGGBn1+lZHiXUr6RJdD0/QhJaIsYDSDCFM5wg+h61l393dxarrT6vLLLDCi+RLs37Bn7oI6VHoVzcf2jZRw+bdRz27zI+T8gXPBz0zitY0Yxipdvu7mT93QuWaX9vqQk0V/ItBH5aRCTPkMp6Ee4NdnbaWbc/bJrcC8Zd7IjfJIwHUenNeUW2rWA1Vb2WO7srq6lMc0SnKg9AwP1Nd14O0vVtJ1S60rU7r7VZG286CRny27OcAdaWIi0t7fqFzR0DcNMDLaCxkMjs0e7OCT79q5zxJHr1jNq7wshspin2SJMNwCCxA7GtTxFeG3vY7NeksZeS5JKpEfRvSmC/01bCK0n1JJrp32qY2LbGPTntUQTT9pa9+m5pNRfyMuTWfsmuTWj2stzPII5dxACxkr8w/Ac5p9xDNpN4L5ZFntnj+XbnDVd8MeHLmLxHNm/wDtGnpAYGklH+tY8kj0APFaGu340vbFLob3OktjzHjbLqx4HHYCr9pFS5Y66akqXVmBplrdLo8moaKFshbKS0kf35T/AHR9KwZ7y6n0jUrvV2dbueNIJJZDgsu4HaPyr0a+W307Tl2zJDHIcIXO1XJHAI9a5LW4dWXQltdc0HY73SoFRvmVCOH/AD/nVU6qk7tdfmKVjTPhmSfStPihRDaLGh/fPkAHr8359Ky/7Gt5NW1e31xrVLWIme0NvIN69hgevTrWvpl1qUfhXUtJ0iOSS/s5f3csy/JtY8hc+grFuhZXdrJDcxG41oyRvPLbIR5Qzz9aUJTbab08t/USTMsaTp9xa2EVmhe/hLB4ZSSZos8N6cZrs9XutVj0OzhtYB5jLscw/dBHbPbiuM8SX6ar4pl067uG0u4izBFcLGcSx8bd3p/9eur8E68W0+bS7y1aJrTCxOxyZR059fXiqqczip2vbW3qCaTMnXbddQsLOyiuHbxDp0bXIiUEhuRgZ9RWcRqGmbo7/YtpqrK95BgExyY+97E1sR6np8WpWd/GTa3Es/2WXjO9GyM57Y61z+s2Oq6j4rmSFPNt43WBpiTtkVecsfX3q6ejtLbfUNybTdH0yeLULLS7SK8h24W9lz8jDBAH61qix1D/AIQzUdNmghu5ZHUwozZz6/lXNaPcQaHr1xYXgFrA7kzTK+4IOw47/wCNTal4j1CLQCqzpbTNc7YnTq0R7EdvrVzhKWi12D3eu5uQaM+nSR6nLeolp5G14Yvmy4GNq/j+NYS6hYX2mStemSGKaVgAW/eApyMfXpUuk2i3PhGzkja4lFtfecIycFumRiqPizRTa6oixrJNql/M0iw4+SOP0A9ef0px+K0nr/kDOluNS8RarM17Z31tBbTYMcRUEqoGACce1FX/AA6mnado1taXKzieEFXAGRnJzRWDaTso6egJ26Gd4n0XUvD/AIom03VtRRri7tBMj7P3ZZc9+3Sp/Ad7b2Gi3d8rXEgZ2aQS8AlR2+tZur33iDU4r3WZngvTdziMLGN4hxztHp6Vq+OhcW+n6bprWwgt50RbiWNfudyfY8/pWlnKKpzer3+Q4bXe5T8QWmoagrajolikVtqsGZt+DtbPU56c4INSa1b6mml21vq0K6zYuIlDxN80bgc4x0NZxvV0qWWO3eS/0yKIRI8Z4Y9QRnrznIrQ8N6rdT3F1FYL5Wo/Z2lWLZ8p6Y4PercHFX0sv69SdCHwRoN3ceJ7yG8jka7itHktriVsbZAfkXHfjio9VsL+40S7GtJL/bhl/dSK/Kgdj2+hrrNB1pvDtjY32u2WdQkLNvA6LnowqO8m1bWdXmleFF01xvhkUYBUkEE1n7SfPd7d/TsOFm2milpvifWvDOgWfh7UQII75SZpmjBZAeMH145rI8PWdlFeDRZ/Mv8AS75POFwuVwwzjA9Bjmuh8XNLpr2glje9iv5DHKzrkx5AHB/Hr7VnS2uoaRHpunWYD2rTNbzBjnCseTkdOpOaUXFxbWjl/V/kLltsdVa29smlRG2Md4tsCkYBzkjtmquirq3iFdRt9Y0/yoYwHt4/unqcj/69R2Wi2+g6FfWek3UpmBaRpm+baSOOKxFvNVtp5LlbxRP5McEsm/5AMg5z61jCHPflfzZTTaJx4fS90hb/APs2e3fS5iqnJKZPUkn0qK8uDfyGOwS3kle3UtLEQSSvcjr6itiw8Z6rrfhrV9DmtIrdCv8ArjnDoTyQc8565rDtLLw/o8L3FqLs3ltA0LKGzwec/rWsXNN8y1vp1CN7anR6RPcXWkMpeOF4lI3sfuBR39K5hbCDUUl1JHa5vYcJB+8xv/vYHfANN0+R9P0hpIlZ31JtskUh3fKDjA/A1q2egz2nippWVILG3x9nC8Bc9/w5osqbk7/0ipS5tjN0HRZNG8Q21vJZSfZ1gMwvXJJBIyVJ6YHIqC+sdNXXbK+luhJA87LvwcKeu3HfrXTm+urjUbvQZF32zbpRcgk/Mee/GD0xWfdaYtpa26x273cscwlAI+VcDAzRGo73k9WTGLaMfx3PcaRpWpQarLb2rWF/aT2UDuqSMizqc4J3AgMTnsM1X8a2c+rHWtY0+fTNU0y2vFS4msZ45G2H/VnKseSBzim/GXww3jLQ31yziX/hItKiBuIYx89zZjoxHd484Pqv+7XR6dpA8HfDSy8N2U4h1lSLvVQn3hLIoJRj/srtX6g15tCrWjimuVa2v6d/mYpS57WOV8HtHqmsQvdWC26RQPuk5QMpHCj396t2sDatot1b2H2uyW1VpAvJMp3evYgV6BqsHh/VNMgksLwwXRQCZouBkDniuS8QS6hZXuyxuQ+kywGN9nyuzEYz65zivTjV53orPzNnd6sdp9vdLb2dndJfIlxZ7JZXYlYyWODj16VNd60tv4S1GwmtjeLYgW7GQ7fNDHBYY9ABTNL0vxBLp2yHUW+wzWkW0yHJ3qecdweta+gi5txdW17ZwSpISQWAyr4+8PXNRNx1vZ2YWvHzKcF3qcV7pkFpam30s2yOsLLlduOefXOa1vEeuvo1/YQRW/2mGVh5kiHIgz0yKy4by9S/1CSebzFMYhitZMgIRj5h+v51Zlsk1CVpYo3uXmVUlRiQq46471nKKck5LQqzSHeJL8NbKllcxQ3LOPnA4IzzkjoakWw1JrWWznljurOdOD5gBHpg+ua57xB4e1C01m6ubGJX0x41Pl7sbAByTn3o0RNeDW+GAtXAbaxB2irUI+zThJfMafNuXr3RdR0mbzNLsN4ujtu0nk3LIvsc4qLxF4Gu4pItQ0pmguEjAX5wiqvoanmsdVtHdPOmMMjFgVYlQfpVk3EeqaPJprrcrc7sYdyEcD26g0uaatKLT7ha5x/jnSp0DTQWsYsDErtcRfM3nE/Nj0BNSyeItQksbR7ixuYWsZYUW8iQ+ZLH1ww7/UV2fhvR0tyti1xImmSsRcwzANn0Kt25q6+oMmtTafa2dxcbFIiwvDKB+gx3odb7Nr2I5V9o47UbmfxfrIikH2D7Lcf6Rbs2FnjP3TjufUe9cnqtwi6jK+hacYBazlnkc4HmDpwexAOK0xZwajJeX8txdw3pu97wRn7qKecMeuK2b++0q6sktZYgJLhiyBhy23OMgdT0reK5LJLT+vvFa4RXSa1BHpmp3k9vqnltchbFuANuQrGrOl+K3Glm+uU8vU1Q28SMCRKFIxwe/vXPSW9zF4duX+ztJqBHk/aLVdrrEOcH3/mKTRniiu7LSvEJluoZLmNbe4jyjwBhkA5+vIqXTi73Wn9f1YS93VnYz20Wv6Lp83iUm22y+ZCYerZPQ/Wuc8Yrq0t7b6lBczXNjdj7PJBISDCVOCDj6ZFWV0/VfCOrWlu7nUbe7uHUISSFVf5VbjvoNfvFs763eGJJRcBFBGeORx3+tZwXK+eOsf66FPWzL+p6691e3PhzRbj7OsNnE0V67dHHOPfPSsfVNa+ya3FpVpGh1O5iUXlxFHj5sdR/OswaTPquua1Kb5pUsZ/tAt41yWAB+UN+VaulXSXUGnXd1p0Uck4NvLNMcSIOgGff1oUIx217+tggmtjK0MXevWsseoLYm1tYZQ0rY88vztJPXH+FZdjdS3enaZb6nc3Fq5mxaXSDKoo7E9xk112inSdBs9fviztA0gXYmH5H8P8A+ur/AIf8MQXVlpsRkElggkvWjf5XJIJAA7DtxVOsoN3Vl/wLitE4HU9QntNQv8Tw3f2W7RkV7fH7wcZGOMe1bdjrt1os9jbapYq8moTeaZI+FCk9OfTNOtdYksdMjvr2zti9xK8jIibWKg4U/X61Zn0Iy6bZrd6w02ZfNhM2ARuHMYz3rSTWimtClG+xz+pRWSavrltc+W1q9wii33ZkClshw39PepdQ0zTb/wDewTHT9SCEW0MowPkP3se9XPF+iG7ja4gsJpbtXRGnjXaQqjqfp3/Cs+DXr62k0651XTre6MUDrHezA5zydo7Ht+dUm3FOO/8AwCdVuiDxVevnQ7ezsJYZLaHMksJIE79ScV6BZ63bTM+qzSRNc21orGCRceWfTJrB0i6e+8Py3dkwW5aFhJbIMtBzlsdwCvQ1jzTL4isUh0+YRxQx4uGlXBYA+vcfWplBTXK9LfqETeHiCzu/38V15aSfNsCA4J6j880VDpd7okVhFGNGtTsBUkSEZIPJxRS5UtOV/gWqxB4e0rN+9npt95JtpBcOs52KSf4QO5xx71owXM9/ry2+pW9wbe9LxEHjZHkgH8xWLepdT39xqcKNc6c4WWI8K4IwOQPSuq8OajYz3Vpo/wBuae6fDpOxz5Z7x5q6l7c2+n3E3srjb+x0u2806bpVxFPZQeWFB+V8nG/3NJolmDZMEuIZNQRHbauN5OPlBPbBqzqOr2Gqfa0SW4WGw5kkCcNzjArn/DomTxPqt1bae72rQv5bqSAwyCMGs4qTg76P+u4lsVLX+1rm+tdMulea3S5ZJ4yMtHnGST+P6V6Lpd5LpUF1pqLDNESRbjqQAMY/Oql3Y2ulJDdWdo8K36/aLgbzlSR90H61g639vsf7Ov7KN3uImZdmNxxj+IepqJP29lsv1HFRteRJFq2orp18mrQukZDFZ5Bjym+vpWHYQX7XsOkwM02orH9tRy3ySKcEAHvxXbXtomsaPLbXitCssYEiB+QSMjP41keELq8vvDxtHWK0udNkEUUhi+cxj+Dd9c1UalotpJf1uKV1sV0s20TQbsTarDJqGqsPLkYkBcHkE9vSsDVNBv7GMLfyrNbyWrv5UMw3u4OQQO+K3PF0c2p3ui25tRMRJ5cnkgjOSP0qXVNNh1fV9Sh01JrLxH4aIP8AZ9xtHnQZBWWPk7kOevuuetL26puPO7OV/wDgE7aM421lurzT1S1uZLLT4AMrJyRgc/Wu0l0eTw74fttVkjEwvYyscjnhgRxkevNY1pp2p6RbWa3cKyWd+7SXcL4baT2B9McjHeuu1+5vJPBiidWW0scYUgHy1IwDg961q1G3FR2b/r8Rq5maO1xqKQyysgdJMICNoxXXeKymh6RaXFqJtQnupRDMQu5UB7jH6VyN6lxqVrp09iJPsi267BjB3Y6kfWuqspL/AEvwtd/a/wB1BJD5iEf3x/8AXxXLWV3GXnsVJuysYt9fS3Whf8S+xkiu2lNuFbPyr13exrCh1C/vV1CRbjzJII9qxgYGOhwOlTS6xreqzW949q0cMVwoWRF2eYDwfrVtPM029nVLKJUmPXZjdz0zW0Y8itZXBakHg+XVP7b0/U4SEmRsb2+UgD1HcEZBrcvrKztPE9rBrMU1zJrl1iGdPlCbjli3vzV7QdV0vTb+dXJeZoyqKfuhzWRZeJdUl1hUvmhl+zMfLSQD5T257VlLnqTcoqyS9CXzdDrvFvwp0ePTd+n3c9mkJMkkW8sJfrk8fhXIeJIXazshZ2ita2qeXIkYyfqe/SpTrmoavdyy3d1I0aFlQZ4DL7VdtrW9ivzdxOywzxNnA+6SMHPvWcPaU7e0ldocU4K7dzlLrzbmGGwsVmt4mK3Eb7jtIAwQT+J49q0I9PlvPDus29/d4AdfKmzggL0JHvVbQroaBNd6Pqu7z73j53BVB2b8ataTo6vYX9hc3slyqEqNyYK4569TXRN29NHfv5lK0mU4Xis/D2mSa9dxyRlmjjniJLHByAfUD3p/hmW60jxw1vdXJnnuYVeFVPyKGIILE8DCjk+lJ/ZZOo6No32JbnSN++YsPmDE8nPYDiuN+I3ju0j8beI/DcllbaUTetpR1aHcfs9lv2v+7AJL7BtyP4SRjPNc2JxUKKs9ea//AAPTzMpvl0Z3l148/tCykuhp8Y0O9vnstPYA+ZcwIArznPABfOAPcfw5OP4i1JtNvNDkgv8Ay7YvsaPbyy54yPpWrdXsDahpWn6PDA2gfYEbT5Uw4CrwQrDgkYIbH8Wc81paqbODTtLzDa3VyQWbzEDGIg9M44Jowy5IQurt/wDBHFWj6nGaf4q1S1aeEq2pX0FwAkBBUIrcYz37Vs6nrd6/iH9xHZSWSQbmjLDzd2MkA9znpW/oGspdeIfMs9NSTzIizzSIN27HGfXpgVynhXw2dW8cTHTrxJJYd0uxyQwIPTH14ro9xtynG1kO9tTovBuo6ZfRXEomm8yTAMDc+S5P8q09F1kz6/caVZh28jDl5V8sHnoD6Z/OuU1HTUsdfxbzrY3DlzdwEklnzwfTk10mmi6JRp9sYjXmTfjI9Kwqwi05d/6+Zpq0c74ytL+HWbm8gWFYJmPmwrFyrE5yD6V3NzoulX+g22ux2Mbz2UO8wIvVgvII6gmub17UWg0o32n3MItfN8qQbcnd2G41Z8NeKdspWZ4txUeZE44Ye/vSnGpKmnHoNxvrB6nIXeoaisd7r2kWrpbPCFOnsCWikz1x3GM1YsbXU9WsNW1TXIIUgs4VuoYl+VshckZ612ev61otuiXFqrJcMctCnzKVzycVw2p2niK/0me6uZlk04BnMFqcGZOq/p/KtYScle3L5vcTu9jIsbTUrm2e7sNT8iC5tjItvK+XRyegHXnHWrN/rWpwWn2e8ghRlh23F6EJOMYwMd+gqg9nfHS4dbt3KN5PltbKcyIqHv8AXqK3tMuX1mSKCKzee0uLN53Zz8zMFJ2+nUY/GumVt3rb8CNOpyvh+9uLWGG4062uzNE/+kTID+9jPY+lFjbWOo6ktvdi+hjmkzDIx4JH8OPfpmuy8H69Dqdu0N3GmmbF+z+Wh2mQFTjGe4xWTJZtpV9Yx2du+qRKZJGnueGi44HBxjvmn7T3mmrMFHTQZokltpfhLWr6K0JJuxuiuWyi9fpzzWxrt1bXWj2t7LeHTZXtwEaN8qCRwOOcHpWZNrNj4i8Oy29pKunx28oN0s/KuCcA5+tXtT8GRapNp0z3yLaR2oLRwYCSyD7u3PAz0rFtJ3lpr+gtjJudaEOiW9s1sLrVIIxIwkTcPLznj14xUA0ptT0W/msmjupoZftEcDMQ0SnlgccZrQaWLz7rxFrNhPbT2WIEtkPBHKjcO2KpaFcahpeqRxWBhtlvHSWIN/y1B7H25PFaq9ny6P8Apl3vuadl4nkutTshaXsT2wjke6WTMe2Mrgj6jtWNDbRX3hCWwaORyt2bnTt7DMwPysoHfgA/Wuk1UWd5rV5HDY2zDy9jCHAX1YcY96y7i90TTGtJxYzSPZfurRU5HJJx9ealLS8V2J5dbkVraf2LpdxrlqDd3NwBbz20bbfLkPUce1Mt7WwXVYBppaKyRAl7BKxGGPQj1wf1FWLceG5dE020Y3VrcXMhuEIbcXcHGGP8qr6qm3xNPptzbfYo3G/7T3J28FvbPXFXF3bve+oI7+x0bw7a2scU4ieUZLM8nJyc/wBaK8TmS6vJGnkjLM55ZJMA444oqfqc3rzshqNzuPGNtp2lvq76Pfs8F3FGwC/dGedi47e9U9CNx4fstMuEst01/Iu2YHHlnnpn1FXbqKyjnsGgslnsLhd5jf5yoUE7Tjrj2pmpzyX0Gnanr8ezRIyIxb2WOJVIxx2yK1XwqO68/wAinpZFixme3WW4n0mQxajctbXC5O1RjOR6HnNbFtc3WgapFZWF3E2im2kiKffaNmBKuPxqPxlNcSaq9oNSjttKayjuw8uEY9wCBznt+ArI1W2tj43sIWkDwXlpEjeScorEdc+nes0lU1l1X9fMV01qSWBv5dQ03TLbUZJHsvnuDI2FbLZOM/eGCBWprCnQPEb6hczyKNTcQi3YEKmec59PSuTtdLiv1vZ7q7ktzY3Sxh0+ZpB2+g4rYGu6hHfpY+ILYX2JeLphlY4wMq3/ANeqnDX3de/5gkLdo0l1qWq39w8ETKIXijBO5uAuO2OM1c1y5j1iy0Ox0y6kt7qYvMWwV3KnBz75BxV/+3tLlu/7EhYXN1OQHG0FAc5yD34NdDB4es5Ji97bbzFEYkkjODGp7LWE6vLZyVrbfcU0tkcTYTjU9B1LV44WWTTGVTHvPzjPX/GrPiSX7X4bs/FCXSabrejW5ntb2cfIw532sg/jR+QB6nHRjXS6zNpvh/wg8NokIuGfaAV+Z19SOh7VlxNeah4Uv7fX9D0/VrMbZoLWeEcnb95WGGU7cgEEdTXPiYuvSdl10uyZQujA8E/E+Txxf+INPi0y3sbeDSGu7dD+8fzUkjL4b02lsDHQckmr738upRm3uIZBp8iLGELH53UD5/fFV/AHhfwbpPiTTtetbjUNEFzDNbXGny/6VA4lidCokADrgkN8wYccnvXS+Po7P+0rSHTnUxWtqgJQ8SZ6k4rLAqpCTp1Yu/cKaa0kZ81nfy2FtIreXCgCbVO3AHQ0y816VHXS7hzdW6oA+8bth77RW7bso0aJ7pt6MAgycdPSs6/0u3kuJZbeMjccSOOSorqhOLdpo0STKd/4mc6RNLaoX8plGGXoM44rrPCKWR+HlxJclWnDNKoc5ZWbpz2rnoNEEkc7Wav5Gze0jYIOOcmqFtdr5d0ovGTzV8tYtuAecfy5olTjOPLDuhPUrT6dLDrMl1MSLYDzGYc8egHrTTEmq615dhHIxn+ba/BU9/yrT0GHM7o5t3hCNvIc8jHXmtrw6dHGkXGt2a7IraNgrN8uecHjvWk6rh5vYfMcmlzFazy+QgRl+8SSS2TzgdvWto6+9xo4hQDzYpz+8LYwmOAar2g0fUb1b2xkKvHJgxSJ198VWuIbdp74bktYVcAM/GD/AHv/AK1OXLJ2a1Qb6jb65j1rVIbbVtNWWIMsbNGSsmwHI2sOorpvFWl3axx6lpCvFaEYfa+SG9/wArmNb1O70+/0+DSW/drGp3YzvB6n6VYsde1BltPs9w8sSTYlhC8NzwCPSocJPllGyXYm2t0LbrPfaosi3TKJSI5IiD97Iwwx0HrWb4p8HeFtN8d694h1FP8AhJtQub9547LmO0gVmJBkPWUjjgYXsc1s6ytqvicfYnaC+No8jqhyi7uo47+lReD9MNtaPa6mQ9y7MAGO4kdf51hVo06vLOpsun9egOKnqyp4o1oiWLVSZhK8CRwWpG2GCMdVRRwo47VqJHcahbQTWyAvKiyIGHO7HSsPRdLutQ0S8gv7s/aoLttpkwxUAdPp/hUqXVlrGrabNbaoYJ9KHmyW75RZdvOVIrdxjFKMOn5dB3tHQu3l1YeG/Edo5le2jmxujVcl3x/Eewyax9Jm1XQtZn8QyWXkM8rh5LY7gI+vT39a3UEetXT3mtRQvYbhJbF8DaMnexPpmqmjQw6Pe6za20r3sVyBLHO4zEVB6ehPOKSdk01d21Jtd2XUuNDYa/Z2/iZZzHA8rC4SRskOBzn9DWe2ryJdazYalJELPYs1pMhBBUj7vvUGr6gqeFNb0y20QraRL5sexjwWIDN9K0rPwnE/w90m4kiT7S8Az83Tk7c1K5Y/Htey8upfvRfJLRmLeyXEfhexs7Wza80+7uTPdSFOcjoF9BjvV/U9JtSNS17w3cW7ttQPbSPkiNR82BWL4jTW00qxglkEKxSlIo4W2+YvHb0q14StLu08TW9kNOmP2tmheVhlY0PPP9fpWslaPOn3+YKL1kuhVW0t7q0jnsZfPkyHC55XPVc+tdbpsepWempqEEnmxImw2w5+Uf1rnZ9CuPD2uz2tncW10lyhdADgBxnFSeFfEM1roEcmoyuzNcskkg+7GOwPvRUvOPuaorn7nSeH5dK1G6mnQPGzctETkKe+B6U7UfDK3GoSzaGJIbrbiELJtVeOuKyI2sRqpSFvJmZhkpxuzzkduat+IdWuNHuoEtEkuTM+GQLgxj1BrncJKa5HuupdlYg1nR9P/wCEc8nXfMM8KMXkgXD5OOR64xTohqFlC9npcFve25tUNrM64kJ2gkMO55P5VY8D+Lori8Sw8QJHKkrMQso3OR3HuK6Oys9Cj1GVdk1vaSlmwHIbGOAP/rVM5Sptxmr9fIhJbpM86lnt4NAvbbWdMTzroB41iURscHk8DtVzSraTU9JFlM6P4fkVZLVGO2WJ1IyPcHBrqr3w3b3tjHm5Vp3V0hJY7wD/AAn0OK4O58L6iYLPSrG+FybRpA8TtiVQ3AAI6AEfrWsakJrR2dyWuu5p3qzaNfaq1wscyaicQ/MGCqo4JU/XFLoWm6dq0cG2PF7aL1Zsnax7D27VkaXaXsejxeYWhv8ASXea6ivAXDRAgfKa3fDupWbavA2lWEn2W+Vnmuj0Qgk7cfSrn7sHy79/68hKXVGL4mto/CUcE9inmOZCuJm4OepxWNFH53kaON2buQXgljb5Y2wfl5rpfEV7BqV9HDrNujWQZpIgBhkJ4xn+lc/pHh631iXVMNdQQxSI8c45OAcbdv8AnFbQbUL1N+/5fcVMjsdE1DULa3vdRlNglsxjtDHEGAYNkk88c967DVdC1SPS7LVFDahK+fPkA+Yjr09MZrK1mxuItPi0rRllawWYTtdh9wJB5X6VUfTtV0mGPVb3VLkTwTvNFbgltyf3SOgz/KpcnKzTS8rE6rZFZLzwqVBjgnjX+6UJx+NFULi4sLqZp7fTvs8T4IjDZCnHP65orbk9fvGk+526peW+kQT6PZRXf2SQOUlOAIh97+tYNhqyx6jqGpWUsN1bXpMUMTptjR85VcHgEV1HiiG+e3ik0p0SxhdpLnY20ZX+Fvbjp7155dNJPpU0cFrFD5jC5tbaLjPPLj14qaKU02+pM3dmtqWkalq1lJqV2ry6y2ILqMYKiPoMAdDwOlaKeFbGDV9NaG7uo5Cm5YgcrkDBG79K1PBNvbRaC1qdQJmus+ZuIBWRh0p2kRtYZ0PT9015CjuJZV+96gHtUupJXiun5f5IEkSx6BAIfszXKtZEeazBlC7s9Cf/AK9R65ojarqkbfblh0xbXZMsRGXT19/rWDZ6JJceCtQnhgZby7bYyySFQV3Zyo7Gtnwo15bPLod/aCFbCERiQEsX3H1PbnIqJcyvJSu1/Vxx7HPWz6Xp15Oba5SK3CKkV60R3pjrn+Vd1deIJ4IdOTQok1CW4UFpiTtZOhx2z9aw/GWjx6V4PRLa6jEjXG6aSVQC2T90cU67nur+1/4RzSooYc28flzoNqlx97ntTny1UpLVef5ivYu/EXSXuNR063KFRs8xSPU9QTTNEfUrbS/Jkv4riTTpibt1Yfu4uu0+p4ra1H7XF4d0yC9xPPHGEmkJ9OgB71mXtjZeHNA1aZonlW5CSS5bOWPJBPpk9KyjK8FB69vvKbTitNTC8Ta0l7p0VvbWpgtpVCQttwRISSxP4fzrZaS10ywSzuYZGmWFU83jkY60t/ptvc6tb6gqrHaGGNvI4KsSASR6UyKW6vLvN1bJJ++2iJo8/Ie4NaXi4pLZai3Vynq+q3kGlaVLBF5uJ2UcbgDxjPrmtO9mhska8R3ecgG4thxtLD19Kj1i6uorCaPSEXdvSNTEM+WCeT7emavXOlOjzJDLFN5rh5WHIYegz1xUc0bK+m/9MFuaVlNazaZEsDrEyq2UJPzqRxmsG+soLaOKayiMvmnadvI5HNaFmUFzOqOmAuOBjtxWbrl/caFpNrO0PnxTllRwcBefas4JqVo9Q2KPiAPpccK2zFGlTDuefw+nWrWgafbXGk6hZGdfOuUSSEKflTH3v1q5q0llrapbW0sbuIVaUKcmJse9c3JG1oim0nEjgs58nJAPp/WuiF5w5Xox7q5qeEtHitL+RmuElWM7nC+g9KXxD9k8aWr3Hh/dCYpdkqSDALY68dOKl8Nz/b7LU54z5NwQY7RcYwpBGSPqc1j3NhfeGZYrO3lw0wV5nRdoLe5+lTrKo3f3lt+pOrL2gx3dt9lsplWRoPlUsvQE5OD3GKuabqEFrrtzYaXavPcqpEkj4VE+p9e1Vr6G6utQg1K0Mktsi5yhzggcj86pnUm1XRlsEjW216V9zhRtMu0nGT247UOPPr338vUGjeszaWuq5n41SeEjaOi89z/SsB7O7gjuLu0uDMIrncWzhowaf4kL2UCRSRGTVPLTzSrcAd+nvWjofkW9svm58+4O5x1A4xikrwjzrW/9fcXFXKPhW/sNJ1N4tRmWe4upvLY4OFdhlSfxrPvrK9s/GJsraKJ7e6UhGCY2Hqct+H61u+G/B8V9qlzd3zIXV1d4HJwGByrZHY4NLa6rBPql9o0l1A1wdyxhc5HXv6ihzSm3DXTUhO2iMnV9OW5Dfbrh0MlqIisR+VSG6DH0rXsb+TS5tM0zTbUnRktDJJPMDkseo9OtU9R0+20Hw3Gl0Z5JhPgyLxtLdx7Vq65A+o6K1u13HDGIgiKGCmRiOi/Wom4ySXTUpRV7voYmlW949xrrvdRPFqkB+ywlsggdCPyrX8GT6k3hKSw1WGSFonYRSnng88D2rktF0q7l0zTprxJrCWwlKKDnLJnOcduc812tv4q0mMoJVllmyRhR8horRbVoK/6W/wCAHK5e8znNV06S416N9Q8yXTtNgEiyxsN8jHn/AOtV3UPFBuRLf6cqWV0rCR4XfP7rocUXNtJb+JY9XE7HTHQJLaKMkofbpx/SoRBpk/ifWLF7aNbRrYCKdc4KMPT1FP3WlzK9l/w41dM66yltNVu4W0q2gun8sS7oAAApHJye/tXG63rWkaY1zpLafJLC8jSEFCpMnp+dd54Pm0Hwjp1vp2qTxw3CkiI5x5mTkfUc964jxbcK/jGDULW2njhlbcY9vUdMj1rGgk6jVnboTBt3TMie8umurB7/AEgRRSsF86B87R/DkV2M15Y6jaXMdgC99bHbJznAx1/+uKrz3lhb2Js4p1AjLyhpVzgY6fSuP06KCzu47/SLpIY9+ZZJD8hUjkCuhR9or2tbYttxeho+Gms4/EEVxqNo3nwfLE/ZSeOa2tT0qSXXUmMzNbuQX/efd55x+FZl3qcV2Ll5YYI4UXMV4M49s461jaje3OLL7IxuobklA8ZOAR1GD1NXyOUubZ7A2kdbbaneW+pXltqEaJZQNst7ndkzL2J98d6hlItdUN8issUq4E6c/L1JY9iK5eyl1S80iO9tprcJHcFfs87AOwx0T39quaPqLSSz2F5pt4kcuUeRVDKC3r3qPZct2vmNT+4lvdC1hLy21LTZhqEciPExdsB4m7Nnr3p9xdanodzeSw2StpFvGnlxJjKk9cdyQc0zUta1Ky0FtH0qWKOBGEaT8iQEHoc/0roGul07RbC41QPcXJjCS+Sufm98+1KXMviSd9ESt9VY47T/ABk02mT2WpPE160+2ANCFCEjI3HHYis+PUS7QalfXau2TbPa52puB+9x2IrqvFuk6ZqFjHc2ltazeZkvIn3kfGBu9DWNqHhiJPC1l9h/4+VlDKZAD5rZ7nHpW1OULXta7Ek+hFpn9tweI/LaKS4tY1llhigPyR/KSoOO2cV0Gg6dPc2OnjUJppNRvGZkjVclQD3yentUfiTVNV021tL2zihGnCHFw8XDA9Dz/Kq2j6u9pZT6nfabMy6dteCYnly/VSO/BzxUNylHmVu39fMUklsxNc0jSbXVbmHUbu1S7RsSL5m3Bx6Y44xRSXWpaZrdw+oz2kMks53M2zGe39KKpRqW1Wpokv5kUdZa6vdc1X7DdvJpzhHa1jJUsH6HH8zTtFsGt9T0qCSBJZ/KaBwrbiqnJPI6EZrQubZraKS6urV7OARhYWAw7IRgAH+tangI2umWSxwQK85mYCSZsvtYZyMdcYrSVTlhpr/wxlytmBNHo51iIWV1eWt1AxiaJ4jw+OGz3yeKua5Z+IbGDTzHPFHLFyLhnAJJ6g+o56V6NbHQ20a7nsBbi+f5pGKAszr0bnuK5I6suqaz+7jj862Q7opVyrDGdw9DmsoVpTe2i3uCV7l9J5n0WIWZE10qKFkPIyBgkA/j1rNR7yK6h1q/uHVYl8udQhBkXGP61sWMyQ2keYWaUsWYMNvX0A7Vb1VIbvwjcKhaC6nkAyByqdxj6Vip8rtbRsp2sYkENk1yBIv2jTWhAjWT5gR2/wD11n2cF5qHihv7JuxbwKpKqx6DHOB3Gaf4igurDQ9DtNLnjhhZhG8twdrFSRgD25OafqWlrZ+JXtNNk/0m1/eEcj5T29xitoNWbvvf8O4nZ6FzTrPVtNgtJNavftKIZIzMoLIVHQsTWe2mXeoa0kd7PmzYBmiMv+tjz94L6Y71seOteW50nVk0y4uPPNnDC9m2PJhwfmZCOrHOKxfB8iNoZu7+V59bgiaAqTzFGD8o/IVEHPkc2rPbYmLb0sWbFrO0muokklNkG/dvK24gZwFUD6U7Q2lk1KXeZZlPPzZGwc8Yp1kralZSIyJGyuGViuA3qDWpEz2FzZxTFisqli+OhyefeicrXXUt6OxzwvrmOa4iZXW3kcRqVHQHt71AJ7ux1lFlkdIw4GSe2f8ACtrwtb3Oo6552rsEsYtwiiVcZ/2v/wBdU9fEtx4hgtrWHMMmAjBN2/nrn2rSMlz8lumoNmzKkLrdQgKHcMkUoOMlumfbrSxi30u1j0m6MU0VupuGYnILemD0IrAl0+8F5cGZHlhj69gxHTbV+Oya7hvLy6Uxxoi7x6cVi4JLWWgrXdyKKDSftk+t2rywLJGY57fszH+6O2etR+E7CGxmvruWZoljU4jcctn7v1puhXWnm3njvICLZz8vUtkf/WrQNpZy3IgtkJWVFCtvJ+lXJ8t4O/8AwAsY9lqEdojTRjF0ZTuZjkYIyOKz21S91BL6W/jZ0jBlRlXoRxj3FdK2kWl1Y3VvZXcdxLC+GCnO0jjB9etME0OnWcjTKwG7Yse3JPHPFV7SN7xV2NamZYTNPo1i+mTJa6gsvmeXIfkIPGMfhXSWZ0u1mN80dvLrjqI2KE/fPcA9MD865+PTY7af7QJVlQ4CIox1wRkdvSl1O0QXsk9qWDFR5ilflQ8fMD25HWpnGM3ZP+u3oS1cm1nUUuIhD5CrcE480jnGeRVa4uP+Ef077ddxCaQMsaIo4+ufpWlpennVL5ItmZHyFMpG1cfeJPYDGST2FM01bq8lutF1izluIppQYTGNxXBP3SOtLmilyrpq/wDgFNpLQfp1rLa+INQ1u0mVrW7sCqxSMQA+AVH5isexuLiCK51LW7CyRlYyR3ESgPkjkHFamo3Nk0U2iadf2sl3bhUWCKZZXUHOA2DweDxnI7gVlaDoBvLK5WW+S6HmYaGJ9wRl5wainKEouTem3yHBqMubc6LTtUtNW05RMUlR8fupB0PYkVj+JNEt9WDxWLut/GiBN8oWNWzztXrnHem3WsR26i2VkE8ALTlVHA/uj3FUorO11WOO8dpLeWJ8ptfLMeoNVGm4PmWiKb5l5mzpjX+reF7rT543W9so1RmcfNIoPPJ9OK5jQ7fzNcFk8vkurn96wztHQjBrca9vo5o50kdiXAKMfvH3Hp1rRuLNL5ZngeOK9kQ7Q2AQw6c1XN7O6ez/AAZKVlYzdKv3s9X1HRNZKTWUjotvMByMdOntTtbv4bXUobPS4JJrsMIpSykrs9Aar6Yt5etHb60EsdQQMgfYNxAGBn+lXPA+pQaHDfJdSNOHfBcc9eKUo2vJavt0fmJKS1RR8UyabeyiXUmM8OnuEZojh+cce4rvBrEcZgVY0msN6KuBzHERxnPWvOuNT1zVoLVoE09ufs0i4LjpuH86z/Et7MbW0kZlhbTpUilgTI3ADCFfbjn60pUFPli/6uErPU7yzggutbuPtWmZgxIyTNkKijmueu5bC68L3DaJZoZIpmTYwwAMjrjg57ZpIvEOqQy3WjRXf2ix1uUvpUtw2/yLgY83T2btkY8v1yo6s22Ww8M6jpt7ZXtrG8umyN/ptruB2FgwXK9SPlbn2rnw9VSTc/da0tft/mL2rk22ctd67Pp/kWzxW0miyx7JrZRkhupG7saqi/06e6tY7gyWFpaFZ1jjyShyASD3zXXS6ZpzatqmmW7OZI9kkiOvCcZ/TNTaxpLXWrLKLaGSxktxCzbQSRjufrXcqkOnX+vvNOTm26iR+H4X0nUtauLlbpUuBcaftXB2Z5yPTnNPXSHRYdf0+5nQOjS3Fvk5OAc4PTms/QYYNX8V2FjZ3c9vBaNtnicYU89BTbTV9fF1qC27Imn2eolhGEx8gJ49xWTUr8qf39trGTTTsU9Ijgvm0th5otb6QxMZeXV88cf1q9qmr3EFtcWupWd3pxtpRDDPKp2sc8ZP4Vu6eNN1mxuJXaOynjkMkSgjdEoOSw9AeKn/ALK1C907V7bXp21PT7lVlgYucxMMkHHYY4pTqrm97p/Wg+ZrYyNGuLyFZEubZVnliKrMnKtnoWHesWW61nR7S4h1CA3+nxkNHLA25w+e4rqvCsj3lvAl3DFbySqUSJif3qjjIHaszTtE+y63fzWF60dvK+G3Zwjf4U+ZczTRatJaBYavoUumPaXTypggyRyAjDEjt7HFTPBrlolutn5d3ZmYiSJnBDIe/wCFPS1tba9hintojNPJmSdBuEgyMAdhzW3LqH2fXtSt9RjSG1WLz4p1XHkgAfKfUGom7P3Ve+uv6C5raSPKrmHQbe6niV9QUJIwwjDA5PTmivSDouiX5N20NtIZvn3iLO7Peit1i4pWdxOld3ucppd5Hr9+NZ1q6WCG2hI+woC25VGAQPTnn6VrwXtp4eNtNBAbqz1Fh5UuMbY/QD1FYIka+uLi6CRRXjyNZlMhUMPsP6iuqsYo1vNPthGskViu1IXQkKDkZB7+tVUilvt2/rzErpWQuhLY3XiGEwl7VVZiNz8YxzmphYwXXiq/uNLlUN5TIJkYbTgdfSsjxJBHd3sV5NMLC1s+HVT8twDnaVI6k96x9I0MjV0to9STyY1kkkTfgqrDn2PFCipJyvbT1EtDfg8XPY6SXW0SfyroQyzbhgjuc1o2HiS21jxfZ28AlW1SJlHH3yy5BI9jiuLQ79Kax0gNeaejMLsMmGDtwrL+VdHpFlcaHo93cXzxJqixCO3nc9QQNox2IonSppN21e3zE7sg02zsdQE8F/qz3MmnXbbVU7lYNjAyenIrX1XU7VfENybfzTftBsmULuUggDA+nFc/4ds9R0+3v5ZdKbULyV1kNqs0cDSrn5nVn4yOSBg56Vpp4t0KDUXTURceHdVmXZ5WtWT2r4/2ZBuQj3YrXNXxFOlU5Zvp8hNpWTKd1Ja+HrY2Th3ur1zgsASAOOfSrvhjTobK38iORHnILy7s/MSO/wCdUtK8QaJ4v1TUNG0loTrWlebFbLvEiapGB80sTd5AQxwD8y4I6GltxdRTq8cmPNPlh5Bz0z0/Kro1o4im3F69TSMlJaG34O+2SaVcxalCyXTTkwq6bVA9j6ZptpNfxXJttYOyEBm3suQo7YP1zUOj63ftcTx6vFsjhhLI237wIPFWdP8AsQ8OwPP5hNz+7AJ3E89QOwokmpPmW/b9BJFyx1fTlS7ScMkIQqX6EHpWTd3TackKQzfu44wUcjJcE9BV63tLSOSaBk+0nbuzOPlJHr7VfuNN/tGxUeVE8nXMfQfT0rNOEJeQjP1S+ln0iF7UlS+AecHHcCqE1zdQeHZ4ZpFa5ZgW3HnZ7j8a0YtPngmuLW5jzDEQYxnuff8AWsea1urXU5XeAsGyo4yHHp+VaU1HZepXQtTRR3sNotrKqOkRkKxj06/rVLw/qy6deRpeHckhAUOvI9eewqeWaDRNREkKbw4w4ByPfBqK/ijuJmS9WcSOdsJQZ69h7dK0STXK/hf3hui1ZC0ht5RpLT5uJyZez4xxj2zWjqFnBqWmQxMxFyMMzjnJ6VlWUE0NpevCUNwqAkKc446j8OcVH4XnMsnkqWjk8gsyk5/eZPT61nKL1nF7CWhLBM2n3ghaJndgSWJA+UdfripnLSahKmCttPGCGVvvgHoaYLm2vZTYX4b7ShJSUHABI5BPoeM1DYpqQme9dY4Y1yGIUYHptx9OtNrq9H/VrDbMP45eIrjwz4YGi6ba3EOp6xDvv59p/wBHtj0iDY4Z+rDsuAfvVg/DTVpvFfhq2sPEev6mNNtnXTzpumosBmXZmMzzA7mUhSoXHRDyDyfVT4p1FrMQ6fq+oSXMjqM+e3yDdyf/AK1UINb1ufVtQ07XJBNbOpaEzRJvDDowbGSefXvXl/UZzqOdR3XbVaGPsm5amRqWm/Y20iHwxp9nZ2NsPOmtrUbcuMgF2JLMQCeWJPWptPvbS1uUt9Ni+zxzMGZuSXkA/rk1JFpV6FuvsqibYmfkYE5I4DVykV/NZaUzzW88GrbikLOmVfnkgeo6V6tOnDk5I7L9TVpR0Rta7K4uNQtksYQSQ3nP3Hr7/Srq6DM15bpYyRT2btuWdSAT3K/Xg8VN4e36j4cuRrciF/MDxggrsHTv+NV9UsZLSxs4LC4KxC4+0Ryg/NuwQOnahTafItH+GwNtlWe2j165iWJpLaWGTyUUSZJJJIyvvjrV/X7CXS9TSWRZEVkBJxxkYzg1n+HpjF4ht7bUFC3E6GNJTg+Wx4Dn8TV20TV9H0W4t9Yka6t2n8yJmO/BwfXtTk3GSSenb1C75ihd3cOp63Akbs6TckqM7Sq5Iq7pFnHdSeWq+VFJIFLH+EetV9Jt9Os7DUNT0uKVL0ybQG5VVI5x7mtHwzfJH9qM3yLFGZGDD72Oq0SbUXyrYq7tc0fF2k2+j2CppjCadRgyryVB56isK3nW6vrWDUdPSVXtsmQ8FnU559xiiG+vrlFEpZUn+6oG3gmmLcXVrHdR5MjMmAmOVOelTGEoxtJ3Y4ieO/Dl8nw7urfwtoja0bt/OnSGTfJZurArKqA+YWHzAbRgBjkkcHivhD4k1lrHx/e3dzc3WsRpZ3rm4ZndzHPsIYHtiUgjsK9SZnDRWFrdMuqR4mRAdroMZJB9vatfV5or3Sb9b6O0W/u7T7JLqDR7Z8ZVgCy8thlB+bP868qpQl7aNVu+q+79TGVLmfMjl9Ujtl8PXmsSBoZdShEsjxD5y4PT2FJp9pNqcGk/2RqJWdbfzJbeU4ZF9ffNdHDFZz6d5TSQzwR7ZJsjO9EHzKPTPWsOR9PsvEtnqlj5zC8PlRxpggDA5+gGK74Tdmlvr+WxpKT/AAJ3gtdQLLabBNO3kmWIhWVv9qrPiTwR4j0a2tjpN2t2CoEiheTjtjv9a5bTJbRL7xJPaxO0aySyBVPdDnj65NaPg3x7eabqifbHlvLHbty2SUB9fTFU41F/D1trZhNylZplOLQm1zxLd+dC1rG0PlGHBwenA9Oma7TxjqTaR4UGmWUDReZAqCTePkUYHHvVTXfFPkXJns9OWYOuVmjGCMev51BfabF4n8LRSwvJDKZGaUNzn6VnJuTjKorRRKWvvFLSRqOn6bY3t1ax6iIkbbNG2X2noo/Wn2/iizGuppf9l3EaSZD5TBXcOp+lXwdR0/SdO0+0+ztYxoRNcE8qc8cfSsvwjq2pXmvXd6yrd2cAKjeoyR/CR37VVlNSk0uvW3oCuloU31axbVZ9Avt0M0MpEUkgwT/tKfeul1WG31azaCUsLuSIQGYcB1Hdh+VYHxGifXLeK5g0rybzzV2SIhOMDqT+lTeFdVt7geS8hleM+U+7j5x3H1qnFygprdGialbmMvTvES6PZpp95e/6RbFo28qIsowT0PfiirUmkaPJLI4vvL3MSUEo4OeR+eaKv929WtfT/gD9lHuZWgaPDcebp+25GqQQmW2Mh+U45IYdqvaNP4lttcnMbqsltbKxSUDy9pxk56d6y/D89x4fvbmXVnmZbiFjlVy4LAYHPXpiuh1W4RPhyZZIZFRgoMe8B8en9a2rTfNy2vcy1tYxbyK41C9m0S9iXyS5uI7hDhFY84z0x2qvD4fj1TWLiLStQMF2jAzynhAnQgH1zVLUpbufwxGqebZaGjq3znc7N6j17+1bN/caTe6L9l08yWtzeSIfMdcbsdyR0BrRc6Wn4dPUR1uigW97PZ2NlBb2sMgVp84LtjHNYNnb3ckX2DUnYXkTyTIrjJZcE7f04q54I1671cxRXtmWaOQorcFAFH3ie5681m3Wo6pqkmq3EFxbWEkEojiuZPlK89Acd6wipKTT8gs0zVeW11S6g1y0862aCEW08WchM5G4eop3hqzS08NTWj363MF6ZWij1Jd1rGyqdokUhhgkAcKTz0qK6uYik1hpCn+15YFEqqo2XDDqw/Piqs/9tWVxaLJHJFEqqxRV+X/a6d6UqftIODdk+/YHqrHH+G/hHo+mXkF7N4wvLm8tpVb/AIktuIzA45DebIwI5HZD0r0W78V2niB550sWge3Kxq0zhpZpF6ysFVQpPcAYz6VBpVxpWqSXF1ZwSRzSyKkxbjcw9AKp3ccKXV7badArOZPM5OST3wa58Pg6VKTsncpUeRJlibxFe3sy22oWqsrjYrIu3APH41LPpcQhRrO5TfYg7o2bGwnnkVPbz2puoEmkRZdvzIp6fj2rOttMistV1KITNKup4ZHY7ipHOc9xziui6T91W/X+kC7DYruZ4HScysGOWGOq+341cFxPJpyw23n27LJ+8RGwSvsR70qpb2jvBPG0sjERNsGFTPP/AOs1bgtYbCNnBbagJwTljmlOS6L0Dcdp15dmwVr5SJ03MSRyw6DP4Vnfb7y61kWsqbYmIKMOdvHWstdSu7vUZ7ePzdjfOC3QegHtitR5TY2byxkeeeN5zhfwp+y5XqtWDNBzax6lBpN5EkkUiF1Zx8ysM85/pXPgm5n1Seefy9lwPKH+wowSP0qaO9R54ru/jMlzBEN0hbnkHB29Dx/Oo7aSzeS4syCyywO0aTHbtlI4BPp2pxg4/wBfeGyI8mMSFN7rKRIpVsFl/pWjbII5luQybki3ui8MccgfjTNHul1RY5prZLaVF8qWFAcIyqBx7d6W4ngspkTYZklXzCydFXOB/LmiUm3y21GtUJq8EdvYv4jkQfYxJH5cKsPMbPBGP61D4yjup7Cxk04SRwmPfJCDhlJ5G6tG48QqulwWdzaIJYZAzyxAHCg8fjzg1iQW2pQeJARcrNazEjJfIZTyMjsaUFK95dNvQSuWvCcklvKbiCBTcxrkZOQzY+6PrUM+tXWr3dut06iRSWPAXy8e/p7V0Mvgm81e1sp9A1S3c6dcMblRkNuIB4xwT2rLg8NXOq6nfQ6iwtDMfvOcFM85wO2KSq0pSc29fxQKcW79ilpjJ4Z1G4u7CQ3v2yPe/mNhdue3qc1la1f3M/iy11NSUkiw0SN91AOcCp9Ts30uXTG0y4gv9PiJYyleuG5AzyOlWsx30s13MLaO2L+V5k0mFTd0GTzxWsVFe/v5hZPVog1nXJLpoxLB5eG80nb8pzyOKm8h7wMIJhMwHzblwBuPVRTPEWny6MpQh5lDAMz/ADDb2I9q1/Cklsum3N9dwkx3EwgRAduQFzkn2qZSjGmpQQNpK7MfT7W51fStVa3hEOt2MimKRM7pYwMEc/zro724uX8ORuYds8sYDYyQpC81l2XiqzaG4vobZ7VNPk2x7DgyKw6H8q1NS1+51Pwta3uh2rM4lxLFJjgdyP8AGsZ87krrS/3CTtK5z9jdPbWiwSLvLnOGGMitnWrSKylTUrVop/Nt9zQ54DcA8elMurOG6vLZ4pgrzrwh5IxzgH8/yo1eSPTwAqN5Ekm141XLFSBnFVKSk1y7s1bvYqaNqt5qlrewqsX2jyS8ZEeNh9BVBdQ8rwk99euw2XKxqdpYnHUe3NbfhmZZdS1KweGK3aOXZGduCUz0PueKL21g/tTUDdNDHp3CLZ4+UKT97Hrmpuk3G3Zkc2vumLbX5tfGFvfRwM0qWahZWJO5WzkgfjitPWJ8zlWfbGqho/RifWm6tbCOeGQlTbtHtjVWwQPr6Vb8NwwyXRtpFM6jkMwBAx14NW3FRVRLY0typsi01/JsJpHDCKUqhBGMjkHH50kcqzajodrYxxSQWccruwIJRDyxP4d60tKlvZL3Uxc2Dx2US4iZl2liDyPcEVztnaafpmtJejz1FwHtXVTkbX4I9sZ4rPWXNbf/AIBLV4t9jd0WKLULK5Xw0bc3024olymzeCORnvxXPaZp8Gl3yWWq7bTVLm3d5YmbMaKD39jjNX4reDw/4kEtxJOtjHIGRlOcoB0GKz9PtNN8RNqd5FeTXM1753kG5+WaNQOAOemcURb1ab5X1sQ276nRWuqWVhqsOnToJLi7ix5a8qwPofpVTXrjVdEtRJYxmeKWQIIFTICHsfT61javcWZ0jTb18Q6nYKsG9TycdStX/EHiETXNjtvp4IYjE/mKm7PGSrAdcimqTTTSv3v5FObluixrEl3or6d9hdjp0xDOjqMKe45qvo+tXsVndl4DEBKzRhYxGGUdeg7ZrqNLfT/E2l3VvqMavaQ5mgJbDcdq5/UtchsZHinEIsgCFJOSq9KmHvXg43fUEtfQi1TxHr+oaZYXGjjfa2crG5KMGAAI4bPYjNWdEgtJ7u91aMfZ7ef/AFluyj923XOax9Bu1gtdaTQUkkFxIJXIG8FMEcD8ajsrfVIYZk+yyLE5I4G4MCB1H1rX2aScVp/wdRQV22zov+ECg1Qm+glCxzkuoB9aKh0fxJa6TpsNjfRyi5gyj4B9Tj9MUVk3iU7Regm532OW0VG1LX4BLffabOUktNEeBt6KSeRWh8SfKtV0zTxMQsIadmYhSR0H8qzbW5TQp7e9g04SWGcSsF+VnHVhUOsX8viRw15BbREkCDf8ssiZOFBrshSkqilf3RN6WFs9QVNFg0m5USx3TgoZgcAt0xXb/wBh2ujeFYjq9ql5OrEl+QEB4ABqv8OdSsb2O4k1LTLcS6TtYZHyjHC4966STxTDqVtP5iefCqtIYkTBkx0xWNec+bljHRPUHK72OV0vw8mjXUaxXjjR5rUytbvJ+85z2HoaztU0l59HltLFJLq3kvFkYMdrKPUZ6+la8DJq86+JL6N7NIYSixJyCgzzz164rFvdb0TUY7SVZpbANIwEUYzxnq351cOdy/P1/rqF09yc3cUXjC7s1ube3t4rNoI5FB3RgJ3PdhUsNnLBotlY2Gv/AGi6M/nQsGI+UjBU/wCBrV0yPTbeS7fUhamCfEFvI+N78c5/xrmJZdCtbiC502O4uFLlUk3gIXByE9ev86cfedlfS3oxPRnQ2V5a27TyXsBs3ifZny9m4n+Kqdpp81t4nlFwF2gMQ6NkHj/JqzapPaaXeS+LTbiS4lMwQtnYOwB9a19Fa0uIHvzEyNOgeKOT+HAI496yc+RNrrp/w34m17rUwoNON61zbCWGKcskkbk5AA7ewxWvrXha6i0SOSwlWVQfmdXwvfp+NZf2uSzjE6xqruxVif8APFdBpt5PcaZbliVVgW29m570VZVI2ktjNx1Of0K8ge6kOPtcsSZa5Jwqn0Gep96b/aF7Nqd0twjralegX5dmOv1qfxoBHY2kpuIrSEXCM2yP7zevFP8AMuEkkQS+fZyw7kC9DkcH1FUmpLntuC0J/wC1rLStPiu5o2ZWwm0Abh71D4hk+32FrFp8Ymium8wyDgBR0NZ0drPLpsr6hGJYlkHysnLLnmtaFBqBtJ9OSOKCHcpjXgcdBUuMYPmXR/LyHZ9SoLW0VfKd3kurmNU3Dpkf/qqlLpskMRlaLF2RtXzTjC+uD361pQPc2cKyXMKzTl9kYGAV4rP17VrqS9jHzpEVG0ccjjOT+dXDncrIGTak+ooLSCyFuS8W2dwRknoAfTjp61ThguJbyztHXbIVOVTjKk8j6Gs6/C3d7eJJa3EFkrqEmDlWZwQeK6Ua8bm6DR26tchQqyKuDjp1p2lFe6hFfxPYwp8sQQREhZJFO5lY9RiqWp3CaJBZw20Ty2zLu+0MMl27j2xUsVzNb3BEkA8uX5j5o4Y57fnSpd29tera3KB4pCrtlsgZ9BRFNJJ62/EZeXxbe6NZvNpcvkW1nOkkymP/AF4bgH69a6J7qyihtNSikaZNQDyzTXGM8rkKAOn/ANauDkv5rXWruDXUEltLnyo2j7j7p+lSS6nbTM9ncSNJAQRGsaYEIA6n2rKWHUtUv+CTyXdynDeKnnQzFRaux2sg4j57e1WNT8OXUfg9Xurq0l0+WcM0j5DA9itFpodtPYXGy5V42wq7QeGPTINabasiE+H5LeC7tY4U3Gclc7AOFx0PvW05apQ6blSvbQ09O1LT9atZrJNri2jERLDqQODk9qj0nW7bbLpEljD/AGfaK0Yutw4ZupHrmslLS1tPEbXenKTbT4Bs4myQQMFfrVRdfsbrw+IrjSI4YFvRFIq5DYwfmz61h7JPZNp2+RD6JmxpctvcatqenXdkG0yKLzE2r8zEYxnsc1pX1hG+mSW+nymATxjYpHKH+79KyNT07WdSt7SKzuxpkEcgV2Q4ynY+vSsmHW9R0a91S21Cdrm5Mn+iD+AgdWH4c0uRzd4PXsVrc1NK0a40axhurybzbiFsxpn7v0/OrF5Z6n4i0yCOxZLTZceZJcSNhoh7evr+FQ6hBfajp9lO6jBDbkY7eSPvUagt1FYWaS70gHBAOBx3P4VWsmm2ua5fLpY1/FNnbarqhtkvkju7KBXkkhAZptvOT71yOkG71PV49UkgYWhZ1lDEMpIHy/0rUj0eV9Tg1CxuVbaMNt6sD1HHXpV463bRRyW6Wy26RkhUQABvU0o3jHlhr+ncnls/IhcKYhDdOkLof3bbcjHX8qr6vKujaXPeKDJKcITE2M5PX0xxVOC4nm/su/gWSaETNBdwP8yKmchvyJ/Kty01W3u5XgsIEnDrJtTAwAvcfSiSktvmXzXLPivXJp7S0ESON0Ku/HJyorDiuIZ7OaW4wgtR5uAOD6frWxrfiC1vtGlhtt0l7a7fM8xRk4Ht1/Cuc07VLLVdOjtVVVa8YQMEH3S3AP4UUoNU/htYenLZmnFb3Oo+DrpLmWG8vJmV7NSyqyluBySBgH1qv8OrWxvNEgvh5rXFkrwMXUpJDOM74ZU5wQeh7qR0IIDG03T0W70ICVcReQjk/wCsJOSPzHSsvX57jwrb/wDCU38Rt3d47DVbKScIdVi/hljPXz48Z3dxyf4t3NiakqS5ov3b6ryfVHPK8bNm5PdWGqaPNBeW6Ce3OW2gIQfQjHTitPQptL1HTxL5NsLqVPmjYA4Ucc/lWb8JPFdn4n0XWdRbTIIFttTVHjPzu0E0Zx5jH7x3Rn0HPStLwZYWN9qmp2+nXUUEqozpM6ghsdAPanGtCrTlKN0kaJ80eZaBYQ3cVxDusY0spC4nbdsC8cHNcgkFvqAv5rmFrSwtptkk0v3ZRngD+fFdXoV1ql1o9z/a9qHg3Mj7chWxwce+Oap6pJZ6ndadpdnareaDEfNnlDMskbEYxjvW8ZSjJ/p/W5o5yjstwR4fD8nm7BBbyRrHAUbI2nof1rG8FXFzLpOpafDdzR3nmusEs5yME9c1aNml1dwtebjZW26OOJs7UX0Oew65qnJpel3Ol2cXh6/aKGG6dpPmPzE4+4e9acqtZ7vr+Q3LXax3+meG7+Wwge8aF7gqN7FQSTRVOz1i6itYozI8hRdu8gZOKK4pKrdkc0zlb/WrrV/CFpDY6Nvt55/KaMgj7uPmGMdarPY2GoT20d0qQW9iott3OZCRwo+h700zLeHUYBrrYtdOWJY8MuxlxlgOhHuOeaksDCkVsbjVbeV0t/Nzjl+OM+uPzr1IpRTS0+8zjG6bNrwvol7pVu1o1tHJa+b5sjDqxxxkjr7VleMZrXTkSxtnminlHmI6A5jA5we5z2qxpWpapp2hGK61GOTU7lt0ETNztPTP9KsafqV1q+qS/wBu6XaRmxHl/aGG1hIeM++aztJSc5bfmJFDRtTm1LWrNo97280Qjmhk5yMY6dMcZ49as69Yvp7oDo9tcgtiByuAqnnGBVX7fa6f4zhke5VHkgMLGMAor8jP4cVvQaJqesaM1rq87iaKffbXIOfMQjJ/CnO0WpbIq9tCvf6TJJf2s3lq8NvG1z5fdzj7uPrxWHY2BsNJ07ULrTEtrgXLSw265I2jnLA962NcezsdSbVLmeWGSxT7NHk5EzbcgkVFpXiHU3a3t9S04TwywSXMkrphVwCVweg6D86IufKnuvu7kt6j9Z1DSNZVo7ozPLZIt5LgjDKcZWqU+qXWoXbpZ28iWflLJEwU5Axxkir2j2kGoeHJJ7a0Rrq4RkeN1wZ8fwA98dfwpukDUXWLSIZDph0795Pv5ZkIzjHp2x70LljdLp3GpWB5zBoN47KlxcRoX2SdCR1/KtDT3eWxsREDF50av/shSBxVd49OQy3EYkZJGI8nOe3PFXdCv7TU4N0OIvsw8sx5+7is6m10i5bk2s2cA0WaC7Tz4/vgjqD2IrmLE3V+kSIkspiHlqBxjB4FbGpatunNq6krJgFxxjngitHa+mWbpDOvn5J3kYJYjr+FKDlTjZrV7BsxbmySyspmu5wVcEONvQ+1ZiWoGkQiBt8Q+b5T5ZOe4J7g1BYXMVxHLD4nnIiQ7om343N6cVJ4luFlsreC4UQODlUi6BT0yaIwkpKL7/Ii72HT2YSKO5uL6Ioi/M7tyrY4GelVYpJYNOs1mtI5bifMgZkzsXoP5VasNP0vUYWs9Qhm+yQKLg5baXIwMH25q5I9xFrzwRI72eBGihRgDHGT2xT5rPlf+Q72ZnrKb0Qw3DrIxYZXA+TPp7jvSS6WbCO7mX5lGFXacHHXmrCWA043M++JrgDJZm+7nvWTc30sMKqHSeO5di5c/dx/I043k/ceg72F1a9e402Bo0wT8iRk/wAXY5qLUNNgj1W2iEiyOkKCZx0D4yf1/lVmBJ003LwFI1mw237+D3FVpEMUCXJ85HeXaxJyQAOp7ZrWOmkQtcv+J7C0nktros8krAfLn7orP0X+z38R6tJOJVs4bciQE53HHarWrq8g0qH5hLLGJHwMYBOOlT3Dw6berb21pGYrrm6aUn/V9CT6d6yTahy9dSpbIzrKZFtLe7s5GFnODLhx99gcbfrVieRPt7TzW8MUsWAATlvbipLF7N9Pew0yM/2eAzwu49yefTNUvtKTWSxShxOrHDdcL2q0rvb/AIYSv1F0mP8As3UBdIDKI5PtDOg3D8a1NXntr678p7G2jaaTzdikBWOM5/GofKgs7CK6ubxrayeURttTLM5HI/KtW88NWp1proSyJlDGPmGIjtwCtZTnHmvIV0mZGp6ykWpGO5WdTGgConQHHpXnyaxe6r4lt4rSPchmSISOudpLYrtX0+18OCK3vJvt9zPKJd2DmMDoR6n2rD1mCXSNYsbKJ9nnXKXLBRtYjcCP0ranype6Um+R2O38am6stRgsrwyfubfczRpjc/PYcdhVJNUEmkwWt6vmvKWDNnGB1/Ouw8eWravNMul3Cm4dRli33E75Fce9jNZ6UqXUa3ckTfu5cFQB74rlozjOEU9yYNtIS92aej21lJK1wVDDGRx/jVhLWLUMJbktcKQRJOh+bjlT6/WmC/tLqza4v4XWeBo0Kwnghmxk+3SptT1xIJnNvEAVXZGwPU9s1p770S1K3ZR8L6cWudWhluDCIYG2r/CSM5Bo8KNZQ6vp0mjGORoATdhst8jjBIqfU7a217QtPDXH2C8hlZ5WQH94OmPp9an8EeHUg1VmggjtwS0eN2WYdep7VFSorS5t+34fiTLVMyLC4tLXxZqNtJazRQOrSLcueCecHHTaaraMLTVNHv5LeJdPu4OHKdG5yCPTpUHi5b611ieeedbmxJMEPlOCHwc8/SuoNoX0pktwtmjxAblA446mtZNRipX3t+Abu7OS0vUU+3JPCZL2O0IkEbjBHqffmtm7utC8WeE5tQ8XaKL+3guWt7URjybqLdz8sqYyOejBuaSLQxpps7+3ube4t4IiZEU4aV+ccd60dB8T26Q6ak2m+XcXeWRAMrnP3ue+OazxEYVl8NyZ2luQ+DvCGheFtD8RLo2v3MUetWsTR2OoxhJ4njfI+dflb5WYdAaTT9H821mj06TyWZTtkYEGT6Gm+J7cCeO+upQwl5DZ9e34f1rodH0s2NlGJJiwlQyRDOVAPXHp0rGnTjhqfuPd7FxXs1ZHJ2l9rNpusbmdY8oxVWz1x2x3PStuOzg8NwyRajGYr5kSQMJRlkJ6Y9qLaOeyvJp7hI2RF3KzY654NdBd+FrPxfPJqtt5s1y9qkbKW+XjqOelaVasU/e0i92u43JxaZ5u2n6q1u/9namb6JrhzKr8ZjI+7z65rZ0WbTdP8L/Z9SspbJrFmZm2ltysex9elY+pwX2l640OiROZo7XEtsxyGO773pmui1TULe28LQ3OrKxmmKxSRqnzA9cHPHFaVNUktb/eCaerMe+0rUrq6afSbuI2MgDxFpcHBA6iipYvDUzxK9vfTSwuN6sX25B56duuKKOdLTm/A2XJ3M64vikVrreq2aRm8lNrN+62BoyAQyj6fyqxBbyapb6zJYadZJZQRC3t5w/UA8nJPUjvVaS8k1OIrNqME8Nx81naSpuaFQMYz/CccVqanodlHptho9hffYprn960EjNiXI4yRXS3y2T0fz2/rQ4+hQ1fRU0640e7toft88xiV1SXd8oxyAOcdqnub68j0+/u9a0+UpJcKkUMQ2liM9fbpWTbfYGt7kRXJsdVtkFtHcSOQjZJ3EenpXeajFrUWhWaWE32tmgMcrYBLHHDj39KmcnFpS/HTzAxYNA0axsJru8ikLXJLtuYZtd2CQD61euvEk8Nzp+leHbY3EQRFLlt3yDvn6d6ynNtZeGJdO1GK4mhijM11OowQzHIUHuQfX3qKDULEaI8Ph6Ga381PKivOhPQkZPTr2pcjl8Wv5Dfc2/GsdnHbyxBEuL+5dZLe1kHGR1Pv9KqM+rRaVNfX1rGZlsSn2YsFUfNxx647VbkW2MFlc+IHN1d6fGHkeA5JbqPrnFWbuGDW9Jm1LynEktvu8pjwAORkj6VkpcsUn9/+XyDcx9QWXW/DHh280NooG0lW+1wRybTFMDk/Xj60mn6la3mtXn21JUvZbXMkjNncFHQf57Uzw9odpeJpV/YutoWmbz7cscSv1z/ACH0rC+MXjjxb4U1Czj0u80zTJ5IT51tbWcDTxBSAJGfaWVXyMZIOQeMEVlisTHDRd1ffya1/Ejm5NTroLQNZpdwWl01spBlmEeERe2T061XEtxFqb6xYm1h014/KnJK+vUg96p+Edb1+4+FiXPiXWL/AFC/164NwiXMzMsdtE21QF6LvfecgchB6UWuh2NtbzLq0ysJULQwwseW65J/SqwtV1qftZq19lvoaxfNG509jq3huS0a9vjIkS8CVYzgH+6adrn2TU7GC5slRV2rN8xIDdufwwa5SzurPUdHn00WDFIgGUI/G7OAc0X88qXUYg3RwQxiFk52gDrj1rVYe09Lpr8gS1NWLTIbq1WS6EE6qVxs4G4dzVvUWtr65SKVEa5Cc4Ht0z60mnmNNFzYZALjJIwRVBrVprhbhmYkk52kEjb6VO8m29guaulw2N3E9tfrMsckaN5kbAswVunHr0qldeZDqiT29ynlqTuQMB+B9arWgnsrUQ2kXlGYsGycsT0/DGc1X0S3S2mI1DDuXI35ygGOAR6554p8lm5X07C03KtjY3fmald3buhkGF3fxtuGFH0q7DexMLa2uLeOYB+SeGDk9ce1aGy+ur7Vn1i43WCbpLZhgYOcgAehHFR27Ibq2RoVPn8MSuHXjk5/Cm58y1X3eg0aPiie1l01hHIFKYA2DJYD0qlZafK9paBnXyWIkldsfy71laZqNn/aUmnJp9xFDHufzJnBP5dMU/xTpf8Aa+sWN1Z3iQGFQnkljhx17VCi4Whst7jV7WLxvNM1rXpp4JljEUZEaSNtB2Ln8qy7cy66bmC5ZbSC+CrA+QTgHJXPvWV4js9Oj1J/LuGgWKEZQDO5zwQKr6aXuTDBOxBsZg8aEEZB/wAMVvGkuW8X/wAAb7M1b9X8OXsNrEco8W1ge/bHPStDR9OnU6hbtEgJXMFy3OR3HvxU00bagrve+UzbzCnPBHqM8/jU/wDYc9xaTLbT+XtjIV923HsTWcqnu2k9eordTM1PUdITSpNH1uSWLIF1FNCuSjjj8cikfUbnWPEMulW8kiWy2jBJTkeYxQEO3p/9eo9U8PXFl4ct4tUtvOumY7G+8du4MRmtO4vf7W8O6he6KDb3cMHkMr4XYuQTz9BUvl+Ja+fT1Ie9ylpc16mtJpdxGsqWVsqJKy8lz6HuOf0rpdR8M2NzdpruqOTqVsoVEB+Vh05HriuWj1qxutB02C7klEtxm3muo+GRhjDY7jkVq3FnPp/hlrW4vRcamcy2qpklYxw3J6n+VRUi210f59wT6Is69B9hZb+0ZlmvW2vhugGMKB+tVrae8+1wQRsQjvxvGVcd/wADVDSNRe58NR22pl8mUhZX52Htz6VUurPUbSJGtZvNiRyrCB8446/pVxhZckty1sdXrD/2TFHNbaaspc7JQD93pjOK4zxLe6fphdWEzTMu6NB0Uk8DPtzW/wCH9RurmCA34KTP9yJj820Dgn+dc7PNptxNqNnqsglnD7ocjGw88ZooxcXZ9Px/4YI33Nqz0uMWF5rjXhlKWuJrVQSyZxk+9Yy3Fw9peT6dM94hUKojJzhiB+HWun0GO0vbS5vYme1vbq2NvGRJujlwMf5zWP4Pnm0uDVLOW1Fs9vIFZwmGbHWhStzPdqw4N3t3KllpNto15YxalP5llCwmlDH5UY9se5xXW+LbODV4rX7DchGLhnR22rsPPX0A6VzF5P8Aa2nkWJBFMNkiuM7x61JYwFWi6zNuGxH4HTnNZyTnJVL6obp6kt/otyLm2kjuI5LaK9QooO393k5I9q6HVdT0x/Mjt0iklhJRGRceUM9R9RxXLX2pawl6y3SoLfnCRj5fpVHRhJ/aLiJhtnzuJPftRKLlZzewKHVm5cmXUtN2vB80XDMo6ehx71t6hPLbaUPKVv8ARo0j3Zyf881nWclxZXEk6kwF9qsr9D2PNQyW95Z3888E6m2nJyVPyn/GqlFSaXQLakeotci1jkPmSRNhgzjJJPVTjriuh8K3PiTS/B+r3mkrCAiMymY8DjsPas+QHULN7S0uTazNkSSScyMO+B/CPpUOmRvZaXNYw3UstuSRJzgMfSpnacORrqJx5tGQ6b4sspdR0aTUEX7dOvkzMsfB9CfbNbHi1G1i2JhREkUhjwChwOnPesi2tgn9tzzadm1srZVti8Pzeacchvqap6K72tjNLelkUsoJkJyT6in7OLfPDp+oRWpUsvEmoadapaXFpcCWLIO5Mnrx+lFddbhDAhjugUI4LHmih1YX1ig9mu557bx6Zo8hnt/NvJnjM1su3ALE4wR7c1Pql5LqmmXG2xm/tWxjjbzQeg74HtWimoWGlaFFdWUJe5mI+xO8WSmeDkfUGoV1e6utUk/s+7ihklkSOSOKP5ncjn6gHNd2rd7bdWZt3Kj2+raxJZzDQ444TAGlI53MerfWr1vYaq3ixEhE0flqnmEORGVXHatvxPbyeHtc0y7mu3ZIoiotgcLz1P4n+VSeI4tZXW3vdPSU2UVuHGOBIxXge+M9KyVVtK1rNOwDNVu2utYsLaCW1isbpX8+ymwTI3b9RWUlyLaxOl3dlHFLL5j2+zCwoeRknsaomS7+0WOoeJLZFdf+PdsbWLZyM/StiS7TXNKkeK2aK1ui/wBrZxkRKp+baex4zS5OSy6D3RN4ZhtLKa10i5uBLqEkBl+Ubkx1HPfisJLyfT7vUrJp7iWwibc0ls2CTjhTnt1GKdoGow2+s280MezSbRAkV7IMEx9MN79a03mtoprnxRdx74oCUiWADZcZJAz9KqzjJuWt/wA/6+4RUs49ZnMcfhy3jtoJDmLUL5x5FmhHzS+X/wAtJM8LngccHORbstPi0Gx8RWsNil5BJCxurq+k8y41N2+8Zec7eSQo4HXJPzVT1+BVja6v5rtdN1NEkW2hUlozwcY6ACnXGn23ibxJJa28c9lc2iqolY/61AB19D0rmlhoVKntamqt8ltf/gk8qvdmk2rSX2o6FZ2WhLFpsNtFAtuxLNHEoCqAx7dTnvk1WbTdQu/E06ata7IGkPkyQkbBjoD7dBUNsmrXmrvfXAYTaahSIvkCTsBnvV3RIodBink1W+KS3I85YByR7AVryqlHlp22tZXZa0NSx0xdPh1BrVEuLiQh0hLbVwOuKyZ7VTN9pAljW6X7mMmNhyc+1assMSajZTJqKefcK0iFzyyY4wO2Cazdb0/Uf7AnsrECS8eQSnDjJX0BqIS1u3uUmaUMQt7BrdXWS4YhyAR057VPo3lHzpntjDtByCchuOtc89onh21srx4pbq6KgeWrZdQevHfFN8Sa7NJYMmiXAF3ty8e3L7cZxik6bm7R1v1B7HStHFKpit8pJt2ne3A/Gsq4sLeG2E+8PLGfmKAYJ6fSqmhDUNU0p5tRgkimQfKdpUuO5wau6XFb3FvPa/aI8OQdvfpyMUWdO+u24jLje5u9aEURYRSIS6t2wMj+lTfaJfM+xSMIFhPLj5s5H3T7Vr2i6doq3d7PvECAJv8AvE5PQVYtrW2nt57i0KSLdIXV+uTjjPpzTlVXbT9RnKXOlanpiCbT1SVZsgrnPynqOag8F2Uv/CVSi+VZ5gMwqHyE9c+lb2lp5WnTRXci2/OR5j8qemT6CqHg9tP0nxTHpsU3n3FxIFad/VuQP8+taOpJxkt2D2uT2Oi2i+PjFds0oWYTvGq7lKnBIJ7U7xhLpdr4zmkt7YC2mEYRs4zliCw/HAqfUtA1W08dmW3Z47Z380yluD3x9M8Vz+sR6jcxatdXaCVFBjhVUyHJ+Y4I4+UjpUQalKMuboJau5o3dvONSWJIQYpCQrnoPQ1006XNtpVzJbw/aJIk3xoOjt/nmsfS9Qe707TmNsftDqok3cbeOtbY1eSG7WFTHEoyqg9c45P0rGq5uytsN7aGT4VGp22l3yavObu6mnWbyi25oeufpn0puvazYadoi2725tL+9GBCIsnBODuPeufi186NZ6vBLLJc6hLMFjEXJLE8Dd61K2om5gx9iN5qGmyqGMx5Td1Ix1Awa1dF8/M1pdeX9IhLoakekf2dcs00dvDpPyyAMAcNxwe+TV7Qry08RMZ3ikWW0lIhbqNlc1ezNeeHrv8AsSOaT7XcgOmeY8DOcj1rotTS6tfD0SaPEIp02edHF1xj86mavo3rt/w49zL8SXlvHfx6ZdW0wti5ZZemDnj6ikYx2scNxHKY4rjdujU7GHHBx9ag8Ta5NZ2lgl/ZtLLMu5SDhlx1JFTywWWtwNf6ZC0ksSpGy5+8MdVHtWkVaKvt+A7i3YuLPUY7qV40LxbgxG7B2gY/z61TNpbXN5dXj2585WVhkYAYD07jJpfFv2e78NQsJLjMNwsI8pch2A+YZp2sXavZN/ZbtsIWNZD1THBJ9+1EbtK2+x0UnBS97VFPwyjWt5fJcxGGMTFB8+1drDIIB961LjVmubj7HqNv5M+4pkHO9M8H61Pptraapc3kdy0stuttHE244b5f4s+pNZV0LWRbGdX2z226J4iOSMkqc9+Dioqe8721X+RmrpiT23kX00TbvLjbC7ec47Gr8NtvkYzNhXhaRGJxsZTyPrUngoq17qD3wADqCpJzuO4EflzV6f7BNDP9iR2mJwhbnHfI/KodRrR9LD3djn7u+leUNLgAc5/vcVFJDCjxXh+WNTuYg1naJDPqmoyWROC4LAn+HHvWvf6YJNKnhDDMYyWzw3NXaKlyvcu91ZE8t6dce8MTFbWEDCM2cZxzj9aZazT/ANmyQSiRpd42Nt4Qe31qv4Rm/sWxuflUvcKcAkE4HfH41t6Kjvp0sgdYywOWduhzVv3E1bRWsZroVmsXtbuC6eQ7JAUDjlh25/Orepu1hskmK7kUAbDw2OmR+NXbJYoraG3mKum7ezZ6Vj65b3Gq3qTW0bG07S9hjqD6VEZc07S2Q1ua8HiOX+xF025UmOWVXEgHTviq/ipLZrS28+YRYH3MZzmsZNRKyssiqkUQ+X/aPSneK4muNRsiWLW5jBVByT7VSoqNRNabsdtbo07VFNuhh3mPHyk9xRVawu4haRgSyqMcADpz0oolGV2Xc5p9Rlk1i0uNKMDrlYYbQkHZx02n0Peur8P28VnkNZ26+JZS0qlMZUHuB0zXLpZQRSXOs31oLeJ3b7CF4PmNn5voK1NBubvTYlaOwGpa1DMIi+/PlqeRnH4101VzRsv6+fbucb1H32ouVurXWLKW71a1XdtkzhiW4yB2GRVx7bVLi3ttR1C/S2WJN09qz48tc8EKPasjV7bX7iK9urm6WzZnc3MhX50UcjB6kZ9KfdyafZWX9rA3ery6jCtttZCoGAA7E/hxU225fw1/4CBi36211JcXmoX8t7YyXANpHFwYh3z6V09tcWiXh8PWEA+xyxlpxn5sOMkk1yMepxWs91p1pZQvaqn7gyA7mkOMc96ks7e4e5vgJvI1uVR5zLjZGo6gd84olTvGz2X9X+RSdtCPxJLHpuovoSRPewL5ccFomV2DruJHU/41uXGkXEerWJSdFghtnVdPxwwwTnHQ/MeTUnhq+0+4lttR1G3WC9k/0WGSRzunAGC2O1Zmuanfi8vtS02WBfLkW0hPDNjq2PfPWo95vkXT8XsLQet5qENs62N1Fe6l9oSOSNxnyk7/AHv6VfudRu9SsL06FGILiGXY1wwADoO+T6VXvrC1uNWd7yeJY0j+0PDbn987YHGB7mrMsF1d6vp9pG6Q28UDNeWsRJUA9Fb3IpS5X73z/ruHUrK9l4kbToft8k01tGfOWAH5mB659PekibT9X8aCOWSZLm2UKIpULCQKOuen50usadFplpZXPh6SPT7yaYRBWOPMGfmXmoJ9cik1bU5NNTyr+AASTSKNpA4OPTJ9acby+Daz+QNdCDXzaXXibVBp1teC/gt/LiB+6MdSo7VqeDI7iXw8RrrHz5Q/k4bbIQBVnQdH1CP7XqMuoq9zNb/LFtyVzzwR9KzItcsY/LtbjLCENJFdEnAc9ePTNJ+9Hkhraw1qN0iDT7vV4bV7q7GqWyecTztVR/Dnvwatrc+H3tLu1VXmmju/OM4bBQnqQfQUzwjJNDLFOLfzBdKUNxjPT36kVmzW1nfR3tlpkMlperIXmEoOXQf3R6U2rzabY9TsIfsH2a4WyunuFwTK7vjBI5wT2FYukaLY73u7BLi4lt0M7hTnag+8xx1Fc7HbTXGm28Vm5h+ySuGkbO6QHr8vpVnx141tfhPLo1j4STOpXbRX+pJJni36rb4OdokyzHoQNvqK5MZV+qU209Xt/wAEU5ci1NSfV4L2E6fqEsbxTPiHaNpAzkH2P1qtNrVzp+u2+j6aI/skUYBJG089+epye1avi4Wc9ppOpeFbYXFlfYvrZwMkh+NpHqpypHbFZxTS9Wu9aXxAI7UWMCbLtFO5XBHA9s1tSnCpBVEtH0/DYG1uFwgu9O1SBLqL+0EKyNDL1lwfXvj0rMews7u4EOjXHl60xS5Kt90FTkqD68VvXdlavqViZI7R7mdBtcttLeh98iqcltHN4m1O2srF7W7iQqs5YhWyOo960U+3r+n3Db5jo/FGs6rF4kR/KLaVHZb2lIA3OVyQD6g8fhWD4Zj1PWvDbWdrstkuJ2kedmyeOw9zWJq11LBc6XcXlyZJIj5U0ZbPI9e3IxXQyQXMkumTQ2yRaQjvKDA/C8bvmxU+zVOCWnr6XJWmhkeIrubSEiYySDzG8o7xk5HcU6xkaO4sbjUJS0kZI80t/AexzWrYJ/aPiu2NjcxXctniRobgcAHv71qfETQI5NHvtZunEFvGwXZAmTuJxxT9tFNQl1NZTTbTOZu187xFpd7pNtmG4kxNM65+6cH6cVBrIkOuXhjzbxtIvMfDOB396rJbav4YKDT5Xube8RZ/srKSSpGTgdjj0rRsrGWOWVlt2Sa4gJXeM4yMjk9COlWrR1vpYlIWCwfTtUtbPT5H8i4zLvHA39gfbirPhdbuDxlex3rFlLPvyTwAOn09Kfpl9Jp8lvY3UQLb8gA5K5x0Namo6vDbT7oxG4K4kmb09MjrWU3PWNr3W4NdDK17U97+SkMW+ZCu6Xk+X1GD2qjfTPpdnbRQb4bYR7Q3Qu7Dnp14OKWeXTb2JpYJTs4jAZefYgVW8QSQPBaWjea0a7d0zkhkz6j1xVxio2VirGxo1wlloEdjNdIkF2zNGFGCrY9fWqFrbyaL9n0oFLh5mZi2RmNTyGNQapbRG3tLCznCQGclpZTgDIH86fHM80N5PZL58toREJBkvIF9vwFZxi9X0Y9tDZnu9P0ywxkhvNG4xjcHx6n3NcvcO9xq1wyLIBncqngqAOP51Y0LU7y61FRqGkrLC0ZaQyoRls8c+3pUj3SyC5eO5LJ5oRuOh9qORxequwVnqWkUpA0nmYeFgPl4HTNN0yV4JrjDAFgDjrxnH51NaRGGC7EvSXDJuPAIq7dWsMGlmeN8ySqNoHIBqOZRTi9blN3MfWo7GxtYxpDThmfE8jthmHYDHbvWcGnXSgQzSAnJVe4A6VHq1lLK0cnmljgAgHBz3Famn2ZitHjb5lIDuV5MfHFbLlpxWutxWdzW8I2kGpxOUVXvYbfciY+9HnlfrVnTtM+0mWTyitpsLBlOCfbHqKz/AIX61ptn41Z72SWG3EZVXC8ZHr7EVqaf4mWy13WbnTtNTUNCk3OjnOYcnk4/OuatOdOUrJ20IcndxRWMwu0mtLaB1XZkS5598ipLJ57GFLI4yyl2DH72BwAfwq1o+ol4JGkji28tHLjhgenI71m3H2+aVpjZyyxKu2OREJA/GtFq3FrQuxBeaYL11dC0eQJNqLuIA68elXNWsrW602FkkfFvgAgevSpLmGazjt7xC5fy9oVRlmyMGoJtWXTtKNkbaNpZZFdUJ7j1quaTs4vYZYtWsLW3jhbAKDHJorlvIjly87sZWJLFWwOvpRSdJN6svkXY37NopBd3HiSSN9NlmH2RTzg9sY6DGKytDilu9R1x0b+x7+baUZyQpAPOPwpJfEVklnFFHpzXyJmcHdtCex/SsCaS9a4+03tx8tzJkwMdzwxk8Z9Aa640m730/rt+Zy3s7o9J1G8aK0tluo4r6xW3Iu5wAWbA9vwrmL17ldEuNesLs22nSoba1smTiNumSOg781sSSJp/hiFPDNobmWbk7jvwD1JHf0rktSu7m51+wi1JmSNJ1T7LFjYoGCcjpjmsqML7f18hMdC5s0uzqVzBfxLCiQpGPmSQnPH5da6SDSrK60i5uNTeW0v7kHJU/OV9cfzrl/EDWc90NTijbTYIpnQ7QXErDoRW3dz2kmqeH/t17LBNbxCYzvGSsgYbgM/TrWs7tJrQFuU9MvLW6t0S/t7jUZtPuBDD5XyYQ9GbjpxWkI7TRtHuo9KSPVBLMXTd8wDj3FY2n2Lya9CL3VS1vexyzyNCCAI+cZ9T7dqsy6XDaaPHNoNzL9js5zJO03BlYjhRj24oklff/L+riKEIv7OSTUrDT5kvmiWQSHJKgkg4B6811/hGa8a8u7Z1ik1CWNZN4UYLHH3vfmuaGvXWlW8ImuWupQyvLbKNwjD/AHRn29PepvCmpmy8Sy3jaddi/vLkwqqf6qPvvz360qqcovRD21Om+ImmiyttKP8AZ73l0ZArBWIVD1B/OsCK1vr/AMRtbMtvcWWN14IlVAw64Ldz+NdT4g1VtRtYbCWVo7y7zGssfb3rFg8P3s2mWul2FzHcS28j/aSmeSTwT/ewKwoy5YWnp/W5Uk09RtjJquj63Jd6hKsenKuCeibegCr61UtNLm/4SCOF7RLjSrnfNJvG0RqR9/cenWuuj8P6bHek37yXIhKo8TvkRkDofesPV9Qu76HULDXcpauABJEB+5jH3QPUcU41Od+7216fcJbaBI2oaNrFnDZwrFokEPDkg5Y5JOfWnXfi7R7y40mXTbCee5knMUsxG0oM9PfrWTdX1tcX2n6TY3bNYadCs8kkwHzoBksfwPStKex+y3v9v6JeQCOaNUt4guFZ246H86ThHRzWv9b+ot9iJ7S3tPGxd7wyedLuFrg7cEcA+2ayPHHhDRNa8Q6ZqOoxedqep+KdPsr4pLKCYZ/O3rgsQOI1A24wBgVfsrm5tZmgNqL3UVYs1y3KxMewPfFOU3l/qFi8tkYW07xDpuoyStx9ojt/O3he2/8AeDA4HXJHGeXH0HUpd2krbd0KceZE5mn0Dwxp2keHNPktLKK5eRw0jyFWIAYKXJwhxnHTPPrm1eNb6r4km0O5tWaxlijknmjG1i6jd19MnFUrHWNa0yPdrECXivcbVDcNtx0Ht0qhfahqFgJJr6ZvkuFPlqw3bD0z7dsV0woKK5YJLtb+ug+RolMD+ItUupobN7K+sVVYBvyjBOAOe/Fa2s6zd2vhq2XUZY7TV5HxjZksuetRWsUtpaaoDIq/aj5kLGQKQzYyOfaka31a+s5f7SihmuYNojV8bwv94U3ZtXtZDS1JdR0a0az1TdaLdO6efGufmDBeQMfiaggi1G78CrbafbGK7ki2vbg7crkjPPfFQf2Xb2+t6dcXV61tN5ocqHO6QD0Hr2rUtFvLW5v9TvZpbi2WNlhijbJOT7dMVMtFvfr+g2mjC0zw9PDY2enW1w9rrMp/ehnzI8XdQR6eldF/wk+q6F4iHh+fT4rvTJduwzKWwcdfc1Sjjh1O+tNaslm+1afbbjbBvm74yaiHiKbUtYheIuFV9swkTOwn0P4USTqP3lfe/k/62Jcb7mbrWoS+I9fvI7BnS7tpAqSH5dp5GB7Zqt5mqaBIs2vTXDySxLG0bHcVfJJb3GMVq61oL3+pjV7cmO0hQyNJDwSV7fU0221661GLTBJDHcXMrSnyAoJ2KBgsT+NaRfupRWi38ir2ZBfX9lE0rSTq99Im2EdSuR1PpXNQSTLp7xXbB3jmI8pTk4PTNdDpltqEmtJcXK2H2TdhgAAQR0z9KuaneWH/AAklz/ZkRur6KII8SIBE3POPcVamovlSuU2cqdU+yG+mS32yAIEVlBVMdsfnWzqywXcdhdRySIb0BCuzcEYHHX0rrbY6NZeE7z+1rFHuJN2QQC+fSsXQvDhuooWttWltNNnJ3LKgyMGsZVIyd2rJfiNyauGrPY6XZxRXdmt5PMm2ORnIEO08tkd6EuLGz02IWICTTx5Mq/3ifWr+o+HY9Tg1DTdJv/tw09AxdwBjPXBFcfNAbdrXTxI32iL73oM9qdJRqLV69v8AgAnfU1L2XUtAtrS6bbPYK5fysZJJPQmm2Flpzl5jJcPa3Ts+xRhofQHPfOfwq34ohY2mn6RHcyI27zJWAwr4xgA9atQqbaEeURubA2Yxk1E6j5b9/wDMqMEyfUk3W6WoJ2+ViIFc7veqWhAxx+VfIz4YlQBz6VSa7mWX5uVt3LBl5wahuNYzdJCfMJUEsTxkk9aiC5oWRTjYTWLVbPVvL82N/MYEKnJz1APvVq1vD5QtpsLHKNjuDy+f8Kxr1Y2uo5C4yDkAdR716Fo3hKy1QK63MhG3IYAfJx6U5yjBKU9RN8u5yXh9YNO1uaCOPzpLoG2RXxkk8fhXdeG7OLSNDm8pQjlGiZZGU/Xp61zN14f+xapOBdQnUNxltU6F3xgH2qG2M2naVo1hfTxJdLPI91KzjLAn7p/OiqlW+F9jNtc17HbeBtO0LU/Cd/JAUW/iMqyQs33W/hOPeqPh/wAbjw/4ZfSNStfI1W5djCOxz0PsBXmml6dqdhqF+IXuba0ikLyZbJkXOQAf4q0rqaHU/Ednc3KW40y4TERkk/eK4HII+tDw0W2pO8Xr6eQuXmfvvqad/pHia405dRhlRoI22hUcYOe4rKubCYw79S/0a4izI0hblgPb8q07cQYurW91UW9tykYV9yhvQAdxU2jaObvRntTerf3tm7M7MM4jPVTmtFLk1f5G03bTcWzvvAy2sYu9TH2jGZN5Od3fPFFcq8Yd2KaegXOB+4DfrRVvDXfxP7xXfcfcf8iM30T/ANDqC9/5GDUv+uEf8loorrp/E/V/oc/U6DwZ/rrf/r2P86x7f/kO61/10m/lRRUf8vJegEviH/knGl/V/wD0Kuj+IP8AyLum/wDXD/2kKKKxl8cfVgjmvBn+quP+wcf/AEKteX/kmcX/AF8/0oorWp8fzQupg+EP+Qtf/wDXt/hXd+G/+Resfo/9aKKyxfX5fkxxKWkf8he0/wB562PA/wDx9aj/ANfB/lRRWNX4Jei/M6MV/EZg+EP9Xrn/AF+mq3jLrd/7kX8qKK1h/H+79DCPwnMaZ/x9XX/YMk/pW7B/yA/CX/X8v8xRRW1Xf5/oye51Gmf8et3/ANfcn86rav8A8fsf++tFFccf4jOiPwoxPEf/ACNWh/75/nWfr/8AyHb36UUV1Ufs+j/Mip8TNHx//wAgzSP+u6fyrfP/ACUmD/rgP5UUVzr+H8pfoQzlfEf/ACPr/wDXOuu8J/6xf+uZ/nRRTrfwF6I0X8Nk/hP/AJG/xP8A9ea/yFc1p/8Ax5at/wBfqfzNFFZw+J/9uko09S/5Fs/hWB4a/wCR4T/rhJ/6DRRWsP4c/mKr8TJ9X/48F/67r/M03wt/yEr/AP3P60UVcv4bNKfxIk1L/kO3H/XBf51t3/8AyLFn/wBdG/nRRWMtofIurv8AMj+HP/MV/Cqeuf8AI8Tf9ch/Siil/wAxEvT/ACM47l7xH/qbL6P/ADFVbf8A48J/+u6fzFFFRH+H/Xcf2UYMv+rj+p/nVvWv+PqD/cWiij/l3E1+0ZGtf8fa/hXpfgv/AI8pf+ugooqsV/BRnU2Zzcv/ACVWx/3j/Os3xz/yMd7/AL5oorWh8cf8P6mcd2ba/wDHxYf9cD/KuGuf+P21/wB5v6UUVph93/XcqpuZOm/cT/r6b+len/Dn/kP63/1zP8qKKMX/AAn6f5E/ZNXTP+PGL6H+dFFFedP4mdDP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medium power light photomicrograph of a hematoxylin and eosin stained tissue section from a sentinel lymph node. In contrast to the surrounding lymphocytes, melanoma cells have large nuclei and prominent nucleoli. Arrows point to aggregates of melanoma cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vincent Liu, MD and April Wang Armstrong, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_16_42245=[""].join("\n");
var outline_f41_16_42245=null;
var title_f41_16_42246="Epidemiology and transmission of measles";
var content_f41_16_42246=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and transmission of measles",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/16/42246/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/16/42246/contributors\">",
"     Jorge L Barinaga, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/16/42246/contributors\">",
"     Paul R Skolnik, MD, FACP, FIDSA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/16/42246/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/16/42246/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/16/42246/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/16/42246/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/16/42246/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/16/42246/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measles is a highly contagious viral illness characterized by fever, malaise, rash, cough, coryza, and conjunctivitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/1\">",
"     1",
"    </a>",
"    ]. There are no known measles virus reservoirs outside of humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/2\">",
"     2",
"    </a>",
"    ]. The epidemiology and transmission of measles and its complications will be reviewed here. The clinical manifestations, diagnosis, prevention, and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43192?source=see_link\">",
"     \"Clinical presentation and diagnosis of measles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22793?source=see_link\">",
"     \"Prevention and treatment of measles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND GLOBAL ERADICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measles occurs worldwide; control efforts have substantially altered the global distribution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/3\">",
"     3",
"    </a>",
"    ]. Measles incidence has decreased substantially in regions where vaccination has been instituted; measles in the developing world has been attributed to low vaccination rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In developed countries during the prevaccine era, more than 90 percent of children acquired measles by age 15 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Following implementation of routine childhood vaccination at age 12 to 15 months, the age of peak measles incidence during epidemics in the United States shifted to six months of age. This is approximately the time at which transplacentally acquired maternal antibodies are no longer present if the mother has vaccine-induced immunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Worldwide, measles is a significant cause of morbidity and mortality. Precise incidence estimates are difficult to obtain because of heterogeneous surveillance systems and probable under-reporting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/11\">",
"     11",
"    </a>",
"    ]. In 2000, measles was estimated to cause approximately 31 to 39.9 million illnesses worldwide with an estimated 733,000 to 777,000 deaths, making it the fifth most common cause of death in children under 5 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The World Health Assembly adopted the",
"    <span class=\"nowrap\">",
"     WHO/UNICEF",
"    </span>",
"    Global Immunization Vision and Strategy, which included a goal of 90 percent reduction in global measles mortality between 2000 and 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The WHO identified 47 &ldquo;priority countries&rdquo; to focus measles mortality reduction efforts; these nations jointly account for approximately 98 percent of measles deaths. The strategy in these nations includes the following measures: (1) measles immunization with a goal of &gt;90 percent national coverage and &gt;80 percent per-district coverage with two doses of vaccine; (2) surveillance activities, including case investigation and laboratory testing in all suspected cases; and (3) clinical management of measles cases, including administration of vitamin A [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/12,16\">",
"     12,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A model to estimate progress to reaching the above goals suggested that the estimated annual global measles incidence fell by 66 percent between 2000 and 2010, from 4.6 to 1.6 cases per 1000 population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/17\">",
"     17",
"    </a>",
"    ]. During the same period the estimated annual global measles mortality fell by 74 percent; most measles deaths occurred in Africa and India. Further information on measles control is available at the Measles Initiative website, including information for the general public, technical documents, and multimedia presentations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16784714\">",
"    <span class=\"h2\">",
"     Achievements in global measles control",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     The Americas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The WHO-designated Region of the Americas appears to have met its goal of eliminating endemic measles transmission; the last endemic case occurred in 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/13,19,20\">",
"     13,19,20",
"    </a>",
"    ]. This regional success illustrates the feasibility of global measles eradication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/20\">",
"     20",
"    </a>",
"    ]. Imported cases continue to occur, emphasizing the importance of routine vaccination to maintain immunity. Between 1990 and 2008, measles cases fell from approximately 250,000 to 203 cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/19,21\">",
"     19,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A large measles outbreak occurred in 2011 in Quebec, Canada; there were 21 measles importations and 725 cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/22\">",
"     22",
"    </a>",
"    ]. A super-spreading event triggered by one importation resulted in sustained transmission and 678 cases. The overall incidence was 9 per 100,000; the highest incidence occurred among adolescents (75 per 100,000), among whom 22 percent had received two vaccine doses. Two-dose recipients had a milder illness and lower risk of hospitalization than single-dose recipients or unvaccinated individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h4\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the decade before the measles vaccination program began there were as many as 500,000 reported cases of measles per year in the United States; by one estimate, there may have been as many as 4 million cases per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/23\">",
"     23",
"    </a>",
"    ]. About 48,000 were hospitalized, 1000 were chronically disabled and nearly 500 died.",
"   </p>",
"   <p>",
"    The Food and Drug Administration approved a measles vaccine in 1963. Since that time the number of cases has fallen by approximately 99 percent, and measles is no longer considered an endemic disease in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measles imported by travelers to the US is well described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]; of 692 measles cases reported during 2001-2010, 87 percent were import-associated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/27\">",
"     27",
"    </a>",
"    ]. Since 2008 most imported United States cases have been from the European Region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'European Region'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    During 2011, 222 cases of measles were reported in the United States, an increase compared with cases reported during 2001-2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/30\">",
"     30",
"    </a>",
"    ]. Among infected patients who were United States residents, 85 percent were not vaccinated or had unknown vaccination status, but were considered eligible for vaccination. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26857?source=see_link&amp;anchor=H6#H6\">",
"     \"Autism and chronic disease: Little evidence for vaccines as a contributing factor\", section on 'Lack of evidence for association between autism and MMR'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     European Region",
"    </span>",
"    &nbsp;&mdash;&nbsp;The WHO-designated European Region established a goal of measles elimination by the year 2015 (revised from 2010 because of ongoing measles outbreaks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/31\">",
"     31",
"    </a>",
"    ]. Beginning in late 2009, there has been a sharp increase in measles cases in the Region, primarily in Western Europe in 2011. Of the approximately 26,000 cases reported for 2011, an estimated 54 percent occurred in France [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/29\">",
"     29",
"    </a>",
"    ]. The increase in cases has been primarily attributed to lack of vaccination of susceptible populations. Reasons for lack of vaccination include religious or philosophical beliefs, lack of healthcare access, and anti-vaccination movements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/29,31-35\">",
"     29,31-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H534271676\">",
"    <span class=\"h3\">",
"     African Region",
"    </span>",
"    &nbsp;&mdash;&nbsp;The WHO-designated African Region improved coverage rates children from 57 to 73 percent with the first dose of measles vaccine for nine-month-olds between 2001 and 2008. Additionally, &ldquo;catch-up&rdquo; vaccinations targeting a wide age range were offered in 43 of the 46 African Region nations by the end of 2008. The improved vaccination rates were associated with a 93 percent reduction in measles cases, from 492,116 cases in 2001 to 32,278 cases in 2008. Measles outbreaks continue to occur, and failure to vaccinate has been identified as the primary cause. However, given the overall success, the African Region recently established several goals, including the year 2012 goal of reducing measles deaths by 98 percent compared with year 2000 estimates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/36\">",
"     36",
"    </a>",
"    ], and the goal of measles eradication by 2020 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H534271684\">",
"    <span class=\"h3\">",
"     Western Pacific Region",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2005, the WHO-designated Western Pacific Region established a target year of 2012 for measles elimination. For some nations in the Region, measles elimination is hampered by inadequate surveillance and inadequate public health services. As of mid-2009, 24 of the 37 countries and areas that comprise the Region were thought to have eliminated or nearly eliminated measles. The Republic of Korea declared measles eliminated in 2006. China and Japan are thought to have had the majority of measles cases in recent years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/37\">",
"     37",
"    </a>",
"    ]. Japan had a measles epidemic from 2007&ndash;2008, which led to secondary imported cases in Canada and the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/38\">",
"     38",
"    </a>",
"    ]. The Region is estimated to have had 147,986 measles cases in 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H534271701\">",
"    <span class=\"h3\">",
"     Eastern Mediterranean Region",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1997, the WHO-designated Eastern Mediterranean Region set a goal of measles elimination by 2010. Implementing measles control has been a challenge in some areas, in part due to civil unrest, natural disasters, and inadequate public health systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/20,39\">",
"     20,39",
"    </a>",
"    ]. Overall, however, measles cases have declined; in the early 1980s there were approximately 200,000 cases identified annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/39\">",
"     39",
"    </a>",
"    ], but in 2008 12,120 cases were identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/21\">",
"     21",
"    </a>",
"    ]. Measles-related deaths are estimated to have fallen by 75 percent from 2000 to 2007 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H534271718\">",
"    <span class=\"h3\">",
"     Southeast Asia Region",
"    </span>",
"    &nbsp;&mdash;&nbsp;The WHO-designated Southeast Asia Region improved measles vaccine coverage between 2000 to 2008, which was associated with a 46 percent reduction in measles deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/20\">",
"     20",
"    </a>",
"    ]. Nonetheless this Region had approximately 126,000 measles deaths in 2008, representing the majority of all measles deaths in the world for that year (approximately 77 percent). This Region includes India, identified as the only WHO-designated &ldquo;priority country&rdquo; that has not implemented the WHO measles-control strategies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/12,20\">",
"     12,20",
"    </a>",
"    ]. There have been calls for India to improve measles vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/12,20,40\">",
"     12,20,40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology and global eradication'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measles is highly contagious; the attack rate in a susceptible individual exposed to measles is 75 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/41\">",
"     41",
"    </a>",
"    ]. The incubation period for measles is 6 to 19 days (median 13 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/42\">",
"     42",
"    </a>",
"    ]. Subclinical illness is unusual. The period of contagiousness is estimated to be from 5 days before the appearance of rash to 4 days afterwards. Maximum contagiousness is thought to be during the late prodrome phase, when the patient is febrile and has respiratory symptoms. Patients with measles-associated subacute sclerosing panencephalitis are not contagious [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43192?source=see_link\">",
"     \"Clinical presentation and diagnosis of measles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infectious droplets from the respiratory secretions of a patient with measles have been reported capable of remaining airborne for several hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/44\">",
"     44",
"    </a>",
"    ]. Thus, person-to-person contact may not be necessary to transmit measles; the illness may be transmitted in hospitals and physicians' offices. Measles transmission between airplane passengers during flight has also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/45\">",
"     45",
"    </a>",
"    ]. Large measles outbreaks can occur because of high virus transmissibility in areas of crowding such as schools and densely populated communities.",
"   </p>",
"   <p>",
"    The peak incidence of measles in temperate areas occurs in the late winter and early spring. However, cases occur throughout the year and in some regions no seasonal incidence is apparent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EFFECT OF IMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natural measles infection is thought to confer life-long immunity. Immunity due to measles vaccination is also highly protective against clinical measles infection, as illustrated by the marked increase in risk among unvaccinated individuals during measles outbreaks. During an outbreak in the Netherlands, for example, unvaccinated individuals were 224 times more likely to become infected than vaccinated individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Groups at risk for measles include children too young to be vaccinated, individuals who were never vaccinated (including those who declined vaccination for religious or philosophical reasons), individuals who have not received a second dose of measles vaccine, and individuals for whom the vaccine failed to elicit a protective immune response. Travel in the developing world or contact with ill persons arriving from the developing world increases the risk of exposure to measles.",
"   </p>",
"   <p>",
"    In developing countries, a younger age of measles infection has been noted among children born to HIV seropositive mothers than children born to HIV seronegative mothers. In these settings the titer of transplacentally-acquired measles antibody may be reduced. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43192?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical presentation and diagnosis of measles\", section on 'Immunocompromised patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY OF MEASLES COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complication rates associated with measles infection are variable. In the 1990 United States outbreak, the following complication rates were observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/46\">",
"     46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Overall complication rate &mdash; 22.7 percent",
"     </li>",
"     <li>",
"      Diarrhea &mdash; 9.4 percent",
"     </li>",
"     <li>",
"      Otitis media &mdash; 6.6 percent",
"     </li>",
"     <li>",
"      Pneumonia &mdash; 6.5 percent",
"     </li>",
"     <li>",
"      Encephalitis &mdash; 0.1 percent",
"     </li>",
"     <li>",
"      Death &mdash; 0.3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Higher measles complication rates have been observed in developing countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42246/abstract/47-52\">",
"     47-52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    Basics topics (see",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/56/2947?source=see_link\">",
"     \"Patient information: Measles (The Basics)\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H534270916\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measles occurs worldwide. There are no known measles virus reservoirs other than humans. In the prevaccine era, &ge;90 percent of children acquired measles by age 15. Following implementation of routine childhood vaccination at age 12 to 15 months, the age of peak measles incidence during epidemics in the United States shifted to six months of age. This is the time at which transplacentally acquired maternal antibodies are no longer present if the mother has vaccine-induced immunity. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and global eradication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following approval of the measles vaccine in the United States in 1963, the number of cases fell by approximately 99 percent. Isolated outbreaks due to measles importation continue to occur, but measles is no longer considered an endemic disease in the United States. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'United States'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measles in the developing world has been attributed to low vaccination rates. Barriers to measles eradication in these settings include low vaccine coverage rates, vaccination of limited age groups, political conflicts, limited vaccination coverage outside urban areas, malnutrition and displacement. Nonetheless, measles can be controlled even in developing countries with vigilance and organized programs including mass vaccination and catch-up campaigns. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and global eradication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measles is highly contagious; the attack rate in a susceptible individual exposed to measles is 75 percent. The period of contagiousness is estimated to be from five days before the appearance of rash to four days afterwards. Infectious droplets from the respiratory secretions of a patient with measles can remain airborne for several hours. Thus, person-to-person contact is not necessary to transmit measles; the illness may be transmitted in hospitals and physicians' offices. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Natural measles infection is thought to confer life-long immunity. Immunity due to measles vaccination is also highly protective against clinical measles infection. Groups at risk for measles include children too young to be vaccinated, individuals who were never vaccinated, individuals who have not received a second dose of measles vaccine, and individuals for whom the vaccine failed to elicit a protective immune response. Travel in the developing world or contact with individuals arriving from the developing world increases the risk of exposure to measles. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Effect of immunity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/1\">",
"      Moss WJ, Griffin DE. Measles. Lancet 2012; 379:153.",
"     </a>",
"    </li>",
"    <li>",
"     Black, FL. Measles. In: Viral infections in humans: Epidemiology and control, Evans, AS, Kaslow, RA (Eds), Plenum Publishing, New York 1997. p.507.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/3\">",
"      BABBOTT FL Jr, GORDON JE. Modern measles. Am J Med Sci 1954; 228:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/4\">",
"      Global measles mortality reduction and regional elimination: a status report. J Infect Dis 2003; 187(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/5\">",
"      LANGMUIR AD. Medical importance of measles. Am J Dis Child 1962; 103:224.",
"     </a>",
"    </li>",
"    <li>",
"     Markowitz, LE, Katz, SL. Vaccines, Plotkin, SA, Mortimer, EA (Eds), WB Saunders, Philadelphia 1994. p.229.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/7\">",
"      Arya LS, Taana I, Tahiri C, et al. Spectrum of complications of measles in Afghanistan: a study of 784 cases. J Trop Med Hyg 1987; 90:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/8\">",
"      Papania M, Baughman AL, Lee S, et al. Increased susceptibility to measles in infants in the United States. Pediatrics 1999; 104:e59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/9\">",
"      Maldonado YA, Lawrence EC, DeHovitz R, et al. Early loss of passive measles antibody in infants of mothers with vaccine-induced immunity. Pediatrics 1995; 96:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/10\">",
"      Markowitz LE, Albrecht P, Rhodes P, et al. Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Kaiser Permanente Measles Vaccine Trial Team. Pediatrics 1996; 97:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/11\">",
"      Stein CE, Birmingham M, Kurian M, et al. The global burden of measles in the year 2000--a model that uses country-specific indicators. J Infect Dis 2003; 187 Suppl 1:S8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/12\">",
"      Centers for Disease Control and Prevention (CDC). Global measles mortality, 2000-2008. MMWR Morb Mortal Wkly Rep 2009; 58:1321.",
"     </a>",
"    </li>",
"    <li>",
"     Pan American Health Organization. Immunization in the Americas. file://new.paho.org/sur/index.php?option=com_content&amp;task=view&amp;id=91&amp;Itemid=290 (Accessed on November 08, 2010).",
"    </li>",
"    <li>",
"     World Health Organization. Vision and Strategy 2006-2015 www.who.int/vaccines-documents/DocsPDF05/GIVS_Final_EN.pdf (Accessed on October 13, 2011).",
"    </li>",
"    <li>",
"     World Health Organization. WHO/UNICEF joint statement -- global plan for reducing measles mortality 2006-2010. file://www.who.int/immunization/documents/WHO_IVB_05.11/en/index.html (Accessed on November 03, 2010).",
"    </li>",
"    <li>",
"     WHO-recommended surveillance standard of measles. file://www.who.int/immunization_monitoring/diseases/measles_surveillance/en/index.html (Accessed on November 08, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/17\">",
"      Simons E, Ferrari M, Fricks J, et al. Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data. Lancet 2012; 379:2173.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.measlesinitiative.org (Accessed on November 15, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/19\">",
"      Centers for Disease Control and Prevention (CDC). Progress toward measles elimination--region of the Americas, 2002-2003. MMWR Morb Mortal Wkly Rep 2004; 53:304.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Global eradication of measles. file://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_18-en.pdf (Accessed on November 08, 2010).",
"    </li>",
"    <li>",
"     World Health Organization. World Health Statistics, 2010. file://www.who.int/whosis/whostat/2010/en/index.html (Accessed on November 08, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/22\">",
"      De Serres G, Markowski F, Toth E, et al. Largest measles epidemic in North America in a decade--Quebec, Canada, 2011: contribution of susceptibility, serendipity, and superspreading events. J Infect Dis 2013; 207:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/23\">",
"      Bloch AB, Orenstein WA, Stetler HC, et al. Health impact of measles vaccination in the United States. Pediatrics 1985; 76:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/24\">",
"      Centers for Disease Control and Prevention (CDC). Measles--United States, 1999. MMWR Morb Mortal Wkly Rep 2000; 49:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/25\">",
"      Orenstein WA, Papania MJ, Wharton ME. Measles elimination in the United States. J Infect Dis 2004; 189 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/26\">",
"      Centers for Disease Control and Prevention (CDC). Epidemiology of measles--United States, 2001-2003. MMWR Morb Mortal Wkly Rep 2004; 53:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/27\">",
"      Centers for Disease Control and Prevention (CDC). Measles imported by returning U.S. travelers aged 6-23 months, 2001-2011. MMWR Morb Mortal Wkly Rep 2011; 60:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/28\">",
"      Centers for Disease Control and Prevention (CDC). Measles outbreak associated with an arriving refugee - Los Angeles County, California, August-September 2011. MMWR Morb Mortal Wkly Rep 2012; 61:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/29\">",
"      Centers for Disease Control and Prevention (CDC). Increased transmission and outbreaks of measles--European Region, 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/30\">",
"      Centers for Disease Control and Prevention (CDC). Measles - United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/31\">",
"      Centers for Disease Control and Prevention (CDC). Progress toward measles elimination--European Region, 2005--2008. MMWR Morb Mortal Wkly Rep 2009; 58:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/32\">",
"      van den Hof S, Conyn-van Spaendonck MA, van Steenbergen JE. Measles epidemic in the Netherlands, 1999-2000. J Infect Dis 2002; 186:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/33\">",
"      Hahne S, te Wierik MJ, Mollema L, et al. Measles outbreak, the Netherlands, 2008. Emerg Infect Dis 2010; 16:567.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Global eradication of measles. file://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_18-en.pdf (Accessed on December 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/35\">",
"      Centers for Disease Control and Prevention (CDC). Measles outbreak--Netherlands, April 1999-January 2000. MMWR Morb Mortal Wkly Rep 2000; 49:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/36\">",
"      Centers for Disease Control and Prevention (CDC). Progress toward measles control - African region, 2001-2008. MMWR Morb Mortal Wkly Rep 2009; 58:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/37\">",
"      Centers for Disease Control and Prevention (CDC). Progress toward the 2012 measles elimination goal--Western Pacific Region, 1990-2008. MMWR Morb Mortal Wkly Rep 2009; 58:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/38\">",
"      Centers for Disease Control and Prevention (CDC). Progress toward measles elimination--Japan, 1999-2008. MMWR Morb Mortal Wkly Rep 2008; 57:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/39\">",
"      Centers for Disease Control and Prevention (CDC). Progress toward measles mortality reduction and elimination--Eastern Mediterranean Region, 1997-2007. MMWR Morb Mortal Wkly Rep 2008; 57:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/40\">",
"      John TJ, Choudhury P. Accelerating measles control in India opportunity and obligation to act now. Indian Pediatr 2009; 46:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/41\">",
"      SIMPSON RE. Infectiousness of communicable diseases in the household (measles, chickenpox, and mumps). Lancet 1952; 2:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/42\">",
"      Richardson M, Elliman D, Maguire H, et al. Evidence base of incubation periods, periods of infectiousness and exclusion policies for the control of communicable diseases in schools and preschools. Pediatr Infect Dis J 2001; 20:380.",
"     </a>",
"    </li>",
"    <li>",
"     Asher, DM, Gibbs, CJ. Chronic Neurological Diseases Caused by Slow Infections. In: Viral Infections of Humans: Epidemiology and Control, Evans, AS, Kaslow, RA (Eds), Plenum Publishing, New York 1997. p.1027.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/44\">",
"      Bloch AB, Orenstein WA, Ewing WM, et al. Measles outbreak in a pediatric practice: airborne transmission in an office setting. Pediatrics 1985; 75:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/45\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: Multiple cases of measles after exposure during air travel--Australia and New Zealand, January 2011. MMWR Morb Mortal Wkly Rep 2011; 60:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/46\">",
"      Centers for Disease Control (CDC). Measles--United States, 1990. MMWR Morb Mortal Wkly Rep 1991; 40:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/47\">",
"      Beckford AP, Kaschula RO, Stephen C. Factors associated with fatal cases of measles. A retrospective autopsy study. S Afr Med J 1985; 68:858.",
"     </a>",
"    </li>",
"    <li>",
"     Clements, CJ, Cutts, FT. The epidemiology of measles: Thirty years of vaccination. In: Measles Virus, ter Meulen, V, Billeter, MA (Eds), Springer Verlag, Germany 1995. p.13.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/49\">",
"      Hauspie RC, Pagezy H. Longitudinal study of growth of African babies: an analysis of seasonal variations in the average growth rate and the effects of infectious diseases on individual and average growth patterns. Acta Paediatr Scand Suppl 1989; 350:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/50\">",
"      Schaumberg DA, O'Connor J, Semba RD. Risk factors for xerophthalmia in the Republic of Kiribati. Eur J Clin Nutr 1996; 50:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/51\">",
"      Kagame K, Schwab L. Childhood blindness: dateline Africa. Ophthalmic Surg 1989; 20:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42246/abstract/52\">",
"      CHRISTENSEN PE, SCHMIDT H, BANG HO, et al. An epidemic of measles in southern Greenland, 1951; measles in virgin soil. III. Measles and tuberculosis. Acta Med Scand 1953; 144:450.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3019 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-7705E05A5A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_16_42246=[""].join("\n");
var outline_f41_16_42246=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H534270916\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND GLOBAL ERADICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16784714\">",
"      Achievements in global measles control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - The Americas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      United States",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - European Region",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H534271676\">",
"      - African Region",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H534271684\">",
"      - Western Pacific Region",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H534271701\">",
"      - Eastern Mediterranean Region",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H534271718\">",
"      - Southeast Asia Region",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EFFECT OF IMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EPIDEMIOLOGY OF MEASLES COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H534270916\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26857?source=related_link\">",
"      Autism and chronic disease: Little evidence for vaccines as a contributing factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43192?source=related_link\">",
"      Clinical presentation and diagnosis of measles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/56/2947?source=related_link\">",
"      Patient information: Measles (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22793?source=related_link\">",
"      Prevention and treatment of measles",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_16_42247="Anatomy of the popliteal fossa";
var content_f41_16_42247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    Anatomy of the popliteal fossa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 532px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Deep dissection of the popliteal fossa reveals the important neurovascular structures of this region. Observe the thickness of the various muscles. Observe also the popliteal artery lying on the floor of the fossa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley AF II. Clinical Oriented Anatomy, 4th Edition. Baltimore, Lippincott Williams &amp; Wilkins 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_16_42247=[""].join("\n");
var outline_f41_16_42247=null;
var title_f41_16_42248="Epidemiology and pathogenesis of babesiosis";
var content_f41_16_42248=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and pathogenesis of babesiosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/16/42248/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/16/42248/contributors\">",
"     Edouard Vannier, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/16/42248/contributors\">",
"     Jeffrey A Gelfand, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/16/42248/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/16/42248/contributors\">",
"     Johanna Daily, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/16/42248/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/16/42248/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/16/42248/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Babesiosis is an infectious disease caused by protozoa of the genus Babesia that invade and lyse red blood cells. Most cases of human babesiosis are reported from the United States and Europe. The epidemiology of human babesiosis depends on the Babesia species, the density of the tick and vertebrate reservoirs, and the immune status of the infected individuals. Most cases are acquired via tick bite; babesiosis may also be acquired via blood transfusion.",
"   </p>",
"   <p>",
"    The epidemiology and the pathogenesis of human babesiosis will be reviewed here. Clinical manifestations, diagnosis, treatment, and prevention of babesiosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/25/39321?source=see_link\">",
"     \"Clinical manifestations, diagnosis, treatment, and prevention of babesiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BABESIA SPECIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Species characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Babesia species have the following life cycle characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vertebrate host reservoirs",
"     </li>",
"     <li>",
"      Transmission via tick bite",
"     </li>",
"     <li>",
"      Lack of a pre-erythrocytic stage",
"     </li>",
"     <li>",
"      Sporogony by budding (rather than schizogony)",
"     </li>",
"     <li>",
"      Absence of hemozoin deposit in red blood cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Babesia and Plasmodia are both apicomplexan parasites of red blood cells. Their life cycle characteristics differ in that Plasmodium species are transmitted by mosquitoes, have a pre-erythrocytic (hepatic) stage, multiply by schizogony, and leave hemozoin deposit in red blood cells (due to incomplete digestion of hemoglobin).",
"   </p>",
"   <p>",
"    Babesia protozoa belong to the phylum Apicomplexa, class Aconoidasida, order Piroplasmidora. As such, they may appear as pear-shaped organisms (piroplasms) on blood smears. The order Piroplasmidora also includes the family Theileriidae, which differs from Babesia in that Theileria sporozoites invade lymphocytes or macrophages and then red blood cells, whereas Babesia sporozoites readily invade red blood cells.",
"   </p>",
"   <p>",
"    Babesia species have been classified in four clades based on their molecular genetic characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. For each clade, Babesia species that cause babesiosis in humans are listed below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clade 1 contains the B. microti species complex. This complex is genetically diverse and includes B. microti parasites found in mice and other small rodents. It includes the main etiologic agents of human babesiosis in the northeastern and upper midwestern United States.",
"     </li>",
"     <li>",
"      Clade 2 contains B. duncani (WA1, WA2, CA5, CA6) and B. duncani-related organisms (CA1, CA3, CA4), the main etiologic agents of human babesiosis in the western United States.",
"     </li>",
"     <li>",
"      Clade 3 contains B. divergens isolates from cattle in Europe, B. divergens-like organisms identified in humans in Europe and the United States, and B. venatorum, identified in humans in Europe.",
"     </li>",
"     <li>",
"      Clade 4 contains Babesia species that mostly infect ungulates but rarely are transmitted to humans. These include B. bovis and B. bigemina that infect cattle and Babesia KO1, isolated from a patient in South Korea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The phylogenetic classification is generally consistent with classifications based on morphology and life cycle characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Trophozoites of Babesia in clades 1 and 2 are small in diameter (1 to 2.5 microns) and form up to four merozoites arranged in a tetrad (\"Maltese cross\"). Transmission of Babesia in clades 1 and 2 is trans-stadial (eg, from larvae to nymphs) but not trans-ovarial (from adults to eggs), suggesting that vertebrate hosts are needed for short-term maintenance of Babesia clades 1 and 2 in the tick life cycle.",
"   </p>",
"   <p>",
"    Trophozoites of Babesia in clades 3 and 4 typically are large in diameter (2.5 to 5 microns) and form two merozoites only. Exceptions include B. divergens, B. divergens-like organisms, and B. venatorum in clade 3; their trophozoites are small in diameter and their merozoites can be arranged in tetrads in human red blood cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/5,10,11\">",
"     5,10,11",
"    </a>",
"    ]. Transmission of Babesia in clades 3 and 4 is both trans-ovarial (from adults to eggs) and trans-stadial (from larvae to nymphs), suggesting that vertebrate hosts are not essential for short-term maintenance of Babesia clades 3 and 4 in the tick life cycle. These organisms are referred to as \"true\" Babesia species or as Babesia species \"sensu stricto\".",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Babesia microti",
"    </span>",
"    &nbsp;&mdash;&nbsp;Babesia microti is the predominant species causing human babesiosis in the northeastern and upper midwestern regions of the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/1\">",
"     1",
"    </a>",
"    ]. In these regions, the vector for transmission of B. microti is the deer tick Ixodes scapularis (",
"    <a class=\"graphic graphic_figure graphicRef68309 \" href=\"mobipreview.htm?39/6/40037\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Life cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The life cycle of Ixodes scapularis spans over two years and includes deer and mice. Mice are the primary reservoir for B. microti; deer are not competent reservoirs. Adult ticks feed on white-tailed deer, whereas tick larvae and nymphs feed on white-footed mice (",
"    <a class=\"graphic graphic_figure graphicRef65153 \" href=\"mobipreview.htm?39/38/40547\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adult ticks feed on white-tailed deer in the fall (year 1), although deer are not competent reservoirs for B. microti.",
"     </li>",
"     <li>",
"      Tick eggs are laid in the spring (year 2). Although adult ticks may be infected with B. microti, their eggs are not infected (eg, there is no trans-ovarial transmission).",
"     </li>",
"     <li>",
"      Tick larvae hatch in late July (year 2).",
"     </li>",
"     <li>",
"      Tick larvae feed on white-footed mice (Peromyscus leucopus) in late summer (year 2). Mice are the primary reservoir for B. microti and tick larvae become infected when they feed on mice harboring B. microti.",
"     </li>",
"     <li>",
"      Tick larvae molt into nymphs in the spring (year 3). B. microti is transmitted from larvae to nymphs (known as trans-stadial transmission).",
"     </li>",
"     <li>",
"      Tick nymphs feed on white-footed mice in early summer (year 3). Nymphs are primary vectors for transmission of B. microti to humans, but transmission is accidental.",
"     </li>",
"     <li>",
"      Tick nymphs molt into adults in the fall (year 3).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a tick feeds on an infected mouse, Babesia infected red blood cells accumulate in its gut [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Upon repletion of the tick, Babesia gametocytes exit red blood cells and fuse to form zygotes. Zygotes translocate across the tick gut epithelium and locate to its basal lamina. Zygotes become ookinetes, which enter the tick hemolymph and migrate to salivary acini. In the secretory and interstitial cells of the acini, ookinetes hypertrophy into sporoblasts. These sporoblasts remain dormant while larvae overwinter. Sporogony (the process by which a single sporoblast buds off up to 10,000 sporozoites) is initiated when nymphs attach to a vertebrate mammal (",
"    <a class=\"graphic graphic_figure graphicRef65153 \" href=\"mobipreview.htm?39/38/40547\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As tick feeding nears completion, sporozoites are delivered in the dermis of the vertebrate host. Sporozoites eventually reach the host circulation and invade red blood cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Sporozoites become trophozoites that freely move in the red blood cell cytoplasm. Each trophozoite divides into two to four merozoites by binary fission. Egress of merozoites is accompanied by loss of red blood cell membrane integrity. Extracellular merozoites in turn invade red blood cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Babesia divergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Babesia divergens is the species to which most cases of human babesiosis in Europe have been attributed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/5\">",
"     5",
"    </a>",
"    ]. The life cycle of B. divergens differs from that of B. microti in the following ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cattle are the main vertebrate host for B. divergens.",
"     </li>",
"     <li>",
"      Ixodes ricinus transmits B. divergens to cattle and humans. Both nymphs and adult ticks are thought to be transmission vectors.",
"     </li>",
"     <li>",
"      The life cycle of I. ricinus spans over three years; progression from one stage to the next takes one year. Both trans-ovarial transmission (from adults to eggs) and trans-stadial transmission (from larvae to nymphs) occur, suggesting that bovine hosts are not essential for short-term maintenance of B. divergens in the tick life cycle.",
"     </li>",
"     <li>",
"      Merogony yields two merozoites in bovine red blood cells; in human red blood cells, tetrads are noted occasionally.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other species",
"    </span>",
"    &nbsp;&mdash;&nbsp;The life cycles of other Babesia species that rarely infect humans are poorly understood:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      B. duncani and related organisms &mdash; B. duncani was initially referred to as Babesia WA1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/6\">",
"       6",
"      </a>",
"      ]. This organism is closely related to piroplasms of domesticated dogs (B. conradae) in California and to those of wildlife mammals in the western United States. The tick vector for B. duncani is unknown but may be I. pacificus.",
"     </li>",
"     <li>",
"      B. divergens-like organism in the midwestern United States &mdash; In two cases, these organisms were identical to piroplasms obtained from eastern cottontail rabbits on Nantucket Island, Massachusetts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/10\">",
"       10",
"      </a>",
"      ]. The tick vector is thought to be I. dentatus.",
"     </li>",
"     <li>",
"      B. divergens-like organism on the Canary Islands &mdash; The animal reservoir for this organism is unknown but may be rabbits or cattle [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/12\">",
"       12",
"      </a>",
"      ]. The tick vector may be I. ventalloi.",
"     </li>",
"     <li>",
"      Babesia EU1 in Europe &mdash; This organism is provisionally named B. venatorum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/13\">",
"       13",
"      </a>",
"      ]. It is closely related to B. odocoilei, a piroplasm of white-tailed deer in the United States. Animal reservoirs include roe deer; the tick vector is I. ricinus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      B. microti-like organism in Japan &mdash; This organism is distantly related to B. microti found in the United States [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/3\">",
"       3",
"      </a>",
"      ]. The animal reservoir is the field mouse Apodemus speciosus; the tick vector may be I. ovatus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Babesia KO1 in South Korea &mdash; This organism is virtually identical to a Babesia species isolated from sheep in China [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/9\">",
"       9",
"      </a>",
"      ]. The animal reservoir and tick vector are unknown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY: UNITED STATES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Babesia microti",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Geography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Babesiosis caused by B. microti is endemic in the northeastern region of the United States, particularly on the islands off the coast of southern New England, and in the coastal counties of New England [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/1,16\">",
"     1,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Highly endemic areas include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nantucket Island, Martha's Vineyard, Elizabeth Islands, Block Island, Shelter Island, eastern Long Island, and Fire Island.",
"     </li>",
"     <li>",
"      Southeastern Massachusetts, including Cape Cod, southwestern Rhode Island, and eastern Connecticut.",
"     </li>",
"     <li>",
"      Counties east of the Hudson River, in the Lower Hudson Valley.",
"     </li>",
"     <li>",
"      South-central counties in New Jersey.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Areas with low endemicity include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Southern coastal counties in Maine and New Hampshire",
"     </li>",
"     <li>",
"      Northern and central counties in Connecticut",
"     </li>",
"     <li>",
"      Western Long Island",
"     </li>",
"     <li>",
"      Northern and southern counties in New Jersey",
"     </li>",
"     <li>",
"      Counties in Delaware and Maryland",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Babesiosis caused by B. microti is also endemic in the upper midwestern region of the United States, particularly in Minnesota and Wisconsin. A small number of cases have been reported from Indiana. At the beginning of 2011, United States Centers for Disease Control (CDC) added babesiosis to the list of nationally notifiable diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Incidence and prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of babesiosis has increased considerably over the last decade. In New York State alone, more than 2300 cases have been reported since 1986 (when reporting of babesiosis became mandatory). In the last decade more than 1600 cases were reported; more than 1400 cases were reported between 2005 and 2010. The incidence of babesiosis increased even in areas previously regarded as areas of low endemicity, such as the Lower Hudson Valley [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given that the geographic range and the number of annual cases have steadily increased, babesiosis is considered an emerging infectious disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/4,19\">",
"     4,19",
"    </a>",
"    ]. The increase in incidence may be due to several factors including expanding deer population, greater tick density, increased human outdoor activity in wooded areas, and heightened community awareness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/4\">",
"     4",
"    </a>",
"    ]. Deer numbers may be increasing due to reforestation, lack of predators, and insufficient culling. Tick density may be increasing due to greater deer numbers and milder winters.",
"   </p>",
"   <p>",
"    Seroprevalence is the fraction of a population for which antibodies against B. microti antigen are detected at a dilution of &ge;1:64 by immunofluorescence antibody (IFA) test. Seroprevalence varies by study site, year, and time of year (",
"    <a class=\"graphic graphic_table graphicRef64802 \" href=\"mobipreview.htm?14/36/14925\">",
"     table 1",
"    </a>",
"    ). The discrepancy between seroprevalence and the prevalence of clinical disease suggests that asymptomatic infection is common. The prevalence of clinical disease most likely is underestimated because young but otherwise healthy individuals typically experience a mild, self-limited babesial illness, and may not seek medical attention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/20\">",
"     20",
"    </a>",
"    ]. An epidemiology study on Block Island revealed that about 25 percent of adults and 50 percent of children are asymptomatic or experience a mild babesial illness that does not require medical attention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    I. scapularis is the vector for Babesia microti as well as Borrelia burgdorferi and Anaplasma phagocytophilum (the etiologic organisms for Lyme disease and anaplasmosis, respectively). Therefore, individuals exposed to I. scapularis may be infected with any combination of these pathogens. Co-infection with B. microti and B. burgdorferi is fairly common in tick-infested areas (",
"    <a class=\"graphic graphic_table graphicRef76737 \" href=\"mobipreview.htm?41/63/43004\">",
"     table 2",
"    </a>",
"    ), and patients with Lyme disease should be evaluated for babesiosis. Co-infection with A. phagocytophilum is observed less frequently but should be considered in the appropriate epidemiologic circumstances. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/5/6234?source=see_link\">",
"     \"Human ehrlichiosis and anaplasmosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Babesiosis is primarily transmitted via tick bite. Less frequently, transmission may occur via transfusion or perinatally.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tick bite &mdash; The primary mode of transmission is via tick bite; nymphs are the primary vectors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/1-4\">",
"       1-4",
"      </a>",
"      ]. Nymphs are replete with blood about 72 hours following attachment, and sporozoites are generally transmitted to the host on the third day of attachment. Therefore, tick identification and removal during the first 48 hours greatly minimize the risk of transmission. Most infections with B. microti are acquired from May through September; three-fourths of cases are diagnosed during July and August [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/22,23\">",
"       22,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transfusion &mdash; Babesiosis may be transmitted via transfusion of blood products from asymptomatic donors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/24\">",
"       24",
"      </a>",
"      ]. Between 1979 and 2009, 159 cases were identified [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/25\">",
"       25",
"      </a>",
"      ]. Three fourths of cases were reported in the last decade (between 2000 and 2009). The incidence of transfusion-transmitted babesiosis is 1.1 case per million of RBC units distributed for transfusion across the United States [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/26\">",
"       26",
"      </a>",
"      ]. In Connecticut (an endemic area) the risk of acquiring B. microti from an RBC unit is",
"      <span class=\"nowrap\">",
"       1/600",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       1/1800",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/26\">",
"       26",
"      </a>",
"      ]. In Connecticut (an endemic area) the risk of acquiring B. microti from an RBC unit is",
"      <span class=\"nowrap\">",
"       1/600",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       1/1800",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/27\">",
"       27",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Most cases of transfusion-transmitted babesiosis occur from June through November (consistent with the seasonality of tick-acquired babesiosis) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/25,28\">",
"       25,28",
"      </a>",
"      ]. As asymptomatic infection can persist for more than a year, transfusion-transmitted babesiosis may be diagnosed at any time during the year. Transfusion-transmitted babesiosis can occur outside of endemic areas; donors may become infected when traveling in endemic areas and blood products donated in endemic areas may be exported to non-endemic areas.",
"      <br/>",
"      <br/>",
"      Most cases of transfusion-transmitted babesiosis occur via red blood cell units; four cases have been attributed to platelet units contaminated with RBCs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/25\">",
"       25",
"      </a>",
"      ]. Liquid-stored RBCs typically are involved; frozen deglycerolized RBCs are seldom implicated. The median age of liquid-stored RBCs at time of transfusion is 16 days. In few cases, RBC units had been stored for as long as 35 to 40 days. B. microti survives in cryopreserved RBCs because glycerol prevents lysis of the parasite.",
"      <br/>",
"      <br/>",
"      Cases of transfusion-transmitted babesiosis have a median age of 65 years; two-thirds of patients with transfusion-transmitted babesiosis are &gt;50 years; ten percent are infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/25\">",
"       25",
"      </a>",
"      ]. All have significant comorbidity at time of transfusion. The most frequent conditions or procedures linked to transfusion-transmitted babesiosis include hematologic disorders, cardiovascular surgery or procedure, gastrointestinal disease, bleeding and surgery; newborn or babies with complications of prematurity are also at risk. Transfusion-transmitted babesiosis also occurs in patients who have undergone post-traumatic splenectomy or solid organ transplantation. Two thirds of patients with transfusion-transmitted babesiosis in the first four decades of life have hereditary hematological disorders, including sickle cell disease, thalassemia major, and Diamond-Blackfan anemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/25\">",
"       25",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The median interval from transfusion to onset of symptoms is 37 days (range 11 to 176 days) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/25\">",
"       25",
"      </a>",
"      ]. The median interval from symptom onset to diagnosis is six days (range 0 to 54 days). The outcome is fatal in 20 percent of patients, and the median interval from diagnosis to death is seven days (range 0 to 55 days). Potential blood donors with history or symptoms of babesiosis are deferred indefinitely. Such preventive measure fails to exclude asymptomatic individuals or individuals who experienced mild but undiagnosed babesiosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although one-half of seropositive individuals are positive for B. microti DNA, blood donors are not routinely screened for B. microti specific antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/29\">",
"     29",
"    </a>",
"    ]. A cost-effective strategy to screen for B. microti antigen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    DNA among blood donors is needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. An interim analysis of a laboratory-based blood donor screening program suggested that the combined use of B. microti IFA and real-time polymerase chain reaction (PCR) is effective in reducing the incidence of transfusion-transmitted babesiosis among neonates and pediatric sickle cell and thalassemia patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/30\">",
"     30",
"    </a>",
"    ]. Cases of transfusion-transmitted babesiosis should be reported to public health authorities; donors involved in such cases should be deferred indefinitely, and the donor units withdrawn.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Transplacental/perinatal",
"      </span>",
"      transmission &mdash; Four cases of congenital infection with B. microti have been reported in the United States [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/31-33\">",
"       31-33",
"      </a>",
"      ]. Infants were born at term and symptoms developed between the third and fifth week of age. There was no history of tick bites. At the time of diagnosis, parasites were noted in red blood cells (2 to 15 percent parasitemia). In three cases, the mother recalled being bitten by a tick one to seven weeks prior to delivery, but maternal infection was detected at the time of infant diagnosis in only one of four mothers. Both infants and mothers had antibodies against B. microti antigen.",
"      <br/>",
"      <br/>",
"      Infants were successfully treated with intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/kg/d)",
"      </span>",
"      and oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      (25",
"      <span class=\"nowrap\">",
"       mg/kg/d),",
"      </span>",
"      intravenous clindamycin (50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every eight hours) and oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg/d)",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/5/11350?source=see_link\">",
"       atovaquone",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/kg/d)",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (10 or 12",
"      <span class=\"nowrap\">",
"       mg/kg/d).",
"      </span>",
"      In each case, severe hemolysis required a transfusion of packed red blood cells two or three days after initiation of therapy. In one case, persistent hemolysis prompted the addition of azithromycin (10",
"      <span class=\"nowrap\">",
"       mg/kg/d).",
"       <br/>",
"       <br/>",
"       Neonatal",
"      </span>",
"      babesiosis can also be acquired by tick bite or by transfusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/31,34\">",
"       31,34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most young immunocompetent individuals experience a mild self-limited viral-like illness; such patients may not seek clinical attention. In contrast, severe babesiosis often occurs in individuals presenting with the following risk factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &gt;50 years",
"     </li>",
"     <li>",
"      Gender (male)",
"     </li>",
"     <li>",
"      Splenectomy",
"     </li>",
"     <li>",
"      Co-infection with HIV",
"     </li>",
"     <li>",
"      Malignancies",
"     </li>",
"     <li>",
"      Immunosuppression caused by therapies of cancer (including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ) or transplantation",
"     </li>",
"     <li>",
"      Blockade of tumor necrosis factor alpha (TNF-&alpha;) activity (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/35-37\">",
"       35-37",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/25/39321?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations, diagnosis, treatment, and prevention of babesiosis\", section on 'Severe illness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other species",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      B. duncani and related organisms &mdash; Babesiosis due to B. duncani and related organisms is rare; two cases have been described in Washington State (WA1, WA2), and six cases have been described in northern California (including CA1 to CA5) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/38-41\">",
"       38-41",
"      </a>",
"      ]. Of these, five cases were attributed to tick bites and occurred in men &le;50 years; four of the five patients were asplenic (CA1-CA4) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/39,41\">",
"       39,41",
"      </a>",
"      ]. The other three cases were acquired by blood transfusion. One recipient was a 76-year-old normosplenic man with significant comorbidities (megaloblastic anemia, myelodysplasia, and coronary artery disease) (WA2) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/38\">",
"       38",
"      </a>",
"      ]. The second recipient was a premature male infant treated for anemia of prematurity (CA5) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/40\">",
"       40",
"      </a>",
"      ]. The third recipient was 59-year-old sickle cell patient with an autoinfarcted spleen and other comorbidities (congestive heart failure and chronic renal insufficiency) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/42\">",
"       42",
"      </a>",
"      ]. The implicated donors had experienced no or mild symptoms (nausea, fatigue) prior to donation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/38,40,42\">",
"       38,40,42",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The incidence of B. duncani infection remains unclear, as symptomatic cases are too few to validate the serologic testing. Using cut-off titers of 1:256 or 1:320, studies have assessed that seroprevalence ranges from 3.9 to 16.9 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/4,38,39,41\">",
"       4,38,39,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      B. divergens-like organisms &mdash; Cases of babesiosis due to B. divergens-like organisms have been reported in Missouri, Kentucky, and Washington state [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/43-45\">",
"       43-45",
"      </a>",
"      ]. All three patients were asplenic men &ge;50 years with outdoor exposure, though no recollection of a tick bite. The incidence of infection with B. divergens-like organisms is unknown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY: EUROPE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Babesia divergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first documented human case of babesiosis was a 33-year-old asplenic herdsman who grazed his cattle on tick-infested pastures near Zagreb, Croatia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/5\">",
"     5",
"    </a>",
"    ]. The etiologic agent was probably B. divergens, although it was initially identified as B. bovis. Since 1956, about 30 cases in Europe have been attributed to B. divergens, mostly in France, Great Britain and Ireland, particularly in regions with cattle. Isolated cases have been reported from Finland, Sweden, Poland, Spain, and Portugal. The majority of cases were asplenic individuals who became ill between May and September, and all cases were attributed to tick bites.",
"   </p>",
"   <p>",
"    Cattle are the natural host for B. divergens; therefore individuals at risk include farmers, foresters and vacationers engaged in outdoor activities. Serosurveys have demonstrated 0.8 to 1 percent seroprevalence among healthy blood donors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/5,46\">",
"     5,46",
"    </a>",
"    ]. Among patients with clinical or serological Lyme borreliosis, seroprevalence has ranged from 4 to 13 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Babesia microti",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only autochthonous case of babesiosis due to B. microti was a 42-year-old German woman with acute myeloid leukemia who had received multiple blood transfusions prior to chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/48\">",
"     48",
"    </a>",
"    ]. Three other cases of babesiosis due to B. microti were travelers returning to their home country (Austria, Czechoslovakia, the Netherlands) after travel in the Northeastern United States. A case of B. microti infection in Poland is thought to have been acquired in Brazil.",
"   </p>",
"   <p>",
"    Babesiosis caused by B. microti may be under-recognized in Europe; serosurveys have demonstrated 1.5 to 3.4 percent seroprevalence among healthy individuals in regions where I. ricinus ticks are endemic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/46,49,50\">",
"     46,49,50",
"    </a>",
"    ]. Among patients with clinical or serological evidence of Lyme borreliosis, seroprevalence has been estimated at 8.3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Babesia venatorum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Babesia EU1 (provisionally named B. venatorum) has been identified as the etiologic agent of four cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/11,13,51\">",
"     11,13,51",
"    </a>",
"    ]. All patients were men &ge;50 years, and had undergone splenectomy because of Hodgkin's disease or hairy cell leukemia.",
"   </p>",
"   <p>",
"    As sera from patients infected with B. venatorum react with B. divergens antigen, cases attributed to B. divergens may have been caused by B. venatorum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/13\">",
"     13",
"    </a>",
"    ]. In the absence of an IFA test specific for B. venatorum, the incidence of infection with B. venatorum remains unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY: OTHER REGIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated cases of clinical babesiosis been reported around the world, including the Canary Islands, Egypt, South Africa, Mozambique, India, China, Taiwan, South Korea, Japan, and Australia. Asymptomatic infections have been reported from Mexico and Colombia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/9,12,15,16,52-54\">",
"     9,12,15,16,52-54",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Other species'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of Babesia species has been studied in animal models (mostly mice, cattle, and dogs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/55\">",
"     55",
"    </a>",
"    ]. Anemia is a major feature of babesiosis as egress of merozoites is accompanied by rupture of the host red blood cell (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Life cycle'",
"    </a>",
"    above). Hemoglobin that is concomitantly released is immediately complexed by circulating haptoglobin, and taken up by phagocytes. Accordingly, circulating levels of haptoglobin are low in severe babesiosis. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Life cycle'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Hemolysis alone cannot account for the severity of anemia due to babesiosis, as anemia is more severe and prolonged than parasitemia. Replication of Babesia generates reactive oxygen species that alter the structural integrity of red blood cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/56\">",
"     56",
"    </a>",
"    ]. Lipid peroxidation decreases red blood cell deformability and therefore promotes their removal by splenic histiocytes. Opsonization by autologous IgG and perhaps complement factors may also contribute to red blood cell clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/56\">",
"     56",
"    </a>",
"    ]. Anemia is coupled with increased erythropoiesis as evidenced by reticulocytosis.",
"   </p>",
"   <p>",
"    The role of antibodies in host defense against Babesia is not fully understood. Although nearly every individual infected with B. microti develops antibodies by the time parasitemia has cleared, lack of mature B cells in mice does not increase their susceptibility to infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Some immunodeficient hosts, however, may rely on antibodies for clearance of Babesia parasites; in patients with B cell lymphoma treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (anti-CD20), parasites persist despite standard antimicrobial therapy. In these hosts, resolution of parasitemia coincides with seroconversion and requires a prolonged antimicrobial regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/11,59\">",
"     11,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CD4+ T cells are central to host immunity in babesiosis. Babesiosis typically is severe in HIV infected individuals (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/25/39321?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical manifestations, diagnosis, treatment, and prevention of babesiosis\", section on 'Treatment of severe illness due to B. microti'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/57,60,61\">",
"     57,60,61",
"    </a>",
"    ]. In mice with B. microti infection, depletion of CD4+ T cells compromises resistance and prevents resolution of parasitemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/60\">",
"     60",
"    </a>",
"    ]. Deletion of the CD4 gene protects mice from lethal infection with B. duncani [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/62\">",
"     62",
"    </a>",
"    ]. Interferon (IFN)-gamma is critical for host resistance to B. microti and B. duncani [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/57,60,61\">",
"     57,60,61",
"    </a>",
"    ]. The main source of IFN-gamma appears to be CD4+ T cells in B. microti infection, and NK cells in B. duncani infection. Interferon-gamma upregulates the surface expression of MHC class II molecules on antigen presenting cells and upregulates inflammatory cytokine gene expression.",
"   </p>",
"   <p>",
"    Symptoms of babesiosis, such as fever, headache, and myalgia, are characteristics of viral-like illnesses and are suggestive of a host inflammatory response involving pyrogenic cytokines, such as tumor necrosis factor (TNF)-alpha and interleukin (IL)-6. Both cytokines were detected in the blood of a patient with mild babesiosis due to a B. microti-like organism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/1,52\">",
"     1,52",
"    </a>",
"    ]. In addition, inflammatory cytokines likely contribute to the complications associated with severe babesiosis, such as adult respiratory distress and congestive heart failure. In mice infected with B. duncani, manifestations include pulmonary edema, and intravascular margination of leukocytes are noted in the lungs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/63\">",
"     63",
"    </a>",
"    ]. In these mice, TNF-alpha is localized to the alveolar septa, and IFN-gamma around and within pulmonary vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/63\">",
"     63",
"    </a>",
"    ]. Blockade of TNF-alpha activity prevents death of B. duncani infected mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42248/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Babesiosis is an infectious disease due to protozoa of the genus Babesia that invade and lyse host red blood cells. The primary mode of transmission is via tick bite. Less frequently, transmission may also occur via transfusion or perinatally. Babesia species are classified in four clades based on their molecular genetic characteristics. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Species characteristics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Babesia microti is the predominant species causing human babesiosis in the United States. Babesiosis due to B. microti is endemic in the northeastern region of the United States, particularly in the coastal counties and on the islands of southern New England. Babesiosis due to B. microti also is endemic in the upper Midwest of the United States. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Epidemiology: United States'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The transmission cycle of B. microti includes ticks, deer, and mice; adult Ixodes scapularis ticks feed on white-tailed deer (which are not competent reservoirs for B. microti), whereas tick larvae and nymphs feed on white-footed mice (the primary reservoir for B. microti). Nymphs are primary vectors for transmission to humans, which are accidental hosts (",
"      <a class=\"graphic graphic_figure graphicRef65153 \" href=\"mobipreview.htm?39/38/40547\">",
"       figure 2",
"      </a>",
"      ). Sporozoites transmitted to vertebrate hosts by tick feeding enter the circulation and invade red blood cells. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Life cycle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tick feeding introduces sporozoites into the dermis of the vertebrate host. Sporozoites eventually reach the circulation, where they invade red blood cells. Within red cells sporozoites differentiate into trophozoites, and asexual replication of trophozoites generates two to four merozoites. Egress of merozoites is accompanied by rupture of the host cell. Free merozoites in turn invade additional red blood cells. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Life cycle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anemia and fever are major features of babesiosis. Anemia results, in part, from the hemolysis of red blood cells upon egress of merozoites. Non-hemolytic loss of red blood cells may result from their decreased deformability due to lipid peroxidation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      from their opsonization by autologous IgG and complement factors. Fever likely results from the production of inflammatory cytokines, such as TNF-alpha and IL-6. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Babesia divergens is the species to which most cases of human babesiosis in Europe have been attributed; the transmission cycle includes ticks and cattle. The life cycles of other Babesia species that rarely infect humans are poorly understood. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Babesia divergens'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Other species'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/1\">",
"      Vannier E, Gewurz BE, Krause PJ. Human babesiosis. Infect Dis Clin North Am 2008; 22:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/2\">",
"      Homer MJ, Aguilar-Delfin I, Telford SR 3rd, et al. Babesiosis. Clin Microbiol Rev 2000; 13:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/3\">",
"      Hunfeld KP, Hildebrandt A, Gray JS. Babesiosis: recent insights into an ancient disease. Int J Parasitol 2008; 38:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/4\">",
"      Kjemtrup AM, Conrad PA. Human babesiosis: an emerging tick-borne disease. Int J Parasitol 2000; 30:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/5\">",
"      Zintl A, Mulcahy G, Skerrett HE, et al. Babesia divergens, a bovine blood parasite of veterinary and zoonotic importance. Clin Microbiol Rev 2003; 16:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/6\">",
"      Conrad PA, Kjemtrup AM, Carreno RA, et al. Description of Babesia duncani n.sp. (Apicomplexa: Babesiidae) from humans and its differentiation from other piroplasms. Int J Parasitol 2006; 36:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/7\">",
"      Criado-Fornelio A, Martinez-Marcos A, Buling-Sara&ntilde;a A, Barba-Carretero JC. Molecular studies on Babesia, Theileria and Hepatozoon in southern Europe. Part II. Phylogenetic analysis and evolutionary history. Vet Parasitol 2003; 114:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/8\">",
"      Goethert HK, Telford SR 3rd. What is Babesia microti? Parasitology 2003; 127:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/9\">",
"      Kim JY, Cho SH, Joo HN, et al. First case of human babesiosis in Korea: detection and characterization of a novel type of Babesia sp. (KO1) similar to ovine babesia. J Clin Microbiol 2007; 45:2084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/10\">",
"      Holman PJ. Phylogenetic and biologic evidence that Babesia divergens is not endemic in the United States. Ann N Y Acad Sci 2006; 1081:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/11\">",
"      H&auml;selbarth K, Tenter AM, Brade V, et al. First case of human babesiosis in Germany - Clinical presentation and molecular characterisation of the pathogen. Int J Med Microbiol 2007; 297:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/12\">",
"      Olmeda AS, Armstrong PM, Rosenthal BM, et al. A subtropical case of human babesiosis. Acta Trop 1997; 67:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/13\">",
"      Herwaldt BL, Cacci&ograve; S, Gherlinzoni F, et al. Molecular characterization of a non-Babesia divergens organism causing zoonotic babesiosis in Europe. Emerg Infect Dis 2003; 9:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/14\">",
"      Bonnet S, Jouglin M, L'Hostis M, Chauvin A. Babesia sp. EU1 from roe deer and transmission within Ixodes ricinus. Emerg Infect Dis 2007; 13:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/15\">",
"      Wei Q, Tsuji M, Zamoto A, et al. Human babesiosis in Japan: isolation of Babesia microti-like parasites from an asymptomatic transfusion donor and from a rodent from an area where babesiosis is endemic. J Clin Microbiol 2001; 39:2178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/16\">",
"      Vannier E, Krause PJ. Update on babesiosis. Interdiscip Perspect Infect Dis 2009; 2009:984568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/17\">",
"      Centers for Disease Control and Prevention (CDC). Babesiosis surveillance - 18 States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/18\">",
"      Joseph JT, Roy SS, Shams N, et al. Babesiosis in Lower Hudson Valley, New York, USA. Emerg Infect Dis 2011; 17:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/19\">",
"      Jones KE, Patel NG, Levy MA, et al. Global trends in emerging infectious diseases. Nature 2008; 451:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/20\">",
"      Ruebush TK 2nd, Juranek DD, Chisholm ES, et al. Human babesiosis on Nantucket Island. Evidence for self-limited and subclinical infections. N Engl J Med 1977; 297:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/21\">",
"      Krause PJ, McKay K, Gadbaw J, et al. Increasing health burden of human babesiosis in endemic sites. Am J Trop Med Hyg 2003; 68:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/22\">",
"      Hatcher JC, Greenberg PD, Antique J, Jimenez-Lucho VE. Severe babesiosis in Long Island: review of 34 cases and their complications. Clin Infect Dis 2001; 32:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/23\">",
"      White DJ, Talarico J, Chang HG, et al. Human babesiosis in New York State: Review of 139 hospitalized cases and analysis of prognostic factors. Arch Intern Med 1998; 158:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/24\">",
"      Leiby DA. Transfusion-transmitted Babesia spp.: bull's-eye on Babesia microti. Clin Microbiol Rev 2011; 24:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/25\">",
"      Herwaldt BL, Linden JV, Bosserman E, et al. Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med 2011; 155:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/26\">",
"      Tonnetti L, Eder AF, Dy B, et al. Transfusion-transmitted Babesia microti identified through hemovigilance. Transfusion 2009; 49:2557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/27\">",
"      Leiby DA. Babesiosis and blood transfusion: flying under the radar. Vox Sang 2006; 90:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/28\">",
"      Gubernot DM, Lucey CT, Lee KC, et al. Babesia infection through blood transfusions: reports received by the US Food and Drug Administration, 1997-2007. Clin Infect Dis 2009; 48:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/29\">",
"      Leiby DA, Chung AP, Gill JE, et al. Demonstrable parasitemia among Connecticut blood donors with antibodies to Babesia microti. Transfusion 2005; 45:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/30\">",
"      Young C, Chawla A, Berardi V, et al. Preventing transfusion-transmitted babesiosis: preliminary experience of the first laboratory-based blood donor screening program. Transfusion 2012; 52:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/31\">",
"      Fox LM, Wingerter S, Ahmed A, et al. Neonatal babesiosis: case report and review of the literature. Pediatr Infect Dis J 2006; 25:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/32\">",
"      Sethi S, Alcid D, Kesarwala H, Tolan RW Jr. Probable congenital babesiosis in infant, new jersey, USA. Emerg Infect Dis 2009; 15:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/33\">",
"      Aderinboye O, Syed SS. Congenital babesiosis in a four-week-old female infant. Pediatr Infect Dis J 2010; 29:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/34\">",
"      Simonsen KA, Harwell JI, Lainwala S. Clinical presentation and treatment of transfusion-associated babesiosis in premature infants. Pediatrics 2011; 128:e1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/35\">",
"      Taiwo B, Lee C, Venkat D, et al. Can tumor necrosis factor alpha blockade predispose to severe babesiosis? Arthritis Rheum 2007; 57:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/36\">",
"      Cullen G, Sands BE, Yajnik V. Babesiosis in a patient on infliximab for Crohn's disease. Inflamm Bowel Dis 2010; 16:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/37\">",
"      Bogoch II, Davis BT, Hooper DC. Severe babesiosis in a patient treated with a tumor necrosis factor &alpha; antagonist. Clin Infect Dis 2012; 54:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/38\">",
"      Herwaldt BL, Kjemtrup AM, Conrad PA, et al. Transfusion-transmitted babesiosis in Washington State: first reported case caused by a WA1-type parasite. J Infect Dis 1997; 175:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/39\">",
"      Quick RE, Herwaldt BL, Thomford JW, et al. Babesiosis in Washington State: a new species of Babesia? Ann Intern Med 1993; 119:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/40\">",
"      Kjemtrup AM, Lee B, Fritz CL, et al. Investigation of transfusion transmission of a WA1-type babesial parasite to a premature infant in California. Transfusion 2002; 42:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/41\">",
"      Persing DH, Herwaldt BL, Glaser C, et al. Infection with a babesia-like organism in northern California. N Engl J Med 1995; 332:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/42\">",
"      Bloch EM, Herwaldt BL, Leiby DA, et al. The third described case of transfusion-transmitted Babesia duncani. Transfusion 2012; 52:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/43\">",
"      Beattie JF, Michelson ML, Holman PJ. Acute babesiosis caused by Babesia divergens in a resident of Kentucky. N Engl J Med 2002; 347:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/44\">",
"      Herwaldt B, Persing DH, Pr&eacute;cigout EA, et al. A fatal case of babesiosis in Missouri: identification of another piroplasm that infects humans. Ann Intern Med 1996; 124:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/45\">",
"      Herwaldt BL, de Bruyn G, Pieniazek NJ, et al. Babesia divergens-like infection, Washington State. Emerg Infect Dis 2004; 10:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/46\">",
"      Hunfeld KP, Lambert A, Kampen H, et al. Seroprevalence of Babesia infections in humans exposed to ticks in midwestern Germany. J Clin Microbiol 2002; 40:2431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/47\">",
"      Uhnoo I, Cars O, Christensson D, Nystr&ouml;m-Rosander C. First documented case of human babesiosis in Sweden. Scand J Infect Dis 1992; 24:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/48\">",
"      Hildebrandt A, Hunfeld KP, Baier M, et al. First confirmed autochthonous case of human Babesia microti infection in Europe. Eur J Clin Microbiol Infect Dis 2007; 26:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/49\">",
"      Foppa IM, Krause PJ, Spielman A, et al. Entomologic and serologic evidence of zoonotic transmission of Babesia microti, eastern Switzerland. Emerg Infect Dis 2002; 8:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/50\">",
"      Genchi C. Human babesiosis, an emerging zoonosis. Parassitologia 2007; 49 Suppl 1:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/51\">",
"      Blum S, Gattringer R, Haschke E, et al. The case: hemolysis and acute renal failure. Babesiosis. Kidney Int 2011; 80:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/52\">",
"      Shaio MF, Lin PR. A case study of cytokine profiles in acute human babesiosis. Am J Trop Med Hyg 1998; 58:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/53\">",
"      Shih CM, Liu LP, Chung WC, et al. Human babesiosis in Taiwan: asymptomatic infection with a Babesia microti-like organism in a Taiwanese woman. J Clin Microbiol 1997; 35:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/54\">",
"      Senanayake SN, Paparini A, Latimer M, et al. First report of human babesiosis in Australia. Med J Aust 2012; 196:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/55\">",
"      Krause PJ, Daily J, Telford SR, et al. Shared features in the pathobiology of babesiosis and malaria. Trends Parasitol 2007; 23:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/56\">",
"      Otsuka Y, Yamasaki M, Yamato O, Maede Y. Increased generation of superoxide in erythrocytes infected with Babesia gibsoni. J Vet Med Sci 2001; 63:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/57\">",
"      Clawson ML, Paciorkowski N, Rajan TV, et al. Cellular immunity, but not gamma interferon, is essential for resolution of Babesia microti infection in BALB/c mice. Infect Immun 2002; 70:5304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/58\">",
"      Cavacini LA, Parke LA, Weidanz WP. Resolution of acute malarial infections by T cell-dependent non-antibody-mediated mechanisms of immunity. Infect Immun 1990; 58:2946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/59\">",
"      Krause PJ, Gewurz BE, Hill D, et al. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis 2008; 46:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/60\">",
"      Igarashi I, Waki S, Ito M, et al. Role of CD4+ T cells in the control of primary infection with Babesia microti in mice. J Protozool Res 1994; 4:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/61\">",
"      Aguilar-Delfin I, Wettstein PJ, Persing DH. Resistance to acute babesiosis is associated with interleukin-12- and gamma interferon-mediated responses and requires macrophages and natural killer cells. Infect Immun 2003; 71:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/62\">",
"      Hemmer RM, Ferrick DA, Conrad PA. Role of T cells and cytokines in fatal and resolving experimental babesiosis: protection in TNFRp55-/- mice infected with the human Babesia WA1 parasite. J Parasitol 2000; 86:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42248/abstract/63\">",
"      Hemmer RM, Ferrick DA, Conrad PA. Up-regulation of tumor necrosis factor-alpha and interferon-gamma expression in the spleen and lungs of mice infected with the human Babesia isolate WA1. Parasitol Res 2000; 86:121.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5734 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-D8E73D39BC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_16_42248=[""].join("\n");
var outline_f41_16_42248=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BABESIA SPECIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Species characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Babesia microti",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Life cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Babesia divergens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other species",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EPIDEMIOLOGY: UNITED STATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Babesia microti",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Geography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Incidence and prevalence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Transmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other species",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EPIDEMIOLOGY: EUROPE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Babesia divergens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Babesia microti",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Babesia venatorum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      EPIDEMIOLOGY: OTHER REGIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5734\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5734|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/6/40037\" title=\"figure 1\">",
"      Tick sizes and appearances",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/38/40547\" title=\"figure 2\">",
"      Lyme transmission cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5734|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/36/14925\" title=\"table 1\">",
"      Babesia seroprevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/63/43004\" title=\"table 2\">",
"      Babesia Lyme coinfection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/25/39321?source=related_link\">",
"      Clinical manifestations, diagnosis, treatment, and prevention of babesiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/48/28425?source=related_link\">",
"      Diagnosis of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/5/6234?source=related_link\">",
"      Human ehrlichiosis and anaplasmosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_16_42249="Prevention and management of acute kidney injury (acute renal failure) in children";
var content_f41_16_42249=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention and management of acute kidney injury (acute renal failure) in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/16/42249/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/16/42249/contributors\">",
"     Prasad Devarajan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/16/42249/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/16/42249/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/16/42249/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/16/42249/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/16/42249/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H265511368\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury (AKI) is defined as the abrupt loss of kidney function that results in a decline in glomerular filtration rate (GFR), retention of urea and other nitrogenous waste products, and dysregulation of extracellular volume and electrolytes. The term AKI has largely replaced acute renal failure (ARF) as it more clearly defines renal dysfunction as a continuum rather than a discrete finding of failed kidney function.",
"   </p>",
"   <p>",
"    Pediatric AKI presents as a wide range of clinical manifestations from a minimal elevation in serum creatinine to anuric renal failure, arises from multiple causes, and occurs in a variety of clinical settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. The milder forms of AKI associated with dehydration are usually fully reversible with timely therapy. However, the prognosis remains guarded for critically-ill children with more severe forms of AKI in whom there is a mortality rate of 50 percent or greater [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevention and management of AKI in children are presented in this topic review. The clinical manifestations and diagnosis of AKI in children and the approach to AKI in newborns are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/53/19290?source=see_link\">",
"     \"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27114?source=see_link\">",
"     \"Acute kidney injury (acute renal failure) in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265511375\">",
"    <span class=\"h1\">",
"     PREVENTION OF ACUTE KIDNEY INJURY (AKI)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H535580717\">",
"    <span class=\"h2\">",
"     Proven measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;General measures to prevent AKI include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fluid administration in some settings, such as hypovolemia",
"     </li>",
"     <li>",
"      Avoidance of hypotension by providing inotropic support in critically-ill children following adequate volume repletion (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26762?source=see_link&amp;anchor=H2#H2\">",
"       \"Initial management of shock in children\", section on 'Early goal-directed therapy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Readjustment of nephrotoxic medications based on close monitoring of renal function and drug levels",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265511382\">",
"    <span class=\"h3\">",
"     Fluid administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid administration in the following settings has successfully prevented AKI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pre-renal AKI due to hypovolemia &ndash; In children with a history and physical findings consistent with hypovolemia, administration of an intravenous fluid bolus with normal saline (10 to 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      over 30 minutes) may prevent more severe intrinsic AKI. The bolus can be repeated twice if necessary, until urine output is re-established. Fluid challenge is",
"      <strong>",
"       contraindicated",
"      </strong>",
"      in patients with obvious volume overload or heart failure.",
"     </li>",
"     <li>",
"      At-risk patients for AKI &ndash; Volume expansion has been successful in preventing AKI in patients at-risk for AKI with the following conditions (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42154?source=see_link&amp;anchor=H8#H8\">",
"       \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\", section on 'Optimizing volume status'",
"      </a>",
"      ). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hemoglobinuria and myoglobinuria (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21847?source=see_link\">",
"       \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Administration of potential nephrotoxins, such as aminoglycosides,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/12/201?source=see_link\">",
"       amphotericin B",
"      </a>",
"      , radiocontrast media,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/8/34949?source=see_link\">",
"       cisplatin",
"      </a>",
"      , and intravenous",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34400?source=see_link\">",
"       acyclovir",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18072?source=see_link&amp;anchor=H5#H5\">",
"       \"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity\", section on 'Prevention'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/5/38998?source=see_link&amp;anchor=H5#H5\">",
"       \"Amphotericin B nephrotoxicity\", section on 'Prevention'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35498?source=see_link&amp;anchor=H3#H3\">",
"       \"Prevention of contrast-induced nephropathy\", section on 'Prevention'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29833?source=see_link&amp;anchor=H15#H15\">",
"       \"Cisplatin nephrotoxicity\", section on 'Prevention'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=see_link&amp;anchor=H7#H7\">",
"       \"Acyclovir: An overview\", section on 'Acute renal failure'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tumor lysis syndrome (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/20/3402?source=see_link&amp;anchor=H21715371#H21715371\">",
"       \"Tumor lysis syndrome: Prevention and treatment\", section on 'Prevention'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Surgical procedures, in which there is a reduction in the intravascular volume during either the intraoperative or postoperative period (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42729?source=see_link&amp;anchor=H254314149#H254314149\">",
"       \"Intraoperative fluid management\", section on 'Hypovolemia and reduced tissue perfusion'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4170?source=see_link&amp;anchor=H12#H12\">",
"       \"Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis\", section on 'Surgery'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265511396\">",
"    <span class=\"h3\">",
"     Nephrotoxin management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of nephrotoxic drugs on the development of AKI in children was illustrated in a retrospective single center study of 1660 noncritical-ill hospitalized children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/9\">",
"     9",
"    </a>",
"    ]. Children who developed AKI as defined by the serum creatinine-based pRIFLE criteria (",
"    <a class=\"graphic graphic_table graphicRef68721 \" href=\"mobipreview.htm?16/10/16555\">",
"     table 1",
"    </a>",
"    ) were more likely to be exposed to one or more nephrotoxic medications than patients without AKI (odd ratio [OR] 1.7; 95% CI 1.04-2.9). The RIFLE criteria consists of three graded levels of injury (Risk, Injury, and Failure) based upon either the magnitude of elevation in serum creatinine or urine output, and two outcome measures (Loss and End-stage renal disease). Both increasing dose and duration of nephrotoxin use were associated with increased development of AKI.",
"   </p>",
"   <p>",
"    As a result, monitoring serum creatinine (ie, measure of kidney function) and drug level (if possible) is important as it enables appropriate adjustment of drug dosing based on the knowledge of altered pharmacokinetics in early AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, clinicians should also monitor drug efficacy and toxicity. However, readjustment of drugs is often challenging as renal function changes and if drug monitoring is not available, as discussed below. (See",
"    <a class=\"local\" href=\"#H265511480\">",
"     'Drug management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265511403\">",
"    <span class=\"h2\">",
"     Unproven pharmacologic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several pharmacologic agents including",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/60/43975?source=see_link\">",
"     mannitol",
"    </a>",
"    , loop diuretics, low-dose dopamine,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/35/5684?source=see_link\">",
"     fenoldopam",
"    </a>",
"    , atrial natriuretic peptide, and N-",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/41/16022?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    have been studied in the prevention of AKI. However,",
"    <strong>",
"     none",
"    </strong>",
"    of these agents have been shown to be of proven benefit. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42154?source=see_link\">",
"     \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265511410\">",
"    <span class=\"h3\">",
"     Mannitol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experimental animal studies suggested that",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/60/43975?source=see_link\">",
"     mannitol",
"    </a>",
"    might be protective by causing a diuresis (thereby minimizing intratubular cast formation) and by acting as a free radical scavenger (thereby minimizing cell injury). In the clinical setting, the efficacy of mannitol for prevention of AKI is inconclusive, and its use can result in significant side effects including volume expansion, hyperosmolality, pulmonary edema and AKI. Its use for prevention of AKI is",
"    <strong>",
"     not",
"    </strong>",
"    recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32451?source=see_link&amp;anchor=H2#H2\">",
"     \"Complications of mannitol therapy\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265511417\">",
"    <span class=\"h3\">",
"     Loop diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loop diuretics such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    induce a diuresis by reducing active NaCl transport in the thick ascending limb of the loop of Henle. It has been proposed that the ensuing decrease in energy requirement may be protective of renal tubule cells, which may be faced with a decrease in energy delivery due to renal hypoperfusion or injury. However, the available evidence from adult clinical studies does not support the routine use of diuretics as a preventive measure for AKI, and in some settings, diuretic use was associated with an increase in serum creatinine. As a result, the routine use of loop diuretics to prevent AKI is",
"    <strong>",
"     not",
"    </strong>",
"    recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42154?source=see_link&amp;anchor=H9#H9\">",
"     \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\", section on 'Diuretics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265511424\">",
"    <span class=\"h3\">",
"     Dopamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of low &ldquo;renal-dose&rdquo; of the inotropic agent dopamine (0.5 to 3",
"    <span class=\"nowrap\">",
"     mg/kg/min)",
"    </span>",
"    is common in the critical care setting due to its renal vasodilatory and natriuretic effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/5\">",
"     5",
"    </a>",
"    ]. However, prospective randomized studies of adult patients at risk for AKI have not shown a beneficial renoprotective effect of &ldquo;low-dose&rdquo; dopamine. In addition, there are significant side effects of dopamine therapy including tachycardia, arrhythmias, myocardial ischemia, and intestinal ischemia. Therefore, the routine use of dopamine for prevention of AKI is",
"    <strong>",
"     not",
"    </strong>",
"    recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42154?source=see_link&amp;anchor=H10#H10\">",
"     \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\", section on 'Dopamine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265511431\">",
"    <span class=\"h3\">",
"     Fenoldopam",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/35/5684?source=see_link\">",
"     Fenoldopam",
"    </a>",
"    is a potent, short-acting, selective dopamine A-1 receptor agonist that increases renal blood flow and decreases systemic vascular resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/11\">",
"     11",
"    </a>",
"    ]. Data are limited in the use of this agent in children at-risk for AKI.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a small retrospective study of 13 critically-ill children receiving",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/35/5684?source=see_link\">",
"       fenoldopam",
"      </a>",
"      , a significant increase in urine output and a reduction in BUN within 24 hours were noted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a small, prospective, single-center randomized, double-blind, controlled trial of 80 children undergoing cardiac surgery requiring cardiopulmonary bypass, patients who received",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/35/5684?source=see_link\">",
"       fenoldopam",
"      </a>",
"      compared with those treated with placebo had lower urinary neutrophil gelatinase-associated lipocalin and cystatin C levels (AKI biomarkers) at the end of surgery, and 12 hours after admission into the pediatric intensive care unit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/13\">",
"       13",
"      </a>",
"      ]. There was also a reduction in the use of diuretics (",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/26/5544?source=see_link\">",
"       furosemide",
"      </a>",
"      ) and vasodilators (",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/36/14917?source=see_link\">",
"       phentolamine",
"      </a>",
"      ) in the fenoldopam group (OR 0.22; 95% CI 0.07-0.7).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar results have been reported in adults. However, because of the heterogeneity amongst studies and inability to verify changes in glomerular filtration rate, the benefits of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/35/5684?source=see_link\">",
"     fenoldopam",
"    </a>",
"    must be confirmed in large randomized, controlled trials prior to routine recommendation of this agent for the prevention of AKI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42154?source=see_link&amp;anchor=H13#H13\">",
"     \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\", section on 'Fenoldopam'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265511438\">",
"    <span class=\"h3\">",
"     Natriuretic peptides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial natriuretic peptide (ANP) and b-type natriuretic peptide (BNP) block tubular reabsorption of sodium and vasodilate the afferent arteriole. The renoprotective effects of these agents have been evaluated primarily in trials of adults undergoing cardiac surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42154?source=see_link&amp;anchor=H14#H14\">",
"     \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\", section on 'Atrial natriuretic peptide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pediatric data for the renoprotective effects of natriuretic peptides are limited. In a small retrospective study of 20 children with decompensated heart failure, recombinant human b-type natriuretic peptide (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    ) resulted in increased urine output and decreased serum creatinine concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/14\">",
"     14",
"    </a>",
"    ]. Because of the paucity of data, the routine use of natriuretic peptides for prophylaxis against AKI is",
"    <strong>",
"     not",
"    </strong>",
"    recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265511445\">",
"    <span class=\"h3\">",
"     N-acetylcysteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;N-",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/41/16022?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    (NAC) is a free radical scavenger antioxidant agent that counteracts the deleterious effects of reactive oxygen species in the generation of tubular injury and also has vasodilatory properties. In adults, several meta-analyses have demonstrated NAC did not provide any additional benefit to placebo in the prevention of AKI in adults following surgery. Although data regarding the use of oral NAC in prevention of contrast-nephropathy in adults are equivocal, NAC is often administered to high-risk patients undergoing a radiologic study that requires the administration of radiocontrast media as it is a well tolerated drug with minimal side effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42154?source=see_link&amp;anchor=H15#H15\">",
"     \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\", section on 'N-acetylcysteine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35498?source=see_link&amp;anchor=H16#H16\">",
"     \"Prevention of contrast-induced nephropathy\", section on 'Acetylcysteine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While NAC is commonly used in children for treatment of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    toxicity and other forms of acute liver failure, there are",
"    <strong>",
"     no",
"    </strong>",
"    data for its renoprotective effects in the pediatric population. The routine use of NAC for AKI prophylaxis in children is therefore",
"    <strong>",
"     not",
"    </strong>",
"    recommended, with the possible exception of judicious use in children at high-risk for contrast-induced nephropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265511452\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF ACUTE KIDNEY INJURY (AKI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic principles of the general management of the child with AKI include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Specific treatment of the underlying cause (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/53/19290?source=see_link&amp;anchor=H17605650#H17605650\">",
"       \"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis\", section on 'Etiology and pathogenesis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fluid management",
"     </li>",
"     <li>",
"      Electrolyte management",
"     </li>",
"     <li>",
"      Nutritional support",
"     </li>",
"     <li>",
"      Adjustment of drug dosing",
"     </li>",
"     <li>",
"      Renal replacement therapy",
"     </li>",
"     <li>",
"      Specific pharmacologic therapies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, prompt consultation and referral to a pediatric nephrologist are recommended for the management of intrinsic AKI, especially in the critically-ill child.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265511459\">",
"    <span class=\"h2\">",
"     Fluid management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fluid status of the child varies depending on the underlying cause, comorbid conditions, and possible previous therapy. Accurate initial assessment is required to determine if the child is hypovolemic, euvolemic, or hypervolemic, and guides initial fluid management. Subsequent fluid therapy is based on careful follow-up with accurate records of fluid input and output, body weights, physical examinations (eg, blood pressure and pulse), and additional invasive monitoring as needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H535581842\">",
"    <span class=\"h3\">",
"     Hypovolemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A child with a clinical history and physical exam consistent with hypovolemia requires emergent intravenous fluid therapy given as a normal saline bolus (10 to 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    over 30 minutes, repeated twice as needed) in an attempt to restore renal function and prevent the progression of prerenal AKI to intrinsic AKI. If urine output does not increase and renal function fails to improve with the restoration of intravascular volume (ie, no decrease in serum creatinine and blood urea nitrogen), bladder catheterization is recommended to confirm anuria. At this point, other forms of invasive monitoring, such as measuring central venous pressure, may be required to adequately assess the child&rsquo;s fluid status and help guide further therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H535581850\">",
"    <span class=\"h3\">",
"     Euvolemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In euvolemic children, ongoing fluid losses (insensible fluid [300 to 500",
"    <span class=\"nowrap\">",
"     mL/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day], urine and gastrointestinal losses) should be balanced by administered fluids including medications and nutrition. Insensible water losses are higher in febrile children and lower in ventilated children due to decreased respiratory losses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6470?source=see_link&amp;anchor=H7#H7\">",
"     \"Maintenance fluid therapy in children\", section on 'Sensible and insensible water loss'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H535581857\">",
"    <span class=\"h3\">",
"     Hypervolemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;On the other hand, a child with signs of fluid overload (edema, heart failure and pulmonary edema) requires fluid removal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fluid restriction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H535581864\">",
"    <span class=\"h4\">",
"     Furosemide",
"    </span>",
"    &nbsp;&mdash;&nbsp;A trial of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    may be attempted to induce a diuresis and convert AKI from an oliguric to a non-oliguric form, thereby simplifying fluid and nutritional management. However, loop diuretic therapy does not significantly alter the natural course of AKI. The dissociation between increasing the urine output and not affecting the course of AKI with diuretic therapy probably reflects the ability of the diuretic to enhance the urine output in those few nephrons that are still functioning. However, there is no effect on nonfunctioning nephrons, and as a result, there is no effect on the course of the renal failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42154?source=see_link&amp;anchor=H20#H20\">",
"     \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\", section on 'Diuretics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a trial of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    is used, it should be given as a single high-dose bolus (2 to 5",
"    <span class=\"nowrap\">",
"     mg/kg/dose)",
"    </span>",
"    to children in the early stages of oliguric AKI with hypervolemia (ie, oliguria of less than 24 hours&rsquo; duration). If the diuretic bolus is effective, a continuous infusion of furosemide (0.1 to 0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour) may be started. Furosemide should be promptly discontinued if the bolus doses do not result in a diuretic response within two hours of bolus administration. The risk of ototoxicity and renal toxicity from furosemide use in this setting is significant due to potential elevated serum levels. Care should also be taken to avoid hypotension from overuse of diuretic therapy as this might result in further kidney injury and in some cases, increase mortality. Loop diuretics should",
"    <strong>",
"     not",
"    </strong>",
"    be used as prolonged therapy for established AKI, but given for a short length of time for volume control in responsive patients because of the risk of adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H535581871\">",
"    <span class=\"h4\">",
"     Critically-ill children",
"    </span>",
"    &nbsp;&mdash;&nbsp;In critically-ill children, the degree of fluid overload is an independent risk factor for mortality, irrespective of severity of illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. This was illustrated in a study of 297 children who received continuous renal replacement therapy from the Prospective Pediatric Continuous Renal Replacement Therapy (ppCRRT) Registry Group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/15\">",
"     15",
"    </a>",
"    ]. Mortality rates for patients who developed fluid overload greater than 20 percent, between 10 and 20 percent, and less than 10 percent were 66, 43, and 29 percent, respectively. After adjusting for severity of illness and intergroup differences, there was a 3 percent increase in mortality for each 1 percent increase in severity of fluid overload.",
"   </p>",
"   <p>",
"    As discussed above, in children with AKI, the fluid status should be determined. We utilize the equation from the 2007 updated American College of Critical Care Medicine Clinical Guidelines for Hemodynamic Support of Neonates and Children with Septic Shock as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Percent fluid overload = [total fluid in (Liters) &ndash; fluid out",
"    <span class=\"nowrap\">",
"     (Liters)]/admission",
"    </span>",
"    weight (kg) x 100",
"   </p>",
"   <p>",
"    Renal replacement therapy (RRT) should be strongly considered for critically-ill children with AKI who are not expected to recover kidney function expeditiously when fluid overload exceeds 10 percent and is performed for those with fluid overload greater than 15 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/7/23673?source=see_link&amp;anchor=H4746416#H4746416\">",
"     \"Pediatric acute kidney injury: Indications, timing, and choice of modality for renal replacement therapy (RRT)\", section on 'Fluid overload'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265511466\">",
"    <span class=\"h2\">",
"     Electrolyte management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrolyte abnormalities are common complications of AKI. In general, electrolyte disturbances are asymptomatic, and require a high-index of suspicion and routine monitoring for early detection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/53/19290?source=see_link&amp;anchor=H20044887#H20044887\">",
"     \"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis\", section on 'Other laboratory findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    General measures to reduce or prevent electrolyte abnormalities in children with AKI include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with oligo-anuric AKI should not receive potassium or phosphorus unless they exhibit significant hypokalemia or hypophosphatemia.",
"     </li>",
"     <li>",
"      Sodium intake should be restricted to 2 to 3",
"      <span class=\"nowrap\">",
"       mEq/kg",
"      </span>",
"      per day to prevent sodium and fluid retention with resultant hypertension.",
"     </li>",
"     <li>",
"      Children with polyuric AKI are at risk for electrolyte losses, which may need to be replaced. Ongoing replacement therapy in such patients can be guided by monitoring plasma and urinary electrolytes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therapy for specific electrolyte problems is discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H535582384\">",
"    <span class=\"h3\">",
"     Hyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia in children with AKI is one of the most common complications of AKI, and is potentially life-threatening. Children with hyperkalemia may often be asymptomatic. In those who are symptomatic, findings are usually non-specific and include malaise, nausea, and muscle weakness. As a result, potassium levels need to be monitored in children with AKI, especially those who are anuric or oliguric.",
"   </p>",
"   <p>",
"    Cardiac arrhythmia is the major life-threatening manifestation of hyperkalemia, and electrocardiogram (ECG) changes should be looked for in all patients suspected to have hyperkalemia. These include (in sequence according to the severity of hyperkalemia): tall peaked T-waves, prolonged PR interval, flattened P-waves, widened QRS complex, ventricular tachycardia, and fibrillation (",
"    <a class=\"graphic graphic_waveform graphicRef80441 \" href=\"mobipreview.htm?11/50/12068\">",
"     waveform 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The urgency of treatment of hyperkalemia is dependent on the level of potassium, the rate of rise, and the presence of signs and symptoms of hyperkalemia. This varies with the underlying cause and its acuity resulting in substantial interpatient variability. Signs of hyperkalemia including ECG changes usually do not occur until the plasma potassium concentration is above 7.0",
"    <span class=\"nowrap\">",
"     mEq/L,",
"    </span>",
"    however, in patients with marked tissue breakdown, rapid and substantial elevations in serum potassium below 7.0",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    may result in significant clinical findings including ECG abnormalities. As a result, aggressive therapy to remove potassium is warranted in such patients even if there is only a modest elevation in serum potassium.",
"   </p>",
"   <p>",
"    Severe life-threatening hyperkalemia (defined as a serum potassium level greater than 6.5",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    or ECG changes attributed to elevated potassium) requires immediate treatment. The following modalities are listed by their rapidity and mode of action, and address the immediate consequences of severe hyperkalemia (",
"    <a class=\"graphic graphic_table graphicRef82874 \" href=\"mobipreview.htm?24/14/24812\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial step is administration of intravenous calcium (",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/13/41175?source=see_link\">",
"       calcium gluconate",
"      </a>",
"      10 percent solution in a dose 0.5 to 1.0 mL per kilogram intravenously over 5 to 15 minutes) to stabilize the cardiac membrane, thus counteracting the destabilizing effects of hyperkalemia.",
"     </li>",
"     <li>",
"      Followed by one of three interventions that promote potassium movement from the extracellular fluid into the cells:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Administration of intravenous glucose and insulin (0.5 to 1.0 g of glucose per kilogram over 30 minutes and 0.1 unit of insulin per kilogram intravenously or subcutaneously).",
"     </li>",
"     <li>",
"      Administration of intravenous",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/56/41862?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      (in a dose of 1 to 2 milliequivalent per kilogram over 30 to 60 minutes).",
"     </li>",
"     <li>",
"      Administration of beta agonists, such as",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/54/39782?source=see_link\">",
"       albuterol",
"      </a>",
"      , via nebulization (2.5 mg if the child weighs less than 25 kilogram or 5 mg if the child weighs more). Albuterol can be administered intravenously at 4 to 5 microgram per kg over 15 minutes, but nebulization is the preferred route of therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, it is important to note that these interventions only transiently lower the plasma potassium concentration; as a result, additional therapy is required to remove potassium from the body.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/38/5733?source=see_link\">",
"     Sodium polystyrene sulfonate",
"    </a>",
"    , an ion exchange resin, is typically used to remove potassium (dose: 1 gram per kilogram given orally or rectally) by exchanging sodium for potassium across the colonic mucosa. Although unlikely to provide substantial benefit, diuretics can be administered to patients with continued urine output. Renal replacement therapy should be considered if medical correction fails to improve hyperkalemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/7/23673?source=see_link&amp;anchor=H4746395#H4746395\">",
"     \"Pediatric acute kidney injury: Indications, timing, and choice of modality for renal replacement therapy (RRT)\", section on 'Indications for and timing of RRT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mild to moderate hyperkalemia (serum potassium of 5.5 to 6.5",
"    <span class=\"nowrap\">",
"     mEq/L)",
"    </span>",
"    is treated by eliminating all sources of potassium, the administration",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/38/5733?source=see_link\">",
"     sodium polystyrene sulfonate",
"    </a>",
"    , and in patients with continued urine output, diuretic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31220631\">",
"    <span class=\"h3\">",
"     Metabolic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elevated anion gap metabolic acidosis is common in AKI and is secondary to the impaired renal excretion of acid, and the impaired reabsorption and regeneration of bicarbonate. In addition, acid production is frequently increased, especially in critically-ill patients due to shock or sepsis. Hyperventilation resulting in respiratory alkalosis may provide some correction of the acidosis.",
"   </p>",
"   <p>",
"    Although there is controversy regarding the use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/56/41862?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    because of its adverse effects, administration of sodium bicarbonate should be initiated in life-threatening situations in which respiratory compensation is inadequate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the acidosis is contributing to worsening hyperkalemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/11/6330?source=see_link&amp;anchor=H21#H21\">",
"     \"Approach to the child with metabolic acidosis\", section on 'Bicarbonate therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H623114399\">",
"    <span class=\"h3\">",
"     Hyperphosphatemia and hypocalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with hyperphosphatemia, oral phosphate binders and dietary restriction of phosphorus are commonly used to decrease intestinal absorption of phosphorus. Intravenous administration of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/13/41175?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    should be considered if hypocalcemia is severe",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    if bicarbonate therapy is required for severe acidosis and hyperkalemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H623114417\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is a common complication in children with AKI. Several contributing factors may cause an elevation in blood pressure including fluid overload and renin-mediated hypertension, often seen in children with glomerulonephritis. Initial management is typically administration of a diuretic. Subsequent management is determined by the severity of hypertension, cause of hypertension, and response to initial therapy (such as diuretics). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/33/23065?source=see_link&amp;anchor=H20#H20\">",
"     \"Management of hypertensive emergencies and urgencies in children\", section on 'Renal disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27626?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of hypertension in children and adolescents\", section on 'Antihypertensive drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265511473\">",
"    <span class=\"h2\">",
"     Nutritional support",
"    </span>",
"    &nbsp;&mdash;&nbsp;AKI is associated with marked catabolism, and aggressive nutritional support is crucial to enhance the recovery process. Adequate nutrition includes normal maintenance requirements and supplemental calories to address the catabolic needs of the patient. Infants should receive at least 120",
"    <span class=\"nowrap\">",
"     Kcal/kg",
"    </span>",
"    per day, and in older children, nutritional intake should be at least 150 percent of maintenance needs.",
"   </p>",
"   <p>",
"    In critically-ill children, AKI is associated with abnormal amino acid synthesis and increased protein catabolism. In addition, renal replacement therapy results in amino acid losses, which often leads to negative nitrogen balance when a standard intake of 1.5",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    of protein is provided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/18\">",
"     18",
"    </a>",
"    ]. Therefore, daily protein intake should be increased to a minimum of 3",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day in critically-ill children with AKI, and additional amino acid supplementation (about 20 percent) should be given to children on hemodialysis or continuous renal replacement therapy to compensate for amino acid loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Some pediatric nephrology experts suggest that protein intake should be targeted to maintain blood urea nitrogen (BUN) at the 40 to 80",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    range as an indication of positive nitrogen balance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperalimentation should be considered early, as the majority of children with AKI will encounter nausea and anorexia and will not be able to tolerate the oral or other enteral routes. If adequate protein and calorie nutrition cannot be achieved because of fluid restriction, renal replacement therapy should be instituted early in the course of the illness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/7/23673?source=see_link&amp;anchor=H4746395#H4746395\">",
"     \"Pediatric acute kidney injury: Indications, timing, and choice of modality for renal replacement therapy (RRT)\", section on 'Indications for and timing of RRT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265511480\">",
"    <span class=\"h2\">",
"     Drug management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic management of children with AKI is best accomplished by close collaboration and consultation with trained pharmacology and pharmacy teams, and nephrologists. Drug management in children with AKI includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoidance of nephrotoxic drugs as they may worsen the injury and delay recovery of function.",
"     </li>",
"     <li>",
"      Readjusting dosing of renally excreted drug &ndash; In patients with reduced renal clearance, drug dosing is often not readjusted and one study reported that approximately 50 percent of patients with AKI will receive drug doses that are 2.5 times the recommended maximum dose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/22\">",
"       22",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In general, the dose of all medications should be adjusted based on residual renal function, in order to avoid toxic accumulation of drugs and their metabolites that are normally excreted by the kidney as well as to avoid worsening the AKI. When the glomerular filtration rate (GFR) falls below 50 percent of normal, most drugs excreted by the kidney will require modifications in dose or scheduling. However, patients with documented AKI in the early phase with a rising creatinine should be assumed to have a GFR of less than 10",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      and medications should be dosed accordingly, irrespective of the absolute value of the serum creatinine, because of the known delay in serum creatinine to rise to steady state levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Drug dosing in the setting of AKI is complicated by the following factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pharmacokinetic changes in patients with impaired renal function include decreases in protein binding, drug metabolism, and potential changes in the volume of distribution due to fluid overload.",
"     </li>",
"     <li>",
"      Accurate determination of renal function in the acute setting is challenging. Although serum creatinine is the most commonly used measurement for renal clearance, it only accurately reflects stable kidney function. As a result, it is an imprecise measure of renal clearance in the acute setting. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/53/19290?source=see_link&amp;anchor=H1562454647#H1562454647\">",
"       \"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis\", section on 'Serum creatinine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Many drugs are significantly cleared by renal replacement therapies. Clearance varies among the renal replacement modalities.",
"     </li>",
"     <li>",
"      Drug monitoring helps to maintain therapeutic levels while preventing drug toxicity. However, for most drugs, monitoring is not available, and in this setting, adequate concentrations for efficacy can only be inferred from clinical response, and there is no ability to determine if these levels are approaching toxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265511487\">",
"    <span class=\"h2\">",
"     Renal replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The common indications for acute renal replacement therapy (RRT) in AKI include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fluid overload that is unresponsive to diuretics and is a hindrance to provision of adequate nutrition and other aspects of standard of care, such as administration of blood products",
"     </li>",
"     <li>",
"      Hyperkalemia unresponsive to nondialytic therapy",
"     </li>",
"     <li>",
"      Uremia defined as a BUN between 80 to 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      Serious and potentially life-threatening complications due to fluid overload such as pulmonary edema, heart failure, and hypertension that is refractory to pharmacologic therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    RRT modalities include hemodialysis (HD), peritoneal dialysis (PD), and continuous RRT (CRRT). The RRT choice depends on the clinical status of the patient, the expertise of the physician, and the availability of appropriate resources [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HD requires central vascular access, specialized equipment and technical personnel, anti-coagulation (except in patients with coagulopathy), and the ability to tolerate a large extracorporeal volume. The advantage of hemodialysis in the setting of AKI lies in its ability to rapidly correct imbalances in fluid, electrolyte, and acid-base status.",
"     </li>",
"     <li>",
"      The advantages of PD include ease of performance and no requirement for specialized equipment, personnel, or systemic anti-coagulation. Peritoneal dialysis is frequently the therapy of choice in neonates and small infants.",
"     </li>",
"     <li>",
"      CRRT is especially useful in patients with hemodynamic instability and multi-organ dysfunction, since it allows continuous management of fluid overload without significant fluid shifts that may occur with HD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    RRT in children with AKI is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/7/23673?source=see_link\">",
"     \"Pediatric acute kidney injury: Indications, timing, and choice of modality for renal replacement therapy (RRT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265511494\">",
"    <span class=\"h2\">",
"     Specific pharmacologic therapies for established AKI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the past couple of decades, several drugs including",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/35/5684?source=see_link\">",
"     fenoldopam",
"    </a>",
"    and atrial natriuretic peptide have demonstrated benefit in animal models of AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/2\">",
"     2",
"    </a>",
"    ]. However, translational research efforts in humans have not yielded encouraging results to date. This may be attributed, at least in part, to the delay in initiating therapies imposed by the imprecision of currently available AKI biomarkers. When early AKI markers are identified and used in clinical practice, it will be easier to ascertain whether these therapies are beneficial in the treatment of pediatric AKI. The current statuses of these interventions for the treatment of established AKI are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42154?source=see_link&amp;anchor=H25#H25\">",
"     \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\", section on 'Fenoldopam'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42154?source=see_link&amp;anchor=H26#H26\">",
"     \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\", section on 'Atrial natriuretic peptide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265511530\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND OUTCOME OF ACUTE KIDNEY INJURY (AKI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric AKI is associated with increased mortality and long-term morbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H639790335\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the overall reported mortality rate of children is between 27 and 29 percent as demonstrated by the following two studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of 228 children in the United States with the diagnosis of AKI from 1979 to 1988, the mortality rate was 27 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/28\">",
"       28",
"      </a>",
"      ]. AKI was defined by oliguria and elevated levels of serum urea nitrogen",
"      <sup>",
"      </sup>",
"      and creatinine that were at least twice the normal value for age.",
"     </li>",
"     <li>",
"      In another retrospective study of 245 children diagnosed with AKI between 1998 and 2001 from the United States, 29 percent did not survive the initial hospitalization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mortality rate increases in critically-ill children with AKI.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest study reported to date, 3396 admissions to a single pediatric intensive care unit (PICU) in the United States were retrospectively analyzed using modified pRIFLE criteria (",
"      <a class=\"graphic graphic_table graphicRef68721 \" href=\"mobipreview.htm?16/10/16555\">",
"       table 1",
"      </a>",
"      ) to define AKI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/30\">",
"       30",
"      </a>",
"      ]. Those patients who presented with AKI on admission to the PICU had a 32 percent (62 of 194 patients) mortality rate, and those who developed AKI at any time during the ICU stay had a 30 percent (104 of 339 patients) mortality rate. Multivariate analysis controlling for age, gender, weight, race, and pediatric index of mortality score demonstrated that mortality was greater in patients with AKI on admission to the PICU than those without AKI (adjusted odds ratio [OR] 5.4, 95 percent CI 3.5 to 8.4). Patients who developed AKI during the PICU stay had an even greater risk of mortality compared with those without AKI (adjusted OR 8.7, 95% CI 6.0-12.6) and had a fourfold increase in length of hospital stay.",
"     </li>",
"     <li>",
"      A similar mortality rate of 36 percent was reported in a Brazilian case series of 110 children with AKI cared for in the PICU from 2002 to 2004 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/31\">",
"       31",
"      </a>",
"      ]. AKI was diagnosed when the serum creatinine concentration was greater than the normal values for the age. The presence of oliguria, multiorgan failure, lactic acidosis, and need for pressors, mechanical ventilation, or dialysis was associated with higher mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, the highest mortality rates are seen in infants, patients who have multi-organ failure, or those receiving renal replacement therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case series from a single tertiary center, infants less than one year of age had a mortality rate of 44 percent compared with a rate of 22 percent in older children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the previously discussed retrospective review, the mortality rate for children with three organ failures was 50 percent compared to the overall mortality rate of 27 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Severe AKI defined as receiving renal replacement therapy in children is associated with a mortality rate between 30 to 50 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/32-34\">",
"       32-34",
"      </a>",
"      ]. In a retrospective analysis of 344 patients from the Prospective Pediatric Continuous Renal Replacement Therapy (ppCRRT) Registry, the overall mortality rate was 42 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/34\">",
"       34",
"      </a>",
"      ]. There was better survival in patients with principal diagnoses of drug intoxication (100 percent), primary renal disease (84 percent), tumor lysis syndrome (83 percent), and inborn errors of metabolism (73 percent). Survival was lowest in liver",
"      <span class=\"nowrap\">",
"       disease/transplant",
"      </span>",
"      (31 percent), pulmonary",
"      <span class=\"nowrap\">",
"       disease/transplant",
"      </span>",
"      (45 percent), and bone marrow transplant (45 percent). Overall survival was better for children who weighed &gt;10 kg (63 versus 43 percent) and for those who were older than one year (62 versus 44 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H639790885\">",
"    <span class=\"h2\">",
"     Morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are limited, several studies report that survivors of pediatric AKI are at risk for long-term complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of 176 children who developed AKI in a single center from 1998 to 2001, 34 percent had either reduced kidney function or were dialysis dependent at hospital discharge [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/32\">",
"       32",
"      </a>",
"      ]. At three to five years of follow-up, the mortality rate was 20 percent and 60 percent had developed evidence of chronic kidney disease (CKD) (eg, proteinuria, decreased GFR, hypertension), and 9 percent developed end-stage renal disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/16/42249/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another case series of 126 critically-ill children with AKI treated at a single tertiary center from 2006 to 2008, 10 percent of patients developed CKD and 47 percent were identified as being at risk for CKD one to three years after their episode of AKI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data strongly suggest that long-term follow-up is necessary for children who survive an episode of AKI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265511537\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265511561\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proven measures for prevention of acute kidney injury (AKI) include vigorous fluid administration in patients at high risk for developing AKI, adequate fluid repletion in those with hypovolemia, avoidance of hypotension in critically-ill children by providing inotropic support as needed, and readjustment of nephrotoxic medications based on close monitoring of renal function and drug levels, if available.",
"     </li>",
"     <li>",
"      The efficacy of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/60/43975?source=see_link\">",
"       mannitol",
"      </a>",
"      , loop diuretics, low-dose dopamine,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/35/5684?source=see_link\">",
"       fenoldopam",
"      </a>",
"      , natriuretic peptides, and N-",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/41/16022?source=see_link\">",
"       acetylcysteine",
"      </a>",
"      for the prevention of AKI is unproven and significant adverse effects are associated with mannitol, loop diuretics, and dopamine. As a result, we do",
"      <strong>",
"       not",
"      </strong>",
"      recommend that any of these pharmacologic agents be routinely used in children with acute AKI (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265511544\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of a child with AKI includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Specific treatment of the underlying cause (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/53/19290?source=see_link&amp;anchor=H17605650#H17605650\">",
"       \"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis\", section on 'Etiology and pathogenesis'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fluid management is crucial in children with AKI. Accurate initial assessment determines if the child is hypovolemic, euvolemic, or hypervolemic, and guides fluid therapy. (See",
"      <a class=\"local\" href=\"#H265511459\">",
"       'Fluid management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hypovolemia &ndash; A child with a clinical history and physical exam consistent with hypovolemia requires immediate intravenous fluid therapy (ie, normal saline bolus) in an attempt to restore renal function and prevent the progression of prerenal AKI to intrinsic AKI. (See",
"      <a class=\"local\" href=\"#H535581842\">",
"       'Hypovolemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Euvolemia &ndash; In euvolemic children, ongoing fluid losses (insensible fluid [300 to 500",
"      <span class=\"nowrap\">",
"       mL/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day], urine and gastrointestinal losses) need to be balanced with administered fluids. (See",
"      <a class=\"local\" href=\"#H535581850\">",
"       'Euvolemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypervolemia &ndash; A child with signs of fluid overload requires fluid removal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fluid restriction. A trial of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/26/5544?source=see_link\">",
"       furosemide",
"      </a>",
"      may be attempted to convert AKI from an oliguric to nonoliguric form in a child with oliguric AKI and hypervolemia. Early consideration for renal replacement therapy is essential in the critically-ill child with AKI and hypervolemia. (See",
"      <a class=\"local\" href=\"#H535581857\">",
"       'Hypervolemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend the following general measures to prevent or reduce electrolyte abnormalities in children with AKI (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H265511466\">",
"       'Electrolyte management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with oliguria or anuria should not receive potassium or phosphorus.",
"     </li>",
"     <li>",
"      Sodium intake should be restricted to 2 to 3",
"      <span class=\"nowrap\">",
"       mEq/kg",
"      </span>",
"      per day to prevent sodium and fluid retention with resultant hypertension.",
"     </li>",
"     <li>",
"      In children with polyuric AKI, electrolyte losses may need to be replaced.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperkalemia is the most common electrolyte complication, and is potentially life-threatening due to cardiac arrhythmia (",
"      <a class=\"graphic graphic_waveform graphicRef80441 \" href=\"mobipreview.htm?11/50/12068\">",
"       waveform 1",
"      </a>",
"      ) . As a result, potassium levels should be monitored in children with AKI. Treatment is based on the severity of hyperkalemia (",
"      <a class=\"graphic graphic_table graphicRef82874 \" href=\"mobipreview.htm?24/14/24812\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H535582384\">",
"       'Hyperkalemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In children with severe life-threatening potassium (defined as a serum potassium level greater than 6.5",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      or electrocardiogram changes attributed to elevated potassium), we recommend emergent therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). These therapies include the administration of calcium, insulin with glucose, beta-2-adrenergic agonists, and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/56/41862?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      In addition, no potassium should be given to these patients, and measures to remove potassium should be implemented. Include",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/38/5733?source=see_link\">",
"       sodium polystyrene sulfonate",
"      </a>",
"      , and diuretic therapy in patients with continued urine output, and if hyperkalemia remains refractory after these interventions, renal replacement therapy.",
"     </li>",
"     <li>",
"      In children with mild to moderate hyperkalemia (serum potassium of 5.5 to 6.5",
"      <span class=\"nowrap\">",
"       mEq/L),",
"      </span>",
"      we recommend a medical regimen that includes eliminating all sources of potassium, the administration",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/38/5733?source=see_link\">",
"       sodium polystyrene sulfonate",
"      </a>",
"      , and in patients with continued urine output, diuretic therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metabolic acidosis is a common abnormality in children with AKI. Although there is controversy regarding the use of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/56/41862?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      because of its adverse effects, we suggest administration of sodium bicarbonate in life-threatening situations in which respiratory compensation is inadequate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the acidosis is contributing to worsening hyperkalemia (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Hypertension is a common complication of AKI. Therapy is based on the severity and cause of hypertension. (See",
"      <a class=\"local\" href=\"#H623114417\">",
"       'Hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that nutritional support consists of a caloric intake that accounts for normal maintenance requirements and the catabolic needs of the child with AKI, especially critically-ill patients (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest that hyperalimentation be given to patients who cannot adequately maintain this nutritional intake enterally (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If fluid restriction limits intake, we suggest that renal replacement therapy be initiated (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H265511473\">",
"       'Nutritional support'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drug management in children with AKI includes avoidance of nephrotoxic agents, and dosing readjustment of renally excreted drugs",
"      <strong>",
"      </strong>",
"      based on residual renal function. (See",
"      <a class=\"local\" href=\"#H265511480\">",
"       'Drug management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for renal replacement therapy in AKI include clinically significant fluid overload unresponsive to diuretic therapy, hyperkalemia that is unresponsive to nondialytic therapy, and uremia. (See",
"      <a class=\"local\" href=\"#H265511487\">",
"       'Renal replacement therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/7/23673?source=see_link&amp;anchor=H4746395#H4746395\">",
"       \"Pediatric acute kidney injury: Indications, timing, and choice of modality for renal replacement therapy (RRT)\", section on 'Indications for and timing of RRT'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265511553\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pediatric AKI is associated with increased mortality, especially in patients who are critically ill",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      require renal replacement therapy. (See",
"      <a class=\"local\" href=\"#H639790335\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with AKI are at long-term risk for developing chronic kidney disease including end-stage renal disease. (See",
"      <a class=\"local\" href=\"#H639790885\">",
"       'Morbidity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265511570\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Abubakr Imam, who contributed to an earlier version of this topic.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/1\">",
"      American Society of Nephrology. American Society of Nephrology Renal Research Report. J Am Soc Nephrol 2005; 16:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/2\">",
"      Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 2006; 17:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/3\">",
"      Devarajan P. Emerging urinary biomarkers in the diagnosis of acute kidney injury. Expert Opin Med Diagn 2008; 2:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/4\">",
"      Zappitelli M. Epidemiology and diagnosis of acute kidney injury. Semin Nephrol 2008; 28:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/5\">",
"      Andreoli SP. Acute kidney injury in children. Pediatr Nephrol 2009; 24:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/6\">",
"      Askenazi D. Evaluation and management of critically ill children with acute kidney injury. Curr Opin Pediatr 2011; 23:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/7\">",
"      Devarajan P. Biomarkers for the early detection of acute kidney injury. Curr Opin Pediatr 2011; 23:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/8\">",
"      Goldstein SL, Devarajan P. Pediatrics: Acute kidney injury leads to pediatric patient mortality. Nat Rev Nephrol 2010; 6:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/9\">",
"      Moffett BS, Goldstein SL. Acute kidney injury and increasing nephrotoxic-medication exposure in noncritically-ill children. Clin J Am Soc Nephrol 2011; 6:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/10\">",
"      Perazella MA. Drug use and nephrotoxicity in the intensive care unit. Kidney Int 2012; 81:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/11\">",
"      Ranucci M, Soro G, Barzaghi N, et al. Fenoldopam prophylaxis of postoperative acute renal failure in high-risk cardiac surgery patients. Ann Thorac Surg 2004; 78:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/12\">",
"      Moffett BS, Mott AR, Nelson DP, et al. Renal effects of fenoldopam in critically ill pediatric patients: A retrospective review. Pediatr Crit Care Med 2008; 9:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/13\">",
"      Ricci Z, Luciano R, Favia I, et al. High-dose fenoldopam reduces postoperative neutrophil gelatinase-associated lipocaline and cystatin C levels in pediatric cardiac surgery. Crit Care 2011; 15:R160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/14\">",
"      Jefferies JL, Price JF, Denfield SW, et al. Safety and efficacy of nesiritide in pediatric heart failure. J Card Fail 2007; 13:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/15\">",
"      Sutherland SM, Zappitelli M, Alexander SR, et al. Fluid overload and mortality in children receiving continuous renal replacement therapy: the prospective pediatric continuous renal replacement therapy registry. Am J Kidney Dis 2010; 55:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/16\">",
"      Foland JA, Fortenberry JD, Warshaw BL, et al. Fluid overload before continuous hemofiltration and survival in critically ill children: a retrospective analysis. Crit Care Med 2004; 32:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/17\">",
"      Brierley J, Carcillo JA, Choong K, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med 2009; 37:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/18\">",
"      Maxvold NJ, Smoyer WE, Custer JR, Bunchman TE. Amino acid loss and nitrogen balance in critically ill children with acute renal failure: a prospective comparison between classic hemofiltration and hemofiltration with dialysis. Crit Care Med 2000; 28:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/19\">",
"      Zappitelli M, Goldstein SL, Symons JM, et al. Protein and calorie prescription for children and young adults receiving continuous renal replacement therapy: a report from the Prospective Pediatric Continuous Renal Replacement Therapy Registry Group. Crit Care Med 2008; 36:3239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/20\">",
"      Brown RO, Compher C, American Society for Parenteral and Enteral Nutrition Board of Directors. A.S.P.E.N. clinical guidelines: nutrition support in adult acute and chronic renal failure. JPEN J Parenter Enteral Nutr 2010; 34:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/21\">",
"      Barletta GM, Bunchman TE. Acute renal failure in children and infants. Curr Opin Crit Care 2004; 10:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/22\">",
"      Awdishu L, Bouchard J. How to optimize drug delivery in renal replacement therapy. Semin Dial 2011; 24:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/23\">",
"      Eyler RF, Mueller BA, Medscape. Antibiotic dosing in critically ill patients with acute kidney injury. Nat Rev Nephrol 2011; 7:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/24\">",
"      Perazella MA. Drug use and nephrotoxicity in the intensive care unit. Kidney Int 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/25\">",
"      Walters S, Porter C, Brophy PD. Dialysis and pediatric acute kidney injury: choice of renal support modality. Pediatr Nephrol 2009; 24:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/26\">",
"      Goldstein SL. Continuous renal replacement therapy: mechanism of clearance, fluid removal, indications and outcomes. Curr Opin Pediatr 2011; 23:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/27\">",
"      Goldstein SL. Advances in pediatric renal replacement therapy for acute kidney injury. Semin Dial 2011; 24:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/28\">",
"      Williams DM, Sreedhar SS, Mickell JJ, Chan JC. Acute kidney failure: a pediatric experience over 20 years. Arch Pediatr Adolesc Med 2002; 156:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/29\">",
"      Askenazi DJ, Feig DI, Graham NM, et al. 3-5 year longitudinal follow-up of pediatric patients after acute renal failure. Kidney Int 2006; 69:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/30\">",
"      Schneider J, Khemani R, Grushkin C, Bart R. Serum creatinine as stratified in the RIFLE score for acute kidney injury is associated with mortality and length of stay for children in the pediatric intensive care unit. Crit Care Med 2010; 38:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/31\">",
"      Bresolin N, Silva C, Halllal A, et al. Prognosis for children with acute kidney injury in the intensive care unit. Pediatr Nephrol 2009; 24:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/32\">",
"      Hui-Stickle S, Brewer ED, Goldstein SL. Pediatric ARF epidemiology at a tertiary care center from 1999 to 2001. Am J Kidney Dis 2005; 45:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/33\">",
"      Bunchman TE, McBryde KD, Mottes TE, et al. Pediatric acute renal failure: outcome by modality and disease. Pediatr Nephrol 2001; 16:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/34\">",
"      Symons JM, Chua AN, Somers MJ, et al. Demographic characteristics of pediatric continuous renal replacement therapy: a report of the prospective pediatric continuous renal replacement therapy registry. Clin J Am Soc Nephrol 2007; 2:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/16/42249/abstract/35\">",
"      Goldstein SL, Devarajan P. Acute kidney injury in childhood: should we be worried about progression to CKD? Pediatr Nephrol 2011; 26:509.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6090 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-9EF4B3CCD6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_16_42249=[""].join("\n");
var outline_f41_16_42249=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H265511537\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H265511368\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H265511375\">",
"      PREVENTION OF ACUTE KIDNEY INJURY (AKI)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H535580717\">",
"      Proven measures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H265511382\">",
"      - Fluid administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H265511396\">",
"      - Nephrotoxin management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H265511403\">",
"      Unproven pharmacologic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H265511410\">",
"      - Mannitol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H265511417\">",
"      - Loop diuretics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H265511424\">",
"      - Dopamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H265511431\">",
"      - Fenoldopam",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H265511438\">",
"      - Natriuretic peptides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H265511445\">",
"      - N-acetylcysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H265511452\">",
"      MANAGEMENT OF ACUTE KIDNEY INJURY (AKI)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H265511459\">",
"      Fluid management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H535581842\">",
"      - Hypovolemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H535581850\">",
"      - Euvolemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H535581857\">",
"      - Hypervolemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H535581864\">",
"      Furosemide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H535581871\">",
"      Critically-ill children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H265511466\">",
"      Electrolyte management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H535582384\">",
"      - Hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31220631\">",
"      - Metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H623114399\">",
"      - Hyperphosphatemia and hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H623114417\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H265511473\">",
"      Nutritional support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H265511480\">",
"      Drug management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H265511487\">",
"      Renal replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H265511494\">",
"      Specific pharmacologic therapies for established AKI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H265511530\">",
"      PROGNOSIS AND OUTCOME OF ACUTE KIDNEY INJURY (AKI)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H639790335\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H639790885\">",
"      Morbidity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H265511537\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H265511561\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H265511544\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H265511553\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H265511570\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6090\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6090|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/10/16555\" title=\"table 1\">",
"      Pediatric RIFLE Classification of AKI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/14/24812\" title=\"table 2\">",
"      Treatment of hyperkalemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6090|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?11/50/12068\" title=\"waveform 1\">",
"      EKG peaked T waves in hyperkalemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27114?source=related_link\">",
"      Acute kidney injury (acute renal failure) in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/53/19290?source=related_link\">",
"      Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/60/10183?source=related_link\">",
"      Acyclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/5/38998?source=related_link\">",
"      Amphotericin B nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/11/6330?source=related_link\">",
"      Approach to the child with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29833?source=related_link\">",
"      Cisplatin nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32451?source=related_link\">",
"      Complications of mannitol therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26762?source=related_link\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42729?source=related_link\">",
"      Intraoperative fluid management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6470?source=related_link\">",
"      Maintenance fluid therapy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/33/23065?source=related_link\">",
"      Management of hypertensive emergencies and urgencies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4170?source=related_link\">",
"      Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/41/18072?source=related_link\">",
"      Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/7/23673?source=related_link\">",
"      Pediatric acute kidney injury: Indications, timing, and choice of modality for renal replacement therapy (RRT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42154?source=related_link\">",
"      Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35498?source=related_link\">",
"      Prevention of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27626?source=related_link\">",
"      Treatment of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/20/3402?source=related_link\">",
"      Tumor lysis syndrome: Prevention and treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_16_42250="ECG atrial fibrillation in WPW";
var content_f41_16_42250=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60790&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1184px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    12-lead electrocardiogram (ECG) showing atrial fibrillation and preexcitation in the Wolff-Parkinson-White (WPW) syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The surface 12 lead ECG shows atrial fibrillation with a rapid ventricular response. The QRS complexes are widened due to antegrade conduction over a left lateral accessory pathway. However, the QRS complexes vary in morphology and duration because of variability in the degree of preexcitation; there is one QRS complex (*) that is conducted without preexcitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_16_42250=[""].join("\n");
var outline_f41_16_42250=null;
var title_f41_16_42251="Screening tests";
var content_f41_16_42251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Screening instruments for late-life depression for use in primary care",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sensitivity percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specificity percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inpatient",
"       </td>",
"       <td class=\"subtitle1\">",
"        Outpatient",
"       </td>",
"       <td class=\"subtitle1\">",
"        Physically ill",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cognitively impaired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two-question screen",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Geriatric Depression Scale (5-item)",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PHQ-9 (9-item)",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cornell Scale for Depression in Dementia (19-item)",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Center for Epidemiologic Studies - Depression Scale (20-item)",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_16_42251=[""].join("\n");
var outline_f41_16_42251=null;
var title_f41_16_42252="GnRH agonists for GDPP";
var content_f41_16_42252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Long-acting gonadotropin-releasing hormone (GnRH) agonists for treatment of gonadotropin-dependent (central) precocious puberty",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        GnRH agonist",
"       </td>",
"       <td class=\"subtitle1\">",
"        Trade names and availability",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose, frequency and method of administration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histrelin acetate subcutaneous implant",
"       </td>",
"       <td>",
"        Supprelin LA (US)",
"       </td>",
"       <td>",
"        Subcutaneous implant. Children &ge;2 years: 50 mg implant surgically inserted every 12 months. Releases approximately 65 mcg per day over 12 months.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Leuprolide (leuprorelin acetate)",
"       </td>",
"       <td>",
"        <p>",
"         Lupron Depot-Ped (one month) (US)",
"        </p>",
"        <p>",
"         Lupron Depot CPP (CAN)",
"        </p>",
"        <p>",
"         Eilgard, Lucrin (EU, AU, SA, elsewhere)",
"        </p>",
"       </td>",
"       <td>",
"        Intramuscular depot injection, given every 28 days. Initial dose by body weight:",
"        <br/>",
"        <ul>",
"         <li>",
"          Patients weighing &le;25 kg: 7.5 mg",
"         </li>",
"         <li>",
"          Patients weighing 25-37.5 kg: 11.25 mg",
"         </li>",
"         <li>",
"          Patients weighing &gt;37.5 kg: 15 mg",
"         </li>",
"        </ul>",
"        Titrate dose upward by 3.75 mg every 4 weeks (increase of approximately 10 mcg/kg/day) as needed to achieve clinical response. Starting doses in Europe are typically lower (eg, 3.75 mg/dose).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lupron Depot-Ped (3 month)",
"       </td>",
"       <td>",
"        Intramuscular depot injection, given every 12 weeks:",
"        <br/>",
"        <ul>",
"         <li>",
"          11.25 or 30 mg",
"         </li>",
"        </ul>",
"        Criteria for selection of the 11.25 mg versus 30 mg dosage have not been established.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Goserelin",
"       </td>",
"       <td>",
"        Zoladex (US, CAN, UK, EU, SA, elsewhere)",
"       </td>",
"       <td>",
"        Subcutaneous implant injected in to the anterior abdominal wall:",
"        <br/>",
"        <ul>",
"         <li>",
"          The 3.6 mg preparation is given once every 28 days",
"         </li>",
"         <li>",
"          The 10.8 mg preparation is given once every 12 weeks",
"         </li>",
"        </ul>",
"        More frequent injections may be needed in some individuals.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Triptorelin",
"       </td>",
"       <td>",
"        Gonapeptyl (UK, EU, SA, elsewhere)",
"       </td>",
"       <td>",
"        Intramuscular depot injection. Initial dose by body weight:",
"        <br/>",
"        <ul>",
"         <li>",
"          Patients weighing &lt;20 kg: 1.875 mg",
"         </li>",
"         <li>",
"          Patients weighing 20-30 kg: 2.5 mg",
"         </li>",
"         <li>",
"          Patients weighing &gt;30 kg: 3.75 mg",
"         </li>",
"        </ul>",
"        Initial three doses given at 14-day intervals with further doses every four weeks. More frequent injections may be needed in some individuals. An 11.25 mg intramuscular depot injection given every 12 weeks is available in some countries.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Approval of these GnRH agonists for use in gonadotropin-dependent precocious puberty (GDPP), dosing, and schedules of administration vary between products in different countries. Consult local product information. Short-acting GnRH preparations requiring daily subcutaneous injections or nasal spray are not recommended due to compliance difficulty; use of these products usually is limited to patients with sterile abscesses from depot injections. Note that the doses used to treat GDPP in children are substantially higher than those used in adults for other indications, such as prostate cancer and endometriosis.",
"    <div class=\"footnotes\">",
"     US: United States; CAN: Canada; EU: European Union; AU: Australia; SA: South America; UK: United Kingdom.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_16_42252=[""].join("\n");
var outline_f41_16_42252=null;
var title_f41_16_42253="Therapy for agents that cause encephalitis";
var content_f41_16_42253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested initial therapy for agents that cause encephalitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        ADEM",
"       </td>",
"       <td>",
"        Corticosteroids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Listeria monocytogenes",
"        </em>",
"       </td>",
"       <td>",
"        Ampicillin plus gentamicin; trimethoprim-sulfamethoxazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Tropheryma whipplei",
"        </em>",
"       </td>",
"       <td>",
"        Ceftiaxone, followed by either trimethoprim-sulfamethoxazole or cefime",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Fungi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Coccidioides",
"        </em>",
"       </td>",
"       <td>",
"        Fluconazole, itraconazole, voriconazole, amphotericin B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Cryptococcus neoformans",
"        </em>",
"       </td>",
"       <td>",
"        Amphotericin B plus flucytosine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Histoplasma capsulatum",
"        </em>",
"       </td>",
"       <td>",
"        Liposomal amphotericin B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Helminths",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Baylisascaris procyonis",
"        </em>",
"       </td>",
"       <td>",
"        Albendazole plus diethylcarbamazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Gnathostoma",
"        </em>",
"       </td>",
"       <td>",
"        Albendazole or ivermectin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Taenia solium",
"        </em>",
"        (cycticercosis)",
"       </td>",
"       <td>",
"        Albendazole and corticosteroids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Mycobacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Mycobacterium tuberculosis",
"        </em>",
"       </td>",
"       <td>",
"        4 drug regimen; consider addition of corticosteroid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Protozoa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Acanthamoeba",
"        </em>",
"       </td>",
"       <td>",
"        Trimethoprim-sulfamethoxazole plus rifampin plus ketoconazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Balamuthia mandrillaris",
"        </em>",
"       </td>",
"       <td>",
"        Pentamidine plus macrolide and fluconazole and sulfadiazine and flucytosine and phenothiazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Naegleria fowleri",
"        </em>",
"       </td>",
"       <td>",
"        Amphotericin B and rifampin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Plasmodium falciparum",
"        </em>",
"       </td>",
"       <td>",
"        Quinine, quinidine or artemether",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Toxoplasma gondii",
"        </em>",
"       </td>",
"       <td>",
"        Pyrimethamine plus sulfadiazine or clindamycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Trypanosoma brucei gambiense",
"        </em>",
"       </td>",
"       <td>",
"        Eflornithine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Trypanosoma brucei rhodesiense",
"        </em>",
"       </td>",
"       <td>",
"        Melarsoprol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Rickettsioses and ehrlichioses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Anaplasma phagocytophilum",
"        </em>",
"       </td>",
"       <td>",
"        Doxycycline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Ehrlichia chafeensis",
"        </em>",
"       </td>",
"       <td>",
"        Doxycycline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Rickettsia rickettsii",
"        </em>",
"       </td>",
"       <td>",
"        Doxycycline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Spirochetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Borrelia burgdorferi",
"        </em>",
"       </td>",
"       <td>",
"        Ceftriaxone, cefotaxime",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Treponema pallidum",
"        </em>",
"       </td>",
"       <td>",
"        Penicillin G",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cytomegalovirus",
"       </td>",
"       <td>",
"        Ganciclovir plus foscarnet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epstein-Barr",
"       </td>",
"       <td>",
"        No specific treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Herpes B virus",
"       </td>",
"       <td>",
"        Valgancyclovir",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Herpes simplex",
"       </td>",
"       <td>",
"        Acyclovir",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Human herpesvirus 6",
"       </td>",
"       <td>",
"        Gancyclovir or foscarnet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Human immunodeficiency virus",
"       </td>",
"       <td>",
"        HAART",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        JC virus",
"       </td>",
"       <td>",
"        Reversal of immunosuppression if possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Measles",
"       </td>",
"       <td>",
"        Ribavirin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nipah",
"       </td>",
"       <td>",
"        Ribavirin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        St. Louis encephalitis",
"       </td>",
"       <td>",
"        Interferon-2 alpha",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Varicella-zoster",
"       </td>",
"       <td>",
"        Acyclovir",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        West Nile",
"       </td>",
"       <td>",
"        No specific treatment",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ADEM: Acute disseminated encephalomyelitis; HAART: Highly active antiretroviral therapy.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: Clinical Practice Guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008; 47:303-27.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_16_42253=[""].join("\n");
var outline_f41_16_42253=null;
var title_f41_16_42254="Cystic thyroid nodule US";
var content_f41_16_42254=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F66403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F66403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Complex cystic thyroid nodule: Appearance on ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 228px; height: 210px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound picture of a complex cystic thyroid nodule showing a degenerating adenoma (arrow) in the wall of the cyst.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy Douglas Ross, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_16_42254=[""].join("\n");
var outline_f41_16_42254=null;
var title_f41_16_42255="Parent questionnaire C";
var content_f41_16_42255=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 515px\">",
"   <div class=\"ttl\">",
"    Questionnaire for parents (continued)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 495px; height: 657px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Speech-Language Pathology Department, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_16_42255=[""].join("\n");
var outline_f41_16_42255=null;
